Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Psychiatry›Condition·Updated Jul 11, 2026·v1

Schizophrenia

Schizophrenia is a chronic, severe mental disorder with a lifetime prevalence of 0.3-0.7%, characterized by positive, negative, and cognitive symptoms. The neurobiology involves dopamine dysregulation with upstream glutamate/GABA deficits. Diagnosis requires ≥2 core symptoms for ≥1 month (DSM-5-TR) with ≥6 months of disturbance, after ruling out medical and substance causes. Management includes antipsychotic pharmacotherapy (first-line: olanzapine, risperidone; treatment-resistant: clozapine), psychosocial interventions (CBT, family therapy, cognitive remediation), and somatic therapies (ECT, rTMS). Long-acting injectables reduce hospitalization and mortality. Rigorous monitoring of metabolic parameters, tardive dyskinesia, and clozapine-related side effects is essential. Suicide risk is highest in young adults and post-discharge. Early intervention services improve outcomes.

High Evidence845 references·3,223 words·13 min read·v1
schizophreniapsychosisantipsychoticclozapinetreatment-resistantearly interventionmetabolic monitoringtardive dyskinesiasuicide preventioncatatonia

Quick Reference

RxDrug of choiceFor first-episode psychosis: olanzapine 15 mg/day or risperidone 6 mg/day. For treatment-resistant schizophrenia: clozapine (target 300-450 mg/day). For acute agitation: inhaled loxapine 10 mg or IM aripiprazole 9.75 mg.
AltAlternativesAmisulpride, aripiprazole, ziprasidone, quetiapine, paliperidone, cariprazine, lumateperone, xanomeline-trospium (KarXT).
⊘AvoidHaloperidol as first-line for first-episode psychosis (high EPS and discontinuation rates). Avoid benzodiazepine monotherapy for psychosis. Avoid indiscriminate antipsychotic polypharmacy.
DxTest of choiceStructured clinical interview (SCID, MINI) for diagnosis. Brain MRI for first episode or atypical features. Urine drug screen to rule out substance-induced psychosis. AIMS every 6 months for TD monitoring.
ScKey scorePANSS (Positive and Negative Syndrome Scale) for symptom severity. Bush-Francis Catatonia Rating Scale for catatonia. Columbia-Suicide Severity Rating Scale (C-SSRS) for suicide risk.
→When to referFirst-episode psychosis → early intervention services. Failure of two antipsychotic trials → clozapine evaluation. Catatonia refractory to lorazepam → ECT. Metabolic complications → cardiology/endocrinology. Pregnancy → perinatal psychiatry.
Schizophrenia requires lifelong management with antipsychotic maintenance, psychosocial support, and rigorous safety monitoring. Early intervention, clozapine for treatment resistance, and LAIs for adherence improve outcomes. The leading cause of premature death is cardiometabolic disease, so metabolic monitoring is essential.
Schizophrenia is a chronic, severe mental disorder with positive, negative, and cognitive symptoms, affecting ~0.7% of the population. This concise bedside reference summarizes key clinical facts, drug doses, critical thresholds, and evidence-based management. It preserves citation numbers from the original detailed wiki page and includes essential tables and Pearls for rapid clinical use.

Overview and Recommendations

Background

  • •Schizophrenia is a chronic, severe mental disorder characterized by positive symptoms (hallucinations, delusions), negative symptoms (avolition, social withdrawal, blunted affect), and cognitive deficits, with onset typically in late adolescence or early adulthood. Lifetime prevalence is 0.3-0.7%, and it is among the top 10 causes of disability worldwide, carrying a standardized mortality ratio of approximately 2.5.
  • •The neurobiology of schizophrenia centers on dopamine dysregulation: elevated striatal presynaptic dopamine synthesis and release drive positive psychotic symptoms, while reduced prefrontal dopamine contributes to negative and cognitive symptoms. This hyperdopaminergic state arises from upstream deficits in glutamatergic (NMDAR hypofunction on PV-positive GABAergic interneurons) and GABAergic systems, leading to hippocampal hyperactivity and excessive drive to the ventral tegmental area and striatum.
  • •The illness follows a prototypical trajectory: a prodromal phase of non-specific symptoms (social withdrawal, cognitive decline, attenuated psychotic symptoms) lasting months to years, followed by a first-episode psychosis (FEP), recurrent acute episodes, and a residual phase dominated by negative and cognitive symptoms. Duration of untreated psychosis (DUP) is a critical prognostic factor, a DUP of 4 weeks predicts >20% more severe symptoms at follow-up relative to 1 week.
  • •Key clinical variants include deficit schizophrenia (enduring, primary negative symptoms in ~25-30% of cases, poor response to antipsychotics), catatonic schizophrenia (prominent psychomotor signs, often requires ECT), paranoid schizophrenia (predominant delusions and hallucinations, relatively preserved cognition), and disorganized (hebephrenic) schizophrenia. DSM-5-TR removed subtypes but retained course specifiers (first episode, multiple episodes, continuous) and cross-cutting dimensional assessments.
  • •Schizophrenia is associated with a 14.5-year reduction in life expectancy, driven by a 2.5-fold increase in all-cause mortality. Excess deaths arise from both natural causes (cardiovascular disease, respiratory infections, cancer) and unnatural causes (suicide, injury). Antipsychotic treatment paradoxically reduces mortality by 52% compared with no use (aHR 0.48), but individual agents carry distinct iatrogenic profiles that require vigilant surveillance.

Evaluation

  • •Suspect schizophrenia in any patient presenting with hallucinations (especially auditory verbal), delusions (persecutory, referential, grandiose), disorganized speech (tangentiality, loosening of associations), or negative symptoms (avolition, social withdrawal, blunted affect) lasting >1 month, with onset in late adolescence or early adulthood.
  • •Ask about the duration of symptoms, prior episodes, duration of untreated psychosis, substance use (especially cannabis, OR 1.37 for causation via Mendelian randomization), family history of psychosis or bipolar disorder, mood symptoms (mania, depression), suicidal ideation (lifetime risk ~10%), violence history, and functional decline in work, school, or social roles.
  • •Examine mental status: assess for positive symptoms (auditory hallucinations, delusions, disorganization), negative symptoms (poverty of speech, avolition, blunted affect), cognitive deficits (attention, memory, executive function), and catatonia (use the Bush-Francis Catatonia Rating Scale; score >10 warrants urgent evaluation). Neurological examination for soft signs (motor incoordination, sensory integration difficulties) may be present.
  • •Confirm DSM-5-TR criteria: at least two of five symptoms (delusions, hallucinations, disorganized speech, grossly disorganized/catatonic behavior, negative symptoms) present for ≥1 month, with at least one being delusions, hallucinations, or disorganized speech. Continuous signs of disturbance must persist for ≥6 months, including prodromal or residual phases. ICD-11 requires ≥1 month of symptoms.
  • •Rule out medical and substance causes: obtain CBC, comprehensive metabolic panel, TSH, vitamin B12, folate, HIV and syphilis serology, and urine drug screen (amphetamines, cocaine, cannabis, opioids, PCP). Brain MRI or CT is indicated for first-episode psychosis, catatonia, or atypical features (late onset, focal neurological signs, cognitive decline, rapid onset). EEG is reserved for suspected seizure disorder or rapidly progressive confusion.
  • •Distinguish from bipolar I disorder with psychotic features (psychosis occurs only during mood episodes; mood episodes are prolonged relative to psychosis), schizoaffective disorder (major mood episode present for the majority of total illness duration with psychosis occurring independently), brief psychotic disorder (<1 month, full recovery), delusional disorder (non-bizarre delusions without prominent hallucinations or disorganization), and substance-induced psychotic disorder (temporal relationship to substance use, resolves with abstinence).
  • •Use rating scales to quantify symptom severity and track change: the Positive and Negative Syndrome Scale (PANSS, 30 items scored 1-7) is the most widely used; the Brief Negative Symptom Scale (BNSS) captures the five consensus domains of negative symptoms; the Clinical Global Impression-Severity (CGI-S) provides a single-item global rating; and the Abnormal Involuntary Movement Scale (AIMS) is used for tardive dyskinesia monitoring.
  • •Assess suicide risk using the Columbia-Suicide Severity Rating Scale (C-SSRS). Risk is highest in young adults (SMR 10.19 for ages 18-34) and in the 90 days after hospital discharge (168.3 per 100,000 person-years). Key predictors include prior suicide attempt (aHR 2.48), comorbid depressive disorder (aHR 1.32), and drug use disorder (aHR 1.55). Clozapine and lithium have evidence for reducing suicidal behavior.
  • •Assess violence risk, particularly when persecutory delusions or substance misuse are present. Modifiable risk factors include medication nonadherence (HR 1.39), substance use (OR 2.36), and persecutory delusions (OR 3.68). Use structured risk assessment tools (e.g., HCR-20, Brøset Violence Checklist) but note limited evidence for effectiveness in reducing aggression.
  • •Determine capacity for treatment consent during acute episodes using the four abilities: communicating a choice, understanding relevant information, appreciating the situation and its consequences, and reasoning rationally. When capacity is impaired, identify a surrogate decision-maker according to local law.

Management

  • •For acute agitation, use inhaled loxapine 10 mg (fastest onset, PANSS-EC reduction within 10 minutes) or intramuscular aripiprazole 9.75 mg (NNT 5 for reducing additional injections). Avoid haloperidol IM due to high acute dystonia risk (RR 7.49) unless necessary; if used, consider adding lorazepam 2 mg IM for enhanced sedation.
  • •For acute psychosis, initiate an antipsychotic at the 95% effective dose: olanzapine 15 mg/day, risperidone 6 mg/day, aripiprazole 11.5 mg/day, or amisulpride. For first-episode patients, avoid haloperidol; use amisulpride, olanzapine, risperidone, or ziprasidone as they are superior for symptom reduction and all-cause discontinuation.
  • •Consider novel non-D2 agents as alternatives: xanomeline-trospium (KarXT) 125 mg/30 mg BID reduced PANSS total score by -8.4 points vs placebo (d=0.60) and improved cognition in a subgroup with baseline impairment; lumateperone 42 mg/day showed efficacy with a favorable metabolic profile; cariprazine was superior to risperidone for predominant negative symptoms (LS mean difference -1.46, effect size 0.31).
  • •For maintenance therapy, continue the effective antipsychotic at the 95% effective dose. Long-acting injectable (LAI) formulations reduce hospitalization risk compared with oral antipsychotics (HR 0.78, 95% CI 0.72-0.84) and are associated with lower all-cause mortality (OR 0.79). Consider LAI early when adherence is uncertain. Available LAIs include aripiprazole once monthly, paliperidone palmitate, zuclopenthixol acetate, and olanzapine pamoate.
  • •Add psychosocial interventions: cognitive behavioral therapy for psychosis (CBTp) reduces relapse (OR 0.45, 95% CI 0.27-0.75); family psychoeducation is the most effective single intervention (OR 0.18, 95% CI 0.12-0.27); cognitive remediation therapy improves global cognition (d=0.29) and functioning (d=0.22); supported employment enhances vocational outcomes.
  • •For treatment-resistant schizophrenia (failure of ≥2 adequate antipsychotic trials), initiate clozapine promptly. Start at 12.5 mg BID, titrate by 25-50 mg daily to target 300-450 mg/day (max 900 mg/day). Clozapine is the only agent with proven superiority in treatment resistance (response rate 62.5% vs 31.7-44.7% for other agents). Mandatory ANC monitoring: weekly for 18 weeks, then biweekly for 1 year, then monthly. Monitor for myocarditis (baseline ECG, troponin, CRP; repeat if symptoms develop).
  • •Use electroconvulsive therapy (ECT) for treatment-resistant schizophrenia or catatonia: combined with antipsychotics, response rate improves (RR 0.76 vs antipsychotics alone). Continuation/maintenance ECT reduces hospitalization risk (adjusted HR 0.68). For catatonia, first-line is lorazepam 1-2 mg IV/IM; if refractory, ECT is indicated.
  • •Monitor metabolic parameters: baseline weight, fasting glucose (or HbA1c), and lipid panel; repeat at 3 months and annually. For high-risk agents (clozapine, olanzapine), monitor every 3-6 months. If weight gain ≥7% of baseline, offer metformin (500-1000 mg BID) and behavioral interventions. Consider GLP-1 receptor agonists (e.g., semaglutide up to 1.0 mg/week) for significant weight gain, which reduced HbA1c and weight by 9.2 kg in patients on clozapine or olanzapine.
  • •Screen for tardive dyskinesia with AIMS every 6 months. If TD develops, reduce antipsychotic dose or switch to a lower-risk agent (aripiprazole, olanzapine). For persistent moderate-to-severe TD, treat with valbenazine 80 mg/day (LS mean AIMS reduction -3.2 vs -0.1) or deutetrabenazine 24-36 mg/day. Vitamin E may prevent deterioration (RR 0.23, low-quality evidence).
  • •What NOT to do: Do not rely on benzodiazepines alone for psychosis (they reduce agitation but do not treat psychotic symptoms). Do not abruptly discontinue antipsychotics without evidence of inefficacy (may precipitate relapse). Do not force IM medication without a lawful capacity assessment or emergency order. Avoid antipsychotic polypharmacy except for clozapine + aripiprazole in carefully selected treatment-resistant cases. Avoid non-dihydropyridine CCBs (diltiazem, verapamil) in patients with heart failure.
  • •When to refer: to early intervention services for first-episode psychosis; to a clozapine clinic for treatment resistance; to cardiology for metabolic complications or QTc prolongation; to obstetrics for pregnancy planning; to neurology if catatonia is refractory or if neurological symptoms emerge.
  • •Discharge criteria from inpatient care: resolution of acute psychosis, stable medication regimen with tolerability, risk assessment indicates safety (no imminent suicide or violence risk), outpatient follow-up arranged with a provider, and a crisis plan in place. Ensure patient has access to community mental health services and psychosocial support.

Board Review — High Yield

  • •Duration of untreated psychosis (DUP), Longer DUP predicts worse symptoms and lower remission rates; a 4-week DUP leads to >20% more severe symptoms at follow-up vs 1 week.
  • •Dopamine hypothesis, Positive symptoms arise from striatal hyperdopaminergia (increased presynaptic dopamine synthesis/release); negative and cognitive symptoms from prefrontal hypodopaminergia.
  • •Clozapine, Only drug with proven superiority in treatment-resistant schizophrenia; requires mandatory ANC monitoring (weekly ×18 weeks, then biweekly, then monthly).
  • •Long-acting injectables (LAIs), Reduce hospitalization risk (HR 0.78) and mortality (OR 0.79) compared to oral antipsychotics; offer early when adherence is uncertain.
  • •Suicide risk, Highest in young adults (SMR 10.19) and post-discharge (168.3 per 100,000 person-years); clozapine and lithium reduce suicidal behavior.
  • •Metabolic syndrome, Antipsychotic-induced weight gain, dyslipidemia, and glucose dysregulation are major drivers of premature death; monitor weight, glucose, lipids at baseline, 3 months, then annually.
  • •Tardive dyskinesia, Annualized incidence 2.6% with SGAs vs 6.5% with FGAs; screen with AIMS every 6 months; treat with valbenazine 80 mg/day.
  • •Catatonia, Use Bush-Francis Catatonia Rating Scale; first-line lorazepam 1-2 mg IV/IM; if refractory, ECT is indicated.
  • •Xanomeline-trospium (KarXT), First non-D2 mechanism approved for schizophrenia; muscarinic M1/M4 agonist; PANSS reduction ~8.4 points vs placebo; minimal EPS or metabolic side effects.
  • •Cognitive remediation therapy, Improves global cognition (d=0.29) and functioning (d=0.22); most effective when combined with psychosocial rehabilitation.

Deep Dive — Evidence Details

References

  1. [1]

    Davies C, Segre G, Estradé A et al.. “Prenatal and perinatal risk and protective factors for psychosis: a systematic review and meta-analysis.” The lancet. Psychiatry (2020). PMID: 32220288 ↗

    L3SR_OBSCited in: Definition, Classification and Nomenclature, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Complications, Comorbidity and Iatrogenic Harm, Special Populations, Pregnancy and Perinatal Psychiatry
  2. [2]

    Nourredine M, Gering A, Fourneret P et al.. “Association of Attention-Deficit/Hyperactivity Disorder in Childhood and Adolescence With the Risk of Subsequent Psychotic Disorder: A Systematic Review and Meta-analysis.” JAMA psychiatry (2021). PMID: 33625499 ↗

    L3SR_OBSCited in: Definition, Classification and Nomenclature
  3. [3]

    Oliver LD, Moxon-Emre I, Lai MC et al.. “Social Cognitive Performance in Schizophrenia Spectrum Disorders Compared With Autism Spectrum Disorder: A Systematic Review, Meta-analysis, and Meta-regression.” JAMA psychiatry (2021). PMID: 33291141 ↗

    L3SR_OBSCited in: Definition, Classification and Nomenclature
  4. [4]

    Leucht S, Cipriani A, Spineli L et al.. “Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.” Lancet (London, England) (2013). PMID: 23810019 ↗

    L1SR_OBSCited in: Definition, Classification and Nomenclature, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Acute Management and Psychiatric Emergencies, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Prognosis and Natural History
  5. [5]

    Aldridge RW, Story A, Hwang SW et al.. “Morbidity and mortality in homeless individuals, prisoners, sex workers, and individuals with substance use disorders in high-income countries: a systematic review and meta-analysis.” Lancet (London, England) (2017). PMID: 29137869 ↗

    L3SR_OBSCited in: Definition, Classification and Nomenclature, Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment, Complications, Comorbidity and Iatrogenic Harm, Special Populations, Pregnancy and Perinatal Psychiatry
  6. [6]

    Howes OD, Whitehurst T, Shatalina E et al.. “The clinical significance of duration of untreated psychosis: an umbrella review and random-effects meta-analysis.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2021). PMID: 33432766 ↗

    L3SR_OBSCited in: Definition, Classification and Nomenclature, Prognosis and Natural History
  7. [7]

    Krystal JH, Kane JM, Correll CU et al.. “Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial.” Lancet (London, England) (2022). PMID: 36528376 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Neurobiology and Pathophysiology, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Acute Management and Psychiatric Emergencies, History and Evolution of Treatment, Prognosis and Natural History, Prevention, Screening and Early Intervention
  8. [8]

    Chatterjee S, Naik S, John S et al.. “Effectiveness of a community-based intervention for people with schizophrenia and their caregivers in India (COPSI): a randomised controlled trial.” Lancet (London, England) (2014). PMID: 24612754 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Acute Management and Psychiatric Emergencies, History and Evolution of Treatment, Complications, Comorbidity and Iatrogenic Harm, Special Populations, Pregnancy and Perinatal Psychiatry
  9. [9]

    Goodkind M, Eickhoff SB, Oathes DJ et al.. “Identification of a common neurobiological substrate for mental illness.” JAMA psychiatry (2015). PMID: 25651064 ↗

    L3SR_OBSCited in: Definition, Classification and Nomenclature, Neurobiology and Pathophysiology
  10. [10]

    Solmi M, Radua J, Olivola M et al.. “Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies.” Molecular psychiatry (2021). PMID: 34079068 ↗

    L3SR_OBSCited in: Definition, Classification and Nomenclature, Epidemiology, Etiology and Risk Factors, Acute Management and Psychiatric Emergencies, Complications, Comorbidity and Iatrogenic Harm
  11. [11]

    Porter A, Fei S, Damme KSF et al.. “A meta-analysis and systematic review of single vs. multimodal neuroimaging techniques in the classification of psychosis.” Molecular psychiatry (2023). PMID: 37563277 ↗

    L3SR_OBSCited in: Definition, Classification and Nomenclature
  12. [12]

    Radua J, Ramella-Cravaro V, Ioannidis JPA et al.. “What causes psychosis? An umbrella review of risk and protective factors.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2018). PMID: 29352556 ↗

    L3REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Special Populations, Pregnancy and Perinatal Psychiatry
  13. [13]

    Leucht S, Priller J, Davis JM. “Antipsychotic Drugs: A Concise Review of History, Classification, Indications, Mechanism, Efficacy, Side Effects, Dosing, and Clinical Application.” The American journal of psychiatry (2024). PMID: 39350614 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Acute Management and Psychiatric Emergencies, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment
  14. [14]

    Weinberger DR. “Thinking About Schizophrenia in an Era of Genomic Medicine.” The American journal of psychiatry (2019). PMID: 30848926 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature
  15. [15]

    Jacquemont S, Huguet G, Klein M et al.. “Genes To Mental Health (G2MH): A Framework to Map the Combined Effects of Rare and Common Variants on Dimensions of Cognition and Psychopathology.” The American journal of psychiatry (2022). PMID: 35236119 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature
  16. [16]

    Cui Y, Li C, Liu B et al.. “Consistent brain structural abnormalities and multisite individualised classification of schizophrenia using deep neural networks.” The British journal of psychiatry : the journal of mental science (2022). PMID: 35144702 ↗

    L3SR_OBSCited in: Definition, Classification and Nomenclature, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
  17. [17]

    Walther S, Stegmayer K, Wilson JE et al.. “Structure and neural mechanisms of catatonia.” The lancet. Psychiatry (2019). PMID: 31196794 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology, Etiology and Risk Factors, Clinical Presentation
  18. [18]

    Fusar-Poli P, Salazar de Pablo G, Rajkumar RP et al.. “Diagnosis, prognosis, and treatment of brief psychotic episodes: a review and research agenda.” The lancet. Psychiatry (2021). PMID: 34856200 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification
  19. [19]

    Lawrie SM, O'Donovan MC, Saks E et al.. “Towards diagnostic markers for the psychoses.” The lancet. Psychiatry (2016). PMID: 27063388 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature
  20. [20]

    Luykx JJ, Gonzalez-Diaz JM, Guu TW et al.. “An international research agenda for clozapine-resistant schizophrenia.” The lancet. Psychiatry (2023). PMID: 37329895 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature
  21. [21]

    van Os J, Kapur S. “Schizophrenia.” Lancet (London, England) (2009). PMID: 19700006 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Special Populations, Pregnancy and Perinatal Psychiatry
  22. [22]

    Koshiyama D, Fukunaga M, Okada N et al.. “White matter microstructural alterations across four major psychiatric disorders: mega-analysis study in 2937 individuals.” Molecular psychiatry (2019). PMID: 31780770 ↗

    L3SR_OBSCited in: Definition, Classification and Nomenclature
  23. [23]

    Jiang Y, Chang X, Feng J. “Towards a unified theory of the aetiology of schizophrenia.” The British journal of psychiatry : the journal of mental science (2024). PMID: 39308237 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature
  24. [24]

    Large M, Farooq S, Nielssen O et al.. “Relationship between gross domestic product and duration of untreated psychosis in low- and middle-income countries.” The British journal of psychiatry : the journal of mental science (2008). PMID: 18827287 ↗

    L3REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature
  25. [25]

    Skryabin V, Kolobov K, Mikhailov M. “Dysphoria in contemporary psychiatry: forgotten affective state in need of diagnostic recognition.” The British journal of psychiatry : the journal of mental science (2026). PMID: 41498284 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature
  26. [26]

    Abi-Dargham A, Moeller SJ, Ali F et al.. “Candidate biomarkers in psychiatric disorders: state of the field.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2023). PMID: 37159365 ↗

    L5OTHERCited in: Definition, Classification and Nomenclature
  27. [27]

    Andreassen OA, Hindley GFL, Frei O et al.. “New insights from the last decade of research in psychiatric genetics: discoveries, challenges and clinical implications.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2023). PMID: 36640404 ↗

    L5OTHERCited in: Definition, Classification and Nomenclature
  28. [28]

    Keshavan MS, Kaneko Y. “Secondary psychoses: an update.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2013). PMID: 23471787 ↗

    L5OTHERCited in: Definition, Classification and Nomenclature, Neurobiology and Pathophysiology, Clinical Presentation, History and Evolution of Treatment
  29. [29]

    Owen MJ, O'Donovan MC. “Schizophrenia and the neurodevelopmental continuum:evidence from genomics.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2017). PMID: 28941101 ↗

    L5OTHERCited in: Definition, Classification and Nomenclature, Severity, Course Specifiers and Risk Stratification
  30. [30]

    Uher R, Zwicker A. “Etiology in psychiatry: embracing the reality of poly-gene-environmental causation of mental illness.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2017). PMID: 28498595 ↗

    L5OTHERCited in: Definition, Classification and Nomenclature
  31. [31]

    Reininghaus U, Böhnke JR, Chavez-Baldini U et al.. “Transdiagnostic dimensions of psychosis in the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP).” World psychiatry : official journal of the World Psychiatric Association (WPA) (2019). PMID: 30600629 ↗

    L4OTHERCited in: Definition, Classification and Nomenclature
  32. [32]

    Reed GM, Keeley JW, Rebello TJ et al.. “Clinical utility of ICD-11 diagnostic guidelines for high-burden mental disorders: results from mental health settings in 13 countries.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2018). PMID: 30192090 ↗

    L4OTHERCited in: Definition, Classification and Nomenclature
  33. [33]

    Hindley G, Frei O, Shadrin AA et al.. “Charting the Landscape of Genetic Overlap Between Mental Disorders and Related Traits Beyond Genetic Correlation.” The American journal of psychiatry (2022). PMID: 36069018 ↗

    L4OTHERCited in: Definition, Classification and Nomenclature
  34. [34]

    Martin LF, Hall MH, Ross RG et al.. “Physiology of schizophrenia, bipolar disorder, and schizoaffective disorder.” The American journal of psychiatry (2007). PMID: 18056246 ↗

    L3OTHERCited in: Definition, Classification and Nomenclature
  35. [35]

    He L, Wei D, Yang F et al.. “Functional Connectome Prediction of Anxiety Related to the COVID-19 Pandemic.” The American journal of psychiatry (2021). PMID: 33900813 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature
  36. [36]

    Sorkin A, Weinshall D, Modai I et al.. “Improving the accuracy of the diagnosis of schizophrenia by means of virtual reality.” The American journal of psychiatry (2006). PMID: 16513875 ↗

    L3OTHERCited in: Definition, Classification and Nomenclature
  37. [37]

    Nucifora LG, MacDonald ML, Lee BJ et al.. “Increased Protein Insolubility in Brains From a Subset of Patients With Schizophrenia.” The American journal of psychiatry (2019). PMID: 31055969 ↗

    L3OTHERCited in: Definition, Classification and Nomenclature
  38. [38]

    Breen G, Prata D, Osborne S et al.. “Association of the dysbindin gene with bipolar affective disorder.” The American journal of psychiatry (2006). PMID: 16946192 ↗

    L3OTHERCited in: Definition, Classification and Nomenclature
  39. [39]

    Aoki Y, Yaju Y, Utsumi T et al.. “Shared decision-making interventions for people with mental health conditions.” The Cochrane database of systematic reviews (2022). PMID: 36367232 ↗

    L1SR_OBSCited in: Definition, Classification and Nomenclature, Special Populations, Pregnancy and Perinatal Psychiatry
  40. [40]

    Essali A, Ali G. “Antipsychotic drug treatment for elderly people with late-onset schizophrenia.” The Cochrane database of systematic reviews (2012). PMID: 22336800 ↗

    L1SR_OBSCited in: Definition, Classification and Nomenclature, Special Populations, Pregnancy and Perinatal Psychiatry
  41. [41]

    Skelton M, Khokhar WA, Thacker SP. “Treatments for delusional disorder.” The Cochrane database of systematic reviews (2015). PMID: 25997589 ↗

    L1SR_OBSCited in: Definition, Classification and Nomenclature
  42. [42]

    Broderick J, Vancampfort D. “Yoga as part of a package of care versus non-standard care for schizophrenia.” The Cochrane database of systematic reviews (2019). PMID: 30990224 ↗

    L1SR_OBSCited in: Definition, Classification and Nomenclature
  43. [43]

    Soares-Weiser K, Rathbone J, Ogawa Y et al.. “Miscellaneous treatments for antipsychotic-induced tardive dyskinesia.” The Cochrane database of systematic reviews (2018). PMID: 29552749 ↗

    L1SR_OBSCited in: Definition, Classification and Nomenclature, Neurobiology and Pathophysiology, Psychopharmacology Monitoring and Safety Surveillance
  44. [44]

    Friston K. “Computational psychiatry: from synapses to sentience.” Molecular psychiatry (2022). PMID: 36056173 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Neurobiology and Pathophysiology
  45. [45]

    Guan F, Ni T, Zhu W et al.. “Integrative omics of schizophrenia: from genetic determinants to clinical classification and risk prediction.” Molecular psychiatry (2021). PMID: 34193973 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature
  46. [46]

    Fiksinski AM, Hoftman GD, Vorstman JAS et al.. “A genetics-first approach to understanding autism and schizophrenia spectrum disorders: the 22q11.2 deletion syndrome.” Molecular psychiatry (2022). PMID: 36192458 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, History and Evolution of Treatment
  47. [47]

    Abu-Mahfouz MS, AlFehaid S, Burqan HM et al.. “Artificial intelligence in mental health care: a scoping review of reviews.” Frontiers in psychiatry (2026). PMID: 41853071 ↗

    L2SR_OBSCited in: Definition, Classification and Nomenclature
  48. [48]

    Hackmann C, Balhara YPS, Clayman K et al.. “Perspectives on ICD-11 to understand and improve mental health diagnosis using expertise by experience (INCLUDE Study): an international qualitative study.” The lancet. Psychiatry (2019). PMID: 31296444 ↗

    L5OTHERCited in: Definition, Classification and Nomenclature
  49. [49]

    Bauer-Staeb C, Jörgensen L, Lewis G et al.. “Prevalence and risk factors for HIV, hepatitis B, and hepatitis C in people with severe mental illness: a total population study of Sweden.” The lancet. Psychiatry (2017). PMID: 28687481 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature
  50. [50]

    Peer M, Prüss H, Ben-Dayan I et al.. “Functional connectivity of large-scale brain networks in patients with anti-NMDA receptor encephalitis: an observational study.” The lancet. Psychiatry (2017). PMID: 28882707 ↗

    L3OTHERCited in: Definition, Classification and Nomenclature, Neurobiology and Pathophysiology
  51. [51]

    Tkachev A, Stekolshchikova E, Vanyushkina A et al.. “Lipid Alteration Signature in the Blood Plasma of Individuals With Schizophrenia, Depression, and Bipolar Disorder.” JAMA psychiatry (2023). PMID: 36696101 ↗

    L3OTHERCited in: Definition, Classification and Nomenclature
  52. [52]

    Dalsgaard S, Thorsteinsson E, Trabjerg BB et al.. “Incidence Rates and Cumulative Incidences of the Full Spectrum of Diagnosed Mental Disorders in Childhood and Adolescence.” JAMA psychiatry (2020). PMID: 31746968 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
  53. [53]

    Kotov R, Leong SH, Mojtabai R et al.. “Boundaries of schizoaffective disorder: revisiting Kraepelin.” JAMA psychiatry (2013). PMID: 24089086 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature
  54. [54]

    Nielsen TT, Bali P, Grove J et al.. “Genetic Architecture and Risk of Childhood Maltreatment Across 5 Psychiatric Diagnoses.” JAMA psychiatry (2025). PMID: 40341348 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature, Risk and Safety Assessment, Capacity and Therapeutic Setting
  55. [55]

    Barr PB, Bigdeli TB, Meyers JL. “Prevalence, Comorbidity, and Sociodemographic Correlates of Psychiatric Disorders Reported in the All of Us Research Program.” JAMA psychiatry (2022). PMID: 35442391 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature
  56. [56]

    McGrath JJ, Petersen L, Agerbo E et al.. “A comprehensive assessment of parental age and psychiatric disorders.” JAMA psychiatry (2014). PMID: 24452535 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature
  57. [57]

    . “Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis.” Lancet (London, England) (2013). PMID: 23453885 ↗

    L3OTHERCited in: Definition, Classification and Nomenclature, Special Populations, Pregnancy and Perinatal Psychiatry
  58. [58]

    van Os J. “A salience dysregulation syndrome.” The British journal of psychiatry : the journal of mental science (2009). PMID: 19182167 ↗

    L5OTHERCited in: Definition, Classification and Nomenclature, Special Populations, Pregnancy and Perinatal Psychiatry
  59. [59]

    Bilsland L, Boyce N. “A better future for mental health science.” The British journal of psychiatry : the journal of mental science (2025). PMID: 40059380 ↗

    L5OTHERCited in: Definition, Classification and Nomenclature
  60. [60]

    Galderisi S, Kaiser S. “The pathophysiology of negative symptoms of schizophrenia: main hypotheses and open challenges.” The British journal of psychiatry : the journal of mental science (2023). PMID: 37232136 ↗

    L5OTHERCited in: Definition, Classification and Nomenclature, Neurobiology and Pathophysiology
  61. [61]

    Tan EJ, Rossell SL. “Questioning the status of aberrant speech patterns as psychiatric symptoms.” The British journal of psychiatry : the journal of mental science (2020). PMID: 32213212 ↗

    L5OTHERCited in: Definition, Classification and Nomenclature, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Acute Management and Psychiatric Emergencies
  62. [62]

    Faraone SV. “Attention-deficit hyperactivity disorder and the shifting sands of psychiatric nosology.” The British journal of psychiatry : the journal of mental science (2013). PMID: 23908337 ↗

    L5OTHERCited in: Definition, Classification and Nomenclature
  63. [63]

    Berna F, Horowitz MA, Javelot H et al.. “DREAMSPHEN: a randomised controlled study comparing dose reduction of antipsychotics vs maintenance treatment in schizophrenia spectrum disorder after stratification based on patients' psychotic phenotype - study protocol of a personalised medicine approach.” BMJ open (2026). PMID: 42285570 ↗

    L5TRIAL_NONRANDOMCited in: Definition, Classification and Nomenclature, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Prognosis and Natural History
  64. [64]

    Adewuya AO, Okewole A, Ola B et al.. “CognIFied: protocol for a pilot randomised controlled trial of a culturally adapted, task-shifted compensatory cognitive training intervention for young adults with first-episode psychosis in Nigeria.” BMJ open (2026). PMID: 41819578 ↗

    L5TRIAL_NONRANDOMCited in: Definition, Classification and Nomenclature
  65. [65]

    Reales-Moreno M, Korda A, Borgwardt S. “Complexity in disguise: a systematic review of fractal analysis in psychiatric neuroimaging.” European radiology (2026). PMID: 42191885 ↗

    L3SR_OBSCited in: Definition, Classification and Nomenclature
  66. [66]

    Estradé A, La-Torraca-Vittori P, Esposito CM et al.. “Basic Self-disorders Across Psychiatric Diagnoses and Risk Syndromes: An Updated Meta-analysis.” Schizophrenia bulletin (2026). PMID: 42108700 ↗

    L3SR_OBSCited in: Definition, Classification and Nomenclature
  67. [67]

    Yamada Y, Fujiwara M, Ishii T et al.. “Impact of Preexisting Schizophrenia Spectrum Disorders on the Receipt of Surgery and Other Treatments for Non-Small Cell Lung Cancer: A Multicenter Nationwide Cohort Study in Japan.” Chest (2026). PMID: 42167588 ↗

    L2COHORTCited in: Definition, Classification and Nomenclature, Complications, Comorbidity and Iatrogenic Harm
  68. [68]

    Li X, Zhuo Y, Meng X et al.. “Cognitive Function Assessment Using a Virtual Reality Serious Game System in Patients With Stable Schizophrenia: Prospective Cohort Study.” JMIR serious games (2026). PMID: 42102386 ↗

    L2COHORTCited in: Definition, Classification and Nomenclature
  69. [69]

    Huot-Lavoie M, Corbeil O, Béchard L et al.. “Gaming Disorder in First Episode Psychosis: Prevalence and Impact on Symptomatology and Functioning in a Prospective Cohort Study.” Schizophrenia bulletin (2026). PMID: 41863358 ↗

    L2COHORTCited in: Definition, Classification and Nomenclature
  70. [70]

    Bastos J, Freitas A, Gandra G et al.. “Psychiatric comorbidity in hospitalised burn patients: A Portuguese population-based observational retrospective study (2000-2015).” Burns : journal of the International Society for Burn Injuries (2026). PMID: 41830718 ↗

    L2COHORTCited in: Definition, Classification and Nomenclature
  71. [71]

    Gaitonde SA, Avet C, de la Fuente Revenga M et al.. “Pharmacological fingerprint of antipsychotic drugs at the serotonin 5-HT2A receptor.” Molecular psychiatry (2024). PMID: 38561467 ↗

    L5OTHERCited in: Definition, Classification and Nomenclature, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  72. [72]

    Chen H, Lei Y, Li R et al.. “Resting-state EEG dynamic functional connectivity distinguishes non-psychotic major depression, psychotic major depression and schizophrenia.” Molecular psychiatry (2024). PMID: 38267620 ↗

    L3OTHERCited in: Definition, Classification and Nomenclature, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
  73. [73]

    Rubio JM, Lencz T, Cao H et al.. “Replication of a neuroimaging biomarker for striatal dysfunction in psychosis.” Molecular psychiatry (2024). PMID: 38177349 ↗

    L3OTHERCited in: Definition, Classification and Nomenclature
  74. [74]

    Schneider-Thoma J, Zhu Y, Qin M et al.. “Comparative efficacy and tolerability of antidopaminergic and muscarinic antipsychotics for acute schizophrenia: a network meta-analysis of randomised controlled trials indexed in international English and Chinese databases.” Lancet (London, England) (2026). PMID: 41763745 ↗

    L1SR_MA_RCTCited in: Neurobiology and Pathophysiology, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Acute Management and Psychiatric Emergencies, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Prognosis and Natural History, Prevention, Screening and Early Intervention
  75. [75]

    Omlor W, Rabe F, Fuchs S et al.. “Estimating Multimodal Structural Brain Variability in Schizophrenia Spectrum Disorders: A Worldwide ENIGMA Study.” The American journal of psychiatry (2025). PMID: 40007253 ↗

    L3SR_OBSCited in: Neurobiology and Pathophysiology
  76. [76]

    Mancini V, Latreche C, Fanshawe JB et al.. “Anticholinergic Burden and Cognitive Function in Psychosis: A Systematic Review and Meta-Analysis.” The American journal of psychiatry (2025). PMID: 40007252 ↗

    L2SR_OBSCited in: Neurobiology and Pathophysiology
  77. [77]

    Warrier V, Kwong ASF, Luo M et al.. “Gene-environment correlations and causal effects of childhood maltreatment on physical and mental health: a genetically informed approach.” The lancet. Psychiatry (2021). PMID: 33740410 ↗

    L2SR_OBSCited in: Neurobiology and Pathophysiology
  78. [78]

    Siskind DJ, Wu BT, Wong TT et al.. “Pharmacological interventions for smoking cessation among people with schizophrenia spectrum disorders: a systematic review, meta-analysis, and network meta-analysis.” The lancet. Psychiatry (2020). PMID: 32828166 ↗

    L1SR_OBSCited in: Neurobiology and Pathophysiology
  79. [79]

    Jalbrzikowski M, Hayes RA, Wood SJ et al.. “Association of Structural Magnetic Resonance Imaging Measures With Psychosis Onset in Individuals at Clinical High Risk for Developing Psychosis: An ENIGMA Working Group Mega-analysis.” JAMA psychiatry (2021). PMID: 33950164 ↗

    L3SR_OBSCited in: Neurobiology and Pathophysiology, Clinical Presentation, Prognosis and Natural History
  80. [80]

    Merritt K, McGuire PK, Egerton A et al.. “Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level: A Mega-analysis of Individual Participant-Level Data.” JAMA psychiatry (2021). PMID: 33881460 ↗

    L2SR_OBSCited in: Neurobiology and Pathophysiology, Severity, Course Specifiers and Risk Stratification
  81. [81]

    Brugger SP, Howes OD. “Heterogeneity and Homogeneity of Regional Brain Structure in Schizophrenia: A Meta-analysis.” JAMA psychiatry (2017). PMID: 28973084 ↗

    L3SR_OBSCited in: Neurobiology and Pathophysiology
  82. [82]

    Radua J, Schmidt A, Borgwardt S et al.. “Ventral Striatal Activation During Reward Processing in Psychosis: A Neurofunctional Meta-Analysis.” JAMA psychiatry (2015). PMID: 26558708 ↗

    L3SR_OBSCited in: Neurobiology and Pathophysiology
  83. [83]

    Bugarski-Kirola D, Arango C, Fava M et al.. “Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe.” The lancet. Psychiatry (2021). PMID: 34861170 ↗

    L1RCTCited in: Neurobiology and Pathophysiology
  84. [84]

    McCutcheon RA, Merritt K, Howes OD. “Dopamine and glutamate in individuals at high risk for psychosis: a meta-analysis of in vivo imaging findings and their variability compared to controls.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2021). PMID: 34505389 ↗

    L3SR_OBSCited in: Neurobiology and Pathophysiology
  85. [85]

    Meltzer-Brody S, Colquhoun H, Riesenberg R et al.. “Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials.” Lancet (London, England) (2018). PMID: 30177236 ↗

    L1RCTCited in: Neurobiology and Pathophysiology, Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment, Prognosis and Natural History, Special Populations, Pregnancy and Perinatal Psychiatry, Prevention, Screening and Early Intervention
  86. [86]

    Brannan SK, Sawchak S, Miller AC et al.. “Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia.” The New England journal of medicine (2021). PMID: 33626254 ↗

    L1RCTCited in: Neurobiology and Pathophysiology, Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment
  87. [87]

    Koblan KS, Kent J, Hopkins SC et al.. “A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia.” The New England journal of medicine (2020). PMID: 32294346 ↗

    L1RCTCited in: Neurobiology and Pathophysiology, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Acute Management and Psychiatric Emergencies, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment, Prognosis and Natural History
  88. [88]

    Choi KH, Wykes T, Kurtz MM. “Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy.” The British journal of psychiatry : the journal of mental science (2013). PMID: 23999481 ↗

    L1SR_OBSCited in: Neurobiology and Pathophysiology
  89. [89]

    Evins AE, Cather C, Pratt SA et al.. “Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial.” JAMA (2014). PMID: 24399553 ↗

    L1RCTCited in: Neurobiology and Pathophysiology, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment, Prognosis and Natural History, Special Populations, Pregnancy and Perinatal Psychiatry
  90. [90]

    Goldsmith DR, Rapaport MH, Miller BJ. “A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression.” Molecular psychiatry (2016). PMID: 26903267 ↗

    L3SR_OBSCited in: Neurobiology and Pathophysiology, Acute Management and Psychiatric Emergencies
  91. [91]

    Solmi M, Fornaro M, Caiolo S et al.. “Efficacy and acceptability of pharmacological interventions for tardive dyskinesia in people with schizophrenia or mood disorders: a systematic review and network meta-analysis.” Molecular psychiatry (2024). PMID: 39695322 ↗

    L1SR_OBSCited in: Neurobiology and Pathophysiology, Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Psychopharmacology Monitoring and Safety Surveillance, Prognosis and Natural History
  92. [92]

    Saint-Georges Z, MacDonald J, Al-Khalili R et al.. “Cholinergic system in schizophrenia: A systematic review and meta-analysis.” Molecular psychiatry (2025). PMID: 40394282 ↗

    L3SR_OBSCited in: Neurobiology and Pathophysiology, Severity, Course Specifiers and Risk Stratification
  93. [93]

    Vancampfort D, Firth J, Stubbs B et al.. “The efficacy, mechanisms and implementation of physical activity as an adjunctive treatment in mental disorders: a meta-review of outcomes, neurobiology and key determinants.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2025). PMID: 40371806 ↗

    L1REVIEW_NARRATIVECited in: Neurobiology and Pathophysiology
  94. [94]

    Kraguljac NV, McDonald WM, Widge AS et al.. “Neuroimaging Biomarkers in Schizophrenia.” The American journal of psychiatry (2021). PMID: 33397140 ↗

    L5REVIEW_NARRATIVECited in: Neurobiology and Pathophysiology, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Risk and Safety Assessment, Capacity and Therapeutic Setting, Prognosis and Natural History
  95. [95]

    Paul SM, Yohn SE, Popiolek M et al.. “Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia.” The American journal of psychiatry (2022). PMID: 35758639 ↗

    L5REVIEW_NARRATIVECited in: Neurobiology and Pathophysiology, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  96. [96]

    Neufeld NH, Blumberger DM. “An Update on the Use of Neuromodulation Strategies in the Treatment of Schizophrenia.” The American journal of psychiatry (2025). PMID: 40165555 ↗

    L5REVIEW_NARRATIVECited in: Neurobiology and Pathophysiology
  97. [97]

    Lieberman JA, Small SA, Girgis RR. “Early Detection and Preventive Intervention in Schizophrenia: From Fantasy to Reality.” The American journal of psychiatry (2019). PMID: 31569988 ↗

    L5REVIEW_NARRATIVECited in: Neurobiology and Pathophysiology, Acute Management and Psychiatric Emergencies
  98. [98]

    Gong Q, Lui S, Sweeney JA. “A Selective Review of Cerebral Abnormalities in Patients With First-Episode Schizophrenia Before and After Treatment.” The American journal of psychiatry (2015). PMID: 26621570 ↗

    L5REVIEW_NARRATIVECited in: Neurobiology and Pathophysiology, Acute Management and Psychiatric Emergencies
  99. [99]

    Khandaker GM, Cousins L, Deakin J et al.. “Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment.” The lancet. Psychiatry (2015). PMID: 26359903 ↗

    L5REVIEW_NARRATIVECited in: Neurobiology and Pathophysiology
  100. [100]

    Lawrie SM. “Brain structure in schizophrenia: what do we know and what next?” The lancet. Psychiatry (2025). PMID: 40840473 ↗

    L5REVIEW_NARRATIVECited in: Neurobiology and Pathophysiology, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
  101. [101]

    Humpston CS, Broome MR. “Thinking, believing, and hallucinating self in schizophrenia.” The lancet. Psychiatry (2020). PMID: 32105619 ↗

    L5REVIEW_NARRATIVECited in: Neurobiology and Pathophysiology, Clinical Presentation, History and Evolution of Treatment
  102. [102]

    Kircher T, Bröhl H, Meier F et al.. “Formal thought disorders: from phenomenology to neurobiology.” The lancet. Psychiatry (2018). PMID: 29678679 ↗

    L5REVIEW_NARRATIVECited in: Neurobiology and Pathophysiology, Acute Management and Psychiatric Emergencies
  103. [103]

    Dietz AG, Goldman SA, Nedergaard M. “Glial cells in schizophrenia: a unified hypothesis.” The lancet. Psychiatry (2019). PMID: 31704113 ↗

    L5REVIEW_NARRATIVECited in: Neurobiology and Pathophysiology
  104. [104]

    Zinkstok JR, Boot E, Bassett AS et al.. “Neurobiological perspective of 22q11.2 deletion syndrome.” The lancet. Psychiatry (2019). PMID: 31395526 ↗

    L5REVIEW_NARRATIVECited in: Neurobiology and Pathophysiology
  105. [105]

    Spies M, Knudsen GM, Lanzenberger R et al.. “The serotonin transporter in psychiatric disorders: insights from PET imaging.” The lancet. Psychiatry (2015). PMID: 26249305 ↗

    L5REVIEW_NARRATIVECited in: Neurobiology and Pathophysiology
  106. [106]

    Jauhar S, Johnstone M, McKenna PJ. “Schizophrenia.” Lancet (London, England) (2022). PMID: 35093231 ↗

    L5REVIEW_NARRATIVECited in: Neurobiology and Pathophysiology, Epidemiology, Etiology and Risk Factors, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Risk and Safety Assessment, Capacity and Therapeutic Setting
  107. [107]

    Hall J. “Schizophrenia - new treatments soon.” The British journal of psychiatry : the journal of mental science (2024). PMID: 39511776 ↗

    L5REVIEW_NARRATIVECited in: Neurobiology and Pathophysiology, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  108. [108]

    Velakoulis D, Walterfang M, Mocellin R et al.. “Frontotemporal dementia presenting as schizophrenia-like psychosis in young people: clinicopathological series and review of cases.” The British journal of psychiatry : the journal of mental science (2009). PMID: 19336778 ↗

    L4REVIEW_NARRATIVECited in: Neurobiology and Pathophysiology
  109. [109]

    McCutcheon RA, Krystal JH, Howes OD. “Dopamine and glutamate in schizophrenia: biology, symptoms and treatment.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2020). PMID: 31922684 ↗

    L5OTHERCited in: Neurobiology and Pathophysiology
  110. [110]

    Burns J. “The social brain hypothesis of schizophrenia.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2006). PMID: 16946939 ↗

    L5OTHERCited in: Neurobiology and Pathophysiology, History and Evolution of Treatment
  111. [111]

    Braff DL, Greenwood TA, Swerdlow NR et al.. “Advances in endophenotyping schizophrenia.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2008). PMID: 18458787 ↗

    L5OTHERCited in: Neurobiology and Pathophysiology
  112. [112]

    Voineskos AN, Hawco C, Neufeld NH et al.. “Functional magnetic resonance imaging in schizophrenia: current evidence, methodological advances, limitations and future directions.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2024). PMID: 38214624 ↗

    L5OTHERCited in: Neurobiology and Pathophysiology, History and Evolution of Treatment
  113. [113]

    Correll CU, Solmi M, Cortese S et al.. “The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2023). PMID: 36640403 ↗

    L5OTHERCited in: Neurobiology and Pathophysiology
  114. [114]

    Joshi YB, Thomas ML, Braff DL et al.. “Anticholinergic Medication Burden-Associated Cognitive Impairment in Schizophrenia.” The American journal of psychiatry (2021). PMID: 33985348 ↗

    L4OTHERCited in: Neurobiology and Pathophysiology, Severity, Course Specifiers and Risk Stratification, Special Populations, Pregnancy and Perinatal Psychiatry
  115. [115]

    Orhan F, Malwade S, Khanlarkhani N et al.. “Kynurenic Acid and Promotion of Activity-Dependent Synapse Elimination in Schizophrenia.” The American journal of psychiatry (2025). PMID: 40165559 ↗

    L5OTHERCited in: Neurobiology and Pathophysiology
  116. [116]

    Woodward ND, Karbasforoushan H, Heckers S. “Thalamocortical dysconnectivity in schizophrenia.” The American journal of psychiatry (2012). PMID: 23032387 ↗

    L3OTHERCited in: Neurobiology and Pathophysiology
  117. [117]

    Vano LJ, McCutcheon RA, Sedlacik J et al.. “Reduced Brain Iron and Striatal Hyperdopaminergia in Schizophrenia: A Quantitative Susceptibility Mapping MRI and PET Study.” The American journal of psychiatry (2025). PMID: 40887951 ↗

    L3OTHERCited in: Neurobiology and Pathophysiology
  118. [118]

    Chakrabarti A, Bagnall A, Chue P et al.. “Loxapine for schizophrenia.” The Cochrane database of systematic reviews (2007). PMID: 17943763 ↗

    L1SR_OBSCited in: Neurobiology and Pathophysiology, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  119. [119]

    Assalman I, Ahmed A, Alhajjar R et al.. “Treatments for primary delusional infestation.” The Cochrane database of systematic reviews (2019). PMID: 31821546 ↗

    L1SR_OBSCited in: Neurobiology and Pathophysiology
  120. [120]

    Schmidt L, Phelps E, Friedel J et al.. “Acetylsalicylic acid (aspirin) for schizophrenia.” The Cochrane database of systematic reviews (2019). PMID: 31425623 ↗

    L1SR_OBSCited in: Neurobiology and Pathophysiology, Epidemiology, Etiology and Risk Factors
  121. [121]

    Singh J, Kour K, Jayaram MB. “Acetylcholinesterase inhibitors for schizophrenia.” The Cochrane database of systematic reviews (2012). PMID: 22258978 ↗

    L1SR_OBSCited in: Neurobiology and Pathophysiology
  122. [122]

    Bergman H, Bhoopathi PS, Soares-Weiser K. “Benzodiazepines for antipsychotic-induced tardive dyskinesia.” The Cochrane database of systematic reviews (2018). PMID: 29352477 ↗

    L1SR_OBSCited in: Neurobiology and Pathophysiology, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Psychopharmacology Monitoring and Safety Surveillance, Complications, Comorbidity and Iatrogenic Harm
  123. [123]

    Tuominen HJ, Tiihonen J, Wahlbeck K. “Glutamatergic drugs for schizophrenia.” The Cochrane database of systematic reviews (2006). PMID: 16625590 ↗

    L1SR_OBSCited in: Neurobiology and Pathophysiology, Severity, Course Specifiers and Risk Stratification
  124. [124]

    Tammenmaa-Aho I, Asher R, Soares-Weiser K et al.. “Cholinergic medication for antipsychotic-induced tardive dyskinesia.” The Cochrane database of systematic reviews (2018). PMID: 29553158 ↗

    L1SR_OBSCited in: Neurobiology and Pathophysiology, Psychopharmacology Monitoring and Safety Surveillance
  125. [125]

    Syed R, Au K, Cahill C et al.. “Pharmacological interventions for clozapine-induced hypersalivation.” The Cochrane database of systematic reviews (2008). PMID: 18646130 ↗

    L1SR_OBSCited in: Neurobiology and Pathophysiology
  126. [126]

    Rathbone J, Soares-Weiser K. “Anticholinergics for neuroleptic-induced acute akathisia.” The Cochrane database of systematic reviews (2006). PMID: 17054182 ↗

    L1SR_OBSCited in: Neurobiology and Pathophysiology, Clinical Presentation, Complications, Comorbidity and Iatrogenic Harm
  127. [127]

    Bergman H, Soares-Weiser K. “Anticholinergic medication for antipsychotic-induced tardive dyskinesia.” The Cochrane database of systematic reviews (2018). PMID: 29341071 ↗

    L1SR_OBSCited in: Neurobiology and Pathophysiology, Psychopharmacology Monitoring and Safety Surveillance
  128. [128]

    Ceraso A, Lin JJ, Schneider-Thoma J et al.. “Maintenance treatment with antipsychotic drugs for schizophrenia.” The Cochrane database of systematic reviews (2020). PMID: 32840872 ↗

    L1SR_OBSCited in: Neurobiology and Pathophysiology
  129. [129]

    Garner B, Phillips LJ, Bendall S et al.. “Antiglucocorticoid and related treatments for psychosis.” The Cochrane database of systematic reviews (2016). PMID: 26725721 ↗

    L1SR_OBSCited in: Neurobiology and Pathophysiology
  130. [130]

    Matthews PRL, Horder J, Pearce M. “Selective noradrenaline reuptake inhibitors for schizophrenia.” The Cochrane database of systematic reviews (2018). PMID: 29368813 ↗

    L1SR_OBSCited in: Neurobiology and Pathophysiology
  131. [131]

    McCutcheon RA, Keefe RSE, McGuire PK. “Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment.” Molecular psychiatry (2023). PMID: 36690793 ↗

    L5REVIEW_NARRATIVECited in: Neurobiology and Pathophysiology, History and Evolution of Treatment
  132. [132]

    Howes OD, Thase ME, Pillinger T. “Treatment resistance in psychiatry: state of the art and new directions.” Molecular psychiatry (2021). PMID: 34257409 ↗

    L5REVIEW_NARRATIVECited in: Neurobiology and Pathophysiology, Epidemiology, Etiology and Risk Factors
  133. [133]

    Yan Z, Rein B. “Mechanisms of synaptic transmission dysregulation in the prefrontal cortex: pathophysiological implications.” Molecular psychiatry (2021). PMID: 33875802 ↗

    L5REVIEW_NARRATIVECited in: Neurobiology and Pathophysiology
  134. [134]

    Guo JY, Ragland JD, Carter CS. “Memory and cognition in schizophrenia.” Molecular psychiatry (2018). PMID: 30242229 ↗

    L5REVIEW_NARRATIVECited in: Neurobiology and Pathophysiology, Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
  135. [135]

    Kahn RS, Sommer IE. “The neurobiology and treatment of first-episode schizophrenia.” Molecular psychiatry (2014). PMID: 25048005 ↗

    L5REVIEW_NARRATIVECited in: Neurobiology and Pathophysiology, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Prognosis and Natural History
  136. [136]

    Villarin JM, Kellendonk C. “An ace in the hole? Opportunities and limits of using mice to understand schizophrenia neurobiology.” Molecular psychiatry (2025). PMID: 40405017 ↗

    L5REVIEW_NARRATIVECited in: Neurobiology and Pathophysiology
  137. [137]

    Militaru AM, Pietreanu AC, Trifu S et al.. “Gut Microbiota in Schizophrenia: Taxonomic Shifts, Beta- Diversity Alterations, and Biomarker Potential: A Systematic Review.” International journal of molecular sciences (2026). PMID: 42196583 ↗

    L3SR_OBSCited in: Neurobiology and Pathophysiology
  138. [138]

    Drake RJ, Husain N, Marshall M et al.. “Effect of delaying treatment of first-episode psychosis on symptoms and social outcomes: a longitudinal analysis and modelling study.” The lancet. Psychiatry (2020). PMID: 32563307 ↗

    L2OTHERCited in: Neurobiology and Pathophysiology
  139. [139]

    Patel Y, Parker N, Shin J et al.. “Virtual Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders.” JAMA psychiatry (2021). PMID: 32857118 ↗

    L3OTHERCited in: Neurobiology and Pathophysiology, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Special Populations, Pregnancy and Perinatal Psychiatry
  140. [140]

    Luykx JJ, Correll CU, Manu P et al.. “Pneumonia Risk, Antipsychotic Dosing, and Anticholinergic Burden in Schizophrenia.” JAMA psychiatry (2024). PMID: 38922592 ↗

    L2OTHERCited in: Neurobiology and Pathophysiology, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Special Populations, Pregnancy and Perinatal Psychiatry
  141. [141]

    Osugo M, Whitehurst T, Erritzoe D et al.. “Role of Serotonin in the Neurobiology of Schizophrenia and Association With Negative Symptoms.” JAMA psychiatry (2026). PMID: 41370075 ↗

    L3OTHERCited in: Neurobiology and Pathophysiology
  142. [142]

    Blasco MB, Nisha Aji K, Ramos-Jiménez C et al.. “Synaptic Density in Early Stages of Psychosis and Clinical High Risk.” JAMA psychiatry (2025). PMID: 39535765 ↗

    L3OTHERCited in: Neurobiology and Pathophysiology
  143. [143]

    Alnæs D, Kaufmann T, van der Meer D et al.. “Brain Heterogeneity in Schizophrenia and Its Association With Polygenic Risk.” JAMA psychiatry (2019). PMID: 30969333 ↗

    L3OTHERCited in: Neurobiology and Pathophysiology
  144. [144]

    Pines AR, Frandsen SB, Drew W et al.. “Mapping Lesions That Cause Psychosis to a Human Brain Circuit and Proposed Stimulation Target.” JAMA psychiatry (2025). PMID: 39937525 ↗

    L3OTHERCited in: Neurobiology and Pathophysiology
  145. [145]

    Colodro-Conde L, Couvy-Duchesne B, Whitfield JB et al.. “Association Between Population Density and Genetic Risk for Schizophrenia.” JAMA psychiatry (2018). PMID: 29936532 ↗

    L2OTHERCited in: Neurobiology and Pathophysiology, Risk and Safety Assessment, Capacity and Therapeutic Setting
  146. [146]

    Wolf DH, Satterthwaite TD, Calkins ME et al.. “Functional neuroimaging abnormalities in youth with psychosis spectrum symptoms.” JAMA psychiatry (2015). PMID: 25785510 ↗

    L3OTHERCited in: Neurobiology and Pathophysiology
  147. [147]

    Voineskos AN, Foussias G, Lerch J et al.. “Neuroimaging evidence for the deficit subtype of schizophrenia.” JAMA psychiatry (2013). PMID: 23467781 ↗

    L3OTHERCited in: Neurobiology and Pathophysiology
  148. [148]

    Shaju A, Mishra BR, Mohapatra D et al.. “Mitochondrial dysfunction in schizophrenia and its modulation by atypical antipsychotic drugs: A randomized controlled trial.” Journal of psychopharmacology (Oxford, England) (2026). PMID: 42362495 ↗

    L1RCTCited in: Neurobiology and Pathophysiology
  149. [149]

    Liddle PF. “Tardive dyskinesia in schizophrenia.” The British journal of psychiatry : the journal of mental science (2013). PMID: 23818532 ↗

    L5OTHERCited in: Neurobiology and Pathophysiology, Psychopharmacology Monitoring and Safety Surveillance, Complications, Comorbidity and Iatrogenic Harm
  150. [150]

    Fernandez-Egea E, Mucci A, Lee J et al.. “A new era for the negative symptoms of schizophrenia.” The British journal of psychiatry : the journal of mental science (2023). PMID: 37424202 ↗

    L5OTHERCited in: Neurobiology and Pathophysiology, Clinical Presentation
  151. [151]

    Andreu-Bernabeu Á, González-Peñas J, Mora A et al.. “Linking prolonged childhood and adolescent loneliness to schizophrenia spectrum disorders: results from EU-GEI study.” The British journal of psychiatry : the journal of mental science (2025). PMID: 40519115 ↗

    L4OTHERCited in: Neurobiology and Pathophysiology, Special Populations, Pregnancy and Perinatal Psychiatry
  152. [152]

    Harrison PJ. “Metabotropic glutamate receptor agonists for schizophrenia.” The British journal of psychiatry : the journal of mental science (2008). PMID: 18245019 ↗

    L5OTHERCited in: Neurobiology and Pathophysiology
  153. [153]

    Dickinson D. “Digit symbol coding and general cognitive ability in schizophrenia: worth another look?” The British journal of psychiatry : the journal of mental science (2008). PMID: 18978311 ↗

    L5OTHERCited in: Neurobiology and Pathophysiology
  154. [154]

    Brandt CL, Eichele T, Melle I et al.. “Working memory networks and activation patterns in schizophrenia and bipolar disorder: comparison with healthy controls.” The British journal of psychiatry : the journal of mental science (2014). PMID: 24434074 ↗

    L3OTHERCited in: Neurobiology and Pathophysiology
  155. [155]

    Ortiz-Gil J, Pomarol-Clotet E, Salvador R et al.. “Neural correlates of cognitive impairment in schizophrenia.” The British journal of psychiatry : the journal of mental science (2011). PMID: 21727234 ↗

    L3OTHERCited in: Neurobiology and Pathophysiology
  156. [156]

    Chen J, He K, Wang Q et al.. “Role played by the SP4 gene in schizophrenia and major depressive disorder in the Han Chinese population.” The British journal of psychiatry : the journal of mental science (2015). PMID: 26450579 ↗

    L3OTHERCited in: Neurobiology and Pathophysiology
  157. [157]

    Koch K, Rus OG, Reeß TJ et al.. “Functional connectivity and grey matter volume of the striatum in schizophrenia.” The British journal of psychiatry : the journal of mental science (2014). PMID: 25012683 ↗

    L3OTHERCited in: Neurobiology and Pathophysiology
  158. [158]

    Zhu Y, Wang S, Gong X et al.. “Associations between hemispheric asymmetry and schizophrenia-related risk genes in people with schizophrenia and people at a genetic high risk of schizophrenia.” The British journal of psychiatry : the journal of mental science (2021). PMID: 35048853 ↗

    L3OTHERCited in: Neurobiology and Pathophysiology
  159. [159]

    Hua JPY, Dal Bon K. “Social Determinants of Health and Neurobiology Across the Schizophrenia Course: A Systematic Review.” JAMA psychiatry (2026). PMID: 42307922 ↗

    L5SR_OBSCited in: Neurobiology and Pathophysiology, Severity, Course Specifiers and Risk Stratification, Prognosis and Natural History
  160. [160]

    Vano LJ, Sedlacik J, Carr RW et al.. “Gray Matter Iron and Neuromelanin in Psychosis: A Systematic Review and Meta-Analysis of MRI Studies.” The American journal of psychiatry (2026). PMID: 42265595 ↗

    L3SR_OBSCited in: Neurobiology and Pathophysiology
  161. [161]

    Wei W, Deng L, Qiao C et al.. “Neural variability in three major psychiatric disorders.” Molecular psychiatry (2023). PMID: 37443193 ↗

    L3OTHERCited in: Neurobiology and Pathophysiology, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification
  162. [162]

    Koskuvi M, Pörsti E, Hewitt T et al.. “Genetic contribution to microglial activation in schizophrenia.” Molecular psychiatry (2024). PMID: 38519640 ↗

    L3OTHERCited in: Neurobiology and Pathophysiology
  163. [163]

    Xie Y, Fu J, Liu L et al.. “Genetic and neural mechanisms shared by schizophrenia and depression.” Molecular psychiatry (2025). PMID: 40175520 ↗

    L3OTHERCited in: Neurobiology and Pathophysiology, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Complications, Comorbidity and Iatrogenic Harm
  164. [164]

    Warren TL, Tubbs JD, Lesh TA et al.. “Association of neurotransmitter pathway polygenic risk with specific symptom profiles in psychosis.” Molecular psychiatry (2024). PMID: 38491343 ↗

    L3OTHERCited in: Neurobiology and Pathophysiology, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
  165. [165]

    de Araujo MTG, Larson JS, Bryant JE et al.. “A Systematic Review of the Magnetic Resonance Imaging Literature Investigating the Deficit Syndrome in Schizophrenia.” Schizophrenia bulletin open (2026). PMID: 42183481 ↗

    L5SR_OBSCited in: Neurobiology and Pathophysiology
  166. [166]

    Grace AA, Uliana D. “Antipsychotic drug action, novel treatment targets, and the failure of current clinical trial designs in evaluating new target molecules.” Biological psychiatry (2026). PMID: 42320782 ↗

    L5TRIAL_NONRANDOMCited in: Neurobiology and Pathophysiology, History and Evolution of Treatment
  167. [167]

    Chang YB, Baleja JD. “The Role of the Ketogenic Diet in Modulating Biochemical Pathophysiology in Psychiatric and Neurodegenerative Disorders.” International journal of molecular sciences (2026). PMID: 42278457 ↗

    L5REVIEW_NARRATIVECited in: Neurobiology and Pathophysiology
  168. [168]

    Sangeeta S, Bharvi SS, Vedavathi S et al.. “Gut-brain axis research in schizophrenia: Historical evolution, emerging computational models, and translational challenges - A narrative review.” Asian journal of psychiatry (2026). PMID: 42250376 ↗

    L5REVIEW_NARRATIVECited in: Neurobiology and Pathophysiology
  169. [169]

    Owen MJ, O'Donovan MC. “Rethinking schizophrenia: insights from genomics and implications for research.” Molecular psychiatry (2026). PMID: 42162224 ↗

    L5REVIEW_NARRATIVECited in: Neurobiology and Pathophysiology
  170. [170]

    Ebrahimi MN, Banazadeh M, Kohlmeier KA et al.. “Heat Shock Proteins in Schizophrenia: Integrating Stress Responses, Molecular Pathways, and Emerging Therapeutic Strategies.” The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry (2026). PMID: 42159268 ↗

    L5REVIEW_NARRATIVECited in: Neurobiology and Pathophysiology
  171. [171]

    Lee T, Eom K, Kim JJ et al.. “Translational Relevance of the MAM Model in Schizophrenia : A Systematic Review of Behavioral and Neurobiological Findings.” Biological psychiatry (2026). PMID: 42419666 ↗

    L5SR_OBSCited in: Neurobiology and Pathophysiology
  172. [172]

    Ramirez J, Maresca T, Lopez P et al.. “Probiotics in reducing negative symptoms of schizophrenia: A systematic review and meta-analysis.” Progress in neuro-psychopharmacology & biological psychiatry (2026). PMID: 42392560 ↗

    L1SR_OBSCited in: Neurobiology and Pathophysiology
  173. [173]

    Prasad K, Bowei O, Theis N. “From microstates to macroscales: A critical review of maximum entropy modeling and energy landscape analysis in functional MRI.” Neuroscience and biobehavioral reviews (2026). PMID: 42361933 ↗

    L5SR_OBSCited in: Neurobiology and Pathophysiology, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
  174. [174]

    Chabert J, Laidi C, Caseras X et al.. “Complement component C4 and neuroimaging in psychiatry: A systematic review.” Brain, behavior, and immunity (2026). PMID: 42315045 ↗

    L2SR_OBSCited in: Neurobiology and Pathophysiology
  175. [175]

    Carbon M, Kane JM, Leucht S et al.. “Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2018). PMID: 30192088 ↗

    L1SR_MA_RCTCited in: Epidemiology, Etiology and Risk Factors, Psychopharmacology Monitoring and Safety Surveillance
  176. [176]

    Docherty AR, Mullins N, Ashley-Koch AE et al.. “GWAS Meta-Analysis of Suicide Attempt: Identification of 12 Genome-Wide Significant Loci and Implication of Genetic Risks for Specific Health Factors.” The American journal of psychiatry (2023). PMID: 37777856 ↗

    L3SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Severity, Course Specifiers and Risk Stratification, Risk and Safety Assessment, Capacity and Therapeutic Setting
  177. [177]

    Lyssenko L, Schmahl C, Bockhacker L et al.. “Dissociation in Psychiatric Disorders: A Meta-Analysis of Studies Using the Dissociative Experiences Scale.” The American journal of psychiatry (2017). PMID: 28946763 ↗

    L4SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
  178. [178]

    Zhou L, Sommer IEC, Yang P et al.. “What Do Four Decades of Research Tell Us About the Association Between Childhood Adversity and Psychosis: An Updated and Extended Multi-Level Meta-Analysis.” The American journal of psychiatry (2025). PMID: 40165558 ↗

    L3SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Risk and Safety Assessment, Capacity and Therapeutic Setting, Special Populations, Pregnancy and Perinatal Psychiatry
  179. [179]

    Ellersgaard D, Jessica Plessen K, Richardt Jepsen J et al.. “Psychopathology in 7-year-old children with familial high risk of developing schizophrenia spectrum psychosis or bipolar disorder - The Danish High Risk and Resilience Study - VIA 7, a population-based cohort study.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2018). PMID: 29856544 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors
  180. [180]

    Hauser RA, Factor SA, Marder SR et al.. “KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.” The American journal of psychiatry (2017). PMID: 28320223 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Psychopharmacology Monitoring and Safety Surveillance, History and Evolution of Treatment, Prognosis and Natural History, Special Populations, Pregnancy and Perinatal Psychiatry
  181. [181]

    . “Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.” The lancet. Psychiatry (2022). PMID: 35026139 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Complications, Comorbidity and Iatrogenic Harm, Prognosis and Natural History, Special Populations, Pregnancy and Perinatal Psychiatry
  182. [182]

    Lai MC, Kassee C, Besney R et al.. “Prevalence of co-occurring mental health diagnoses in the autism population: a systematic review and meta-analysis.” The lancet. Psychiatry (2019). PMID: 31447415 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Complications, Comorbidity and Iatrogenic Harm
  183. [183]

    Højlund M, Köhler-Forsberg O, Gregersen AT et al.. “Prevalence, correlates, tolerability-related outcomes, and efficacy-related outcomes of antipsychotic polypharmacy: a systematic review and meta-analysis.” The lancet. Psychiatry (2024). PMID: 39547246 ↗

    L3SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Complications, Comorbidity and Iatrogenic Harm
  184. [184]

    Halstead S, Cao C, Høgnason Mohr G et al.. “Prevalence of multimorbidity in people with and without severe mental illness: a systematic review and meta-analysis.” The lancet. Psychiatry (2024). PMID: 38642560 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Complications, Comorbidity and Iatrogenic Harm
  185. [185]

    Barry R, Anderson J, Tran L et al.. “Prevalence of Mental Health Disorders Among Individuals Experiencing Homelessness: A Systematic Review and Meta-Analysis.” JAMA psychiatry (2024). PMID: 38630486 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors
  186. [186]

    Walker ER, McGee RE, Druss BG. “Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis.” JAMA psychiatry (2015). PMID: 25671328 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Complications, Comorbidity and Iatrogenic Harm
  187. [187]

    Korchia T, Achour V, Faugere M et al.. “Sexual Dysfunction in Schizophrenia: A Systematic Review and Meta-Analysis.” JAMA psychiatry (2023). PMID: 37703012 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  188. [188]

    Hagi K, Nosaka T, Dickinson D et al.. “Association Between Cardiovascular Risk Factors and Cognitive Impairment in People With Schizophrenia: A Systematic Review and Meta-analysis.” JAMA psychiatry (2021). PMID: 33656533 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Complications, Comorbidity and Iatrogenic Harm
  189. [189]

    Zhuo C, Triplett PT. “Association of Schizophrenia With the Risk of Breast Cancer Incidence: A Meta-analysis.” JAMA psychiatry (2018). PMID: 29516094 ↗

    L3SR_OBSCited in: Epidemiology, Etiology and Risk Factors
  190. [190]

    Charlson F, van Ommeren M, Flaxman A et al.. “New WHO prevalence estimates of mental disorders in conflict settings: a systematic review and meta-analysis.” Lancet (London, England) (2019). PMID: 31200992 ↗

    L4SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Psychiatric Emergencies
  191. [191]

    . “Disease burden attributable to intimate partner violence against females and sexual violence against children in 204 countries and territories, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.” Lancet (London, England) (2025). PMID: 41386261 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Risk and Safety Assessment, Capacity and Therapeutic Setting, Complications, Comorbidity and Iatrogenic Harm, Special Populations, Pregnancy and Perinatal Psychiatry
  192. [192]

    . “Updated trends in the global prevalence and burden of mental disorders, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.” Lancet (London, England) (2026). PMID: 42167272 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification
  193. [193]

    Ward C, Pejović Milovančević M, Kohegyi E et al.. “Efficacy and safety of brexpiprazole in adolescents with schizophrenia: a multicountry, randomised, double-blind, placebo-controlled, phase 3 trial with an active reference.” The lancet. Psychiatry (2025). PMID: 40209740 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Severity, Course Specifiers and Risk Stratification, History and Evolution of Treatment, Prognosis and Natural History, Special Populations, Pregnancy and Perinatal Psychiatry, Prevention, Screening and Early Intervention
  194. [194]

    Horsdal HT, Albiñana C, Zhu Z et al.. “Convergent evidence linking neonatal vitamin D status and risk of neurodevelopmental disorders: a Danish case-cohort study.” The lancet. Psychiatry (2025). PMID: 40379361 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Special Populations, Pregnancy and Perinatal Psychiatry
  195. [195]

    Hu Y, Tian W, Wei C et al.. “Clozapine use and risk of infections in patients with schizophrenia in Hong Kong: a population-based cohort study.” The lancet. Psychiatry (2025). PMID: 40744048 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Complications, Comorbidity and Iatrogenic Harm
  196. [196]

    Hansen HG, Starzer M, Nilsson SF et al.. “Clinical Recovery and Long-Term Association of Specialized Early Intervention Services vs Treatment as Usual Among Individuals With First-Episode Schizophrenia Spectrum Disorder: 20-Year Follow-up of the OPUS Trial.” JAMA psychiatry (2023). PMID: 36811902 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment, Complications, Comorbidity and Iatrogenic Harm, Prognosis and Natural History
  197. [197]

    Correll CU, Solmi M, Veronese N et al.. “Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2017). PMID: 28498599 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Complications, Comorbidity and Iatrogenic Harm, Prevention, Screening and Early Intervention
  198. [198]

    Vancampfort D, Stubbs B, Mitchell AJ et al.. “Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2015). PMID: 26407790 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Prevention, Screening and Early Intervention
  199. [199]

    Wagner E, Mortazavi M, Poddighe L et al.. “Risk of all-cause and cause-specific mortality, and suicide attempt in people with anxiety and stress-related disorders: a systematic review, meta-analysis and meta-regression analysis of 165 studies.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2026). PMID: 42136520 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Complications, Comorbidity and Iatrogenic Harm, Prevention, Screening and Early Intervention
  200. [200]

    Gerlinger G, Hauser M, De Hert M et al.. “Personal stigma in schizophrenia spectrum disorders: a systematic review of prevalence rates, correlates, impact and interventions.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2013). PMID: 23737425 ↗

    L4SR_OBSCited in: Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment
  201. [201]

    Vancampfort D, Correll CU, Galling B et al.. “Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2016). PMID: 27265707 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Prevention, Screening and Early Intervention
  202. [202]

    Tiihonen J, Lönnqvist J, Wahlbeck K et al.. “11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).” Lancet (London, England) (2009). PMID: 19595447 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Complications, Comorbidity and Iatrogenic Harm, Special Populations, Pregnancy and Perinatal Psychiatry
  203. [203]

    Honer WG, Thornton AE, Chen EY et al.. “Clozapine alone versus clozapine and risperidone with refractory schizophrenia.” The New England journal of medicine (2006). PMID: 16452559 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment, Prognosis and Natural History
  204. [204]

    Zhuo C, Zhuang H, Gao X et al.. “Lung cancer incidence in patients with schizophrenia: meta-analysis.” The British journal of psychiatry : the journal of mental science (2019). PMID: 30806345 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors
  205. [205]

    Swinnen SG, Selten JP. “Mood disorders and migration: meta-analysis.” The British journal of psychiatry : the journal of mental science (2007). PMID: 17197650 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors
  206. [206]

    Lagerberg T, Lambe S, Paulino A et al.. “Systematic review of risk factors for violence in psychosis: 10-year update.” The British journal of psychiatry : the journal of mental science (2025). PMID: 40091674 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Risk and Safety Assessment, Capacity and Therapeutic Setting, History and Evolution of Treatment
  207. [207]

    De Hert M, Vancampfort D, Correll CU et al.. “Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation.” The British journal of psychiatry : the journal of mental science (2011). PMID: 21804146 ↗

    L5SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Complications, Comorbidity and Iatrogenic Harm, Prevention, Screening and Early Intervention
  208. [208]

    Smith M, Hopkins D, Peveler RC et al.. “First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis.” The British journal of psychiatry : the journal of mental science (2008). PMID: 18515889 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Prevention, Screening and Early Intervention
  209. [209]

    Fornaro M, Solmi M, Stubbs B et al.. “Prevalence and correlates of major depressive disorder, bipolar disorder and schizophrenia among nursing home residents without dementia: systematic review and meta-analysis.” The British journal of psychiatry : the journal of mental science (2020). PMID: 30864533 ↗

    L4SR_OBSCited in: Epidemiology, Etiology and Risk Factors
  210. [210]

    Liu R, Li D, Ma Y et al.. “Air pollutants, genetic susceptibility and the risk of schizophrenia: large prospective study.” The British journal of psychiatry : the journal of mental science (2024). PMID: 39117363 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Special Populations, Pregnancy and Perinatal Psychiatry
  211. [211]

    Lagerberg T, Gustafsson TT, Molero Y et al.. “Oral glucocorticoids and risk of psychiatric and suicidal behaviour outcomes: population-based cohort study.” The British journal of psychiatry : the journal of mental science (2025). PMID: 40556309 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Severity, Course Specifiers and Risk Stratification, Risk and Safety Assessment, Capacity and Therapeutic Setting, Special Populations, Pregnancy and Perinatal Psychiatry
  212. [212]

    Foa EB, McLean CP, Capaldi S et al.. “Prolonged exposure vs supportive counseling for sexual abuse-related PTSD in adolescent girls: a randomized clinical trial.” JAMA (2013). PMID: 24368465 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment, Special Populations, Pregnancy and Perinatal Psychiatry
  213. [213]

    Muntjewerff JW, Kahn RS, Blom HJ et al.. “Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis.” Molecular psychiatry (2006). PMID: 16172608 ↗

    L3SR_OBSCited in: Epidemiology, Etiology and Risk Factors
  214. [214]

    Pinioti E, Glarou E, Lappas AS et al.. “Examining the safety profile of clozapine versus other antipsychotics: systematic review and meta-analysis.” The British journal of psychiatry : the journal of mental science (2025). PMID: 41146456 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Severity, Course Specifiers and Risk Stratification, Complications, Comorbidity and Iatrogenic Harm
  215. [215]

    Luykx JJ, Visscher R, Winter-van Rossum I et al.. “Clinical symptoms and psychosocial functioning in patients with schizophrenia spectrum disorders testing seropositive for anti-NMDAR antibodies: a case-control comparison with patients testing negative.” The lancet. Psychiatry (2024). PMID: 39300641 ↗

    L3CASE_CONTROLCited in: Epidemiology, Etiology and Risk Factors
  216. [216]

    Radua J, De Prisco M, Oliva V et al.. “Impact of air pollution and climate change on mental health outcomes: an umbrella review of global evidence.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2024). PMID: 38727076 ↗

    L2REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Severity, Course Specifiers and Risk Stratification, Acute Management and Psychiatric Emergencies, Complications, Comorbidity and Iatrogenic Harm
  217. [217]

    Heinz A, Deserno L, Reininghaus U. “Urbanicity, social adversity and psychosis.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2013). PMID: 24096775 ↗

    L5OTHERCited in: Epidemiology, Etiology and Risk Factors
  218. [218]

    Dragioti E, Radua J, Solmi M et al.. “Impact of mental disorders on clinical outcomes of physical diseases: an umbrella review assessing population attributable fraction and generalized impact fraction.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2023). PMID: 36640414 ↗

    L2REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Severity, Course Specifiers and Risk Stratification, Complications, Comorbidity and Iatrogenic Harm
  219. [219]

    Plana-Ripoll O, Musliner KL, Dalsgaard S et al.. “Nature and prevalence of combinations of mental disorders and their association with excess mortality in a population-based cohort study.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2020). PMID: 32931098 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Complications, Comorbidity and Iatrogenic Harm
  220. [220]

    Benedetti A, Pini S, DE Girolamo G et al.. “The psychotic spectrum: a community-based study.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2009). PMID: 19516935 ↗

    L4OTHERCited in: Epidemiology, Etiology and Risk Factors, Prognosis and Natural History
  221. [221]

    Starzer MSK, Nordentoft M, Hjorthøj C. “Rates and Predictors of Conversion to Schizophrenia or Bipolar Disorder Following Substance-Induced Psychosis.” The American journal of psychiatry (2017). PMID: 29179576 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Complications, Comorbidity and Iatrogenic Harm, Prognosis and Natural History
  222. [222]

    Lång U, Metsälä J, Ramsay H et al.. “Doxycycline Use in Adolescent Psychiatric Patients and Risk of Schizophrenia: An Emulated Target Trial.” The American journal of psychiatry (2025). PMID: 41190738 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Special Populations, Pregnancy and Perinatal Psychiatry
  223. [223]

    Tamminga CA, Stan AD, Wagner AD. “The hippocampal formation in schizophrenia.” The American journal of psychiatry (2010). PMID: 20810471 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors
  224. [224]

    Matar HE, Almerie MQ, Makhoul S et al.. “Pericyazine for schizophrenia.” The Cochrane database of systematic reviews (2014). PMID: 24825770 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Acute Management and Psychiatric Emergencies, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Complications, Comorbidity and Iatrogenic Harm
  225. [225]

    Nussbaum A, Stroup TS. “Paliperidone for schizophrenia.” The Cochrane database of systematic reviews (2008). PMID: 18425951 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors
  226. [226]

    Nikvarz N, Vahedian M, Khalili N. “Chlorpromazine versus penfluridol for schizophrenia.” The Cochrane database of systematic reviews (2017). PMID: 28940256 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Acute Management and Psychiatric Emergencies, Complications, Comorbidity and Iatrogenic Harm
  227. [227]

    Wang J, Sampson S. “Sulpiride versus placebo for schizophrenia.” The Cochrane database of systematic reviews (2014). PMID: 24729184 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors
  228. [228]

    Rattehalli RD, Zhao S, Li BG et al.. “Risperidone versus placebo for schizophrenia.” The Cochrane database of systematic reviews (2016). PMID: 27977041 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors
  229. [229]

    Mazhari S, Esmailian S, Shah-Esmaeili A et al.. “Chlorpromazine versus clotiapine for schizophrenia.” The Cochrane database of systematic reviews (2017). PMID: 28387925 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Complications, Comorbidity and Iatrogenic Harm
  230. [230]

    Eslami Shahrbabaki M, Dehnavieh R, Vali L et al.. “Chlorpromazine versus piperacetazine for schizophrenia.” The Cochrane database of systematic reviews (2018). PMID: 30378678 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Prognosis and Natural History
  231. [231]

    Wang J, Omori IM, Fenton M et al.. “Sulpiride augmentation for schizophrenia.” The Cochrane database of systematic reviews (2010). PMID: 20091661 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Severity, Course Specifiers and Risk Stratification
  232. [232]

    Omori IM, Wang J. “Sulpiride versus placebo for schizophrenia.” The Cochrane database of systematic reviews (2009). PMID: 19370694 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors
  233. [233]

    Subramanian S, Völlm BA, Huband N. “Clozapine dose for schizophrenia.” The Cochrane database of systematic reviews (2017). PMID: 28613395 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors
  234. [234]

    Solmi M, Correll CU, Boldrini T et al.. “Guidelines for the prevention of psychosis from the World Federation of Societies of Biological Psychiatry (WFSBP) and EPI Canada.” The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry (2026). PMID: 42201755 ↗

    L1GUIDELINECited in: Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment
  235. [235]

    Geoffroy MC, Baker-Sullivan E, Nitu NJ et al.. “Risk and Protective Factors for Suicide Mortality in Youths: A Systematic Review and Meta-Analysis.” JAMA network open (2026). PMID: 42390862 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Severity, Course Specifiers and Risk Stratification, Risk and Safety Assessment, Capacity and Therapeutic Setting, Complications, Comorbidity and Iatrogenic Harm, Special Populations, Pregnancy and Perinatal Psychiatry
  236. [236]

    Eddy CM. “The many manifestations of magical thinking: a systematic review.” Frontiers in psychiatry (2026). PMID: 42245212 ↗

    L5SR_OBSCited in: Epidemiology, Etiology and Risk Factors
  237. [237]

    Fornaro M, Di Lorenzo C, Steardo L et al.. “Prevalence and outcomes of co-occurring psychiatric and endocrine, metabolic, and nutritional disorders: An atlas based on umbrella review of 254,154,533 records.” European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology (2026). PMID: 42217371 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Complications, Comorbidity and Iatrogenic Harm, Prognosis and Natural History
  238. [238]

    Huang Y, Wang Y, Wang H et al.. “Prevalence of mental disorders in China: a cross-sectional epidemiological study.” The lancet. Psychiatry (2019). PMID: 30792114 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
  239. [239]

    Whiting D, Lichtenstein P, Fazel S. “Violence and mental disorders: a structured review of associations by individual diagnoses, risk factors, and risk assessment.” The lancet. Psychiatry (2020). PMID: 33096045 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Risk and Safety Assessment, Capacity and Therapeutic Setting
  240. [240]

    Williams JA, Burgess S, Suckling J et al.. “Inflammation and Brain Structure in Schizophrenia and Other Neuropsychiatric Disorders: A Mendelian Randomization Study.” JAMA psychiatry (2022). PMID: 35353173 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
  241. [241]

    Jørgensen A, Gronemann FH, Rozing MP et al.. “Clinical Outcomes of Continuation and Maintenance Electroconvulsive Therapy.” JAMA psychiatry (2024). PMID: 39292447 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Acute Management and Psychiatric Emergencies, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Prognosis and Natural History, Special Populations, Pregnancy and Perinatal Psychiatry
  242. [242]

    Pedersen CB, Mors O, Bertelsen A et al.. “A comprehensive nationwide study of the incidence rate and lifetime risk for treated mental disorders.” JAMA psychiatry (2014). PMID: 24806211 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Risk and Safety Assessment, Capacity and Therapeutic Setting, Prognosis and Natural History
  243. [243]

    Koutsouleris N, Dwyer DB, Degenhardt F et al.. “Multimodal Machine Learning Workflows for Prediction of Psychosis in Patients With Clinical High-Risk Syndromes and Recent-Onset Depression.” JAMA psychiatry (2021). PMID: 33263726 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Complications, Comorbidity and Iatrogenic Harm
  244. [244]

    Song J, Pasman JA, Johansson V et al.. “Polygenic Risk Scores and Twin Concordance for Schizophrenia and Bipolar Disorder.” JAMA psychiatry (2024). PMID: 39196586 ↗

    L3OTHERCited in: Epidemiology, Etiology and Risk Factors
  245. [245]

    McIntyre RS, Berk M, Brietzke E et al.. “Bipolar disorders.” Lancet (London, England) (2020). PMID: 33278937 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Severity, Course Specifiers and Risk Stratification, Acute Management and Psychiatric Emergencies, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Risk and Safety Assessment, Capacity and Therapeutic Setting, Complications, Comorbidity and Iatrogenic Harm, Prognosis and Natural History, Special Populations, Pregnancy and Perinatal Psychiatry, Prevention, Screening and Early Intervention
  246. [246]

    Whiteford HA, Degenhardt L, Rehm J et al.. “Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010.” Lancet (London, England) (2013). PMID: 23993280 ↗

    L2REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Complications, Comorbidity and Iatrogenic Harm
  247. [247]

    Lichtenstein P, Yip BH, Björk C et al.. “Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study.” Lancet (London, England) (2009). PMID: 19150704 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Complications, Comorbidity and Iatrogenic Harm
  248. [248]

    Ray WA, Chung CP, Murray KT et al.. “Atypical antipsychotic drugs and the risk of sudden cardiac death.” The New England journal of medicine (2009). PMID: 19144938 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Special Populations, Pregnancy and Perinatal Psychiatry
  249. [249]

    Kim J, Kim H, Kim H et al.. “Incidence and Prognostic Implications of Mental Disorders Among Patients With a Permanent Pacemaker: A Nationwide Cohort Study.” Journal of the American Heart Association (2026). PMID: 42432429 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Complications, Comorbidity and Iatrogenic Harm
  250. [250]

    Curman P, Olbrich H, Kridin K et al.. “Psychiatric Risk in Chronic Spontaneous Urticaria: A Retrospective Cohort Study.” Acta dermato-venereologica (2026). PMID: 42403316 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Severity, Course Specifiers and Risk Stratification, Risk and Safety Assessment, Capacity and Therapeutic Setting, Complications, Comorbidity and Iatrogenic Harm
  251. [251]

    Ronaldson A, Markham S, Dregan A et al.. “Factors associated with infection-related hospitalisations in severe mental illness: a retrospective cohort study.” BMJ mental health (2026). PMID: 42390061 ↗

    L3COHORTCited in: Epidemiology, Etiology and Risk Factors
  252. [252]

    Trott M, Northwood K, Hata T et al.. “Clozapine-Associated Neutropenia among People on Clozapine in Japan: A Nationally Representative Retrospective Cohort Study.” Schizophrenia bulletin (2026). PMID: 42212910 ↗

    L3COHORTCited in: Epidemiology, Etiology and Risk Factors, Psychopharmacology Monitoring and Safety Surveillance
  253. [253]

    Wood SJ. “Autism and schizophrenia: one, two or many disorders?” The British journal of psychiatry : the journal of mental science (2017). PMID: 28373219 ↗

    L5OTHERCited in: Epidemiology, Etiology and Risk Factors, Complications, Comorbidity and Iatrogenic Harm
  254. [254]

    Joukamaa M, Heliövaara M, Knekt P et al.. “Schizophrenia, neuroleptic medication and mortality.” The British journal of psychiatry : the journal of mental science (2006). PMID: 16449697 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Complications, Comorbidity and Iatrogenic Harm, Special Populations, Pregnancy and Perinatal Psychiatry
  255. [255]

    Owen MJ, O'Donovan MC, Thapar A et al.. “Neurodevelopmental hypothesis of schizophrenia.” The British journal of psychiatry : the journal of mental science (2011). PMID: 21357874 ↗

    L5OTHERCited in: Epidemiology, Etiology and Risk Factors, Complications, Comorbidity and Iatrogenic Harm
  256. [256]

    Fazel S, Långström N, Hjern A et al.. “Schizophrenia, substance abuse, and violent crime.” JAMA (2009). PMID: 19454640 ↗

    L4OTHERCited in: Epidemiology, Etiology and Risk Factors, Risk and Safety Assessment, Capacity and Therapeutic Setting, Complications, Comorbidity and Iatrogenic Harm
  257. [257]

    Fernando SM, Scott M, Talarico R et al.. “Association of Extracorporeal Membrane Oxygenation With New Mental Health Diagnoses in Adult Survivors of Critical Illness.” JAMA (2022). PMID: 36286084 ↗

    L3OTHERCited in: Epidemiology, Etiology and Risk Factors, Special Populations, Pregnancy and Perinatal Psychiatry
  258. [258]

    Stogios N, Agarwal SM, Maksyutynska K et al.. “Pharmacological Interventions for Weight Reduction in Patients With Schizophrenia Treated With Antipsychotics: A Systematic Review and Network Meta-Analysis.” JAMA psychiatry (2026). PMID: 42418179 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors
  259. [259]

    Sommerhoff C, Bort M, Prisco M et al.. “The Prevalence of Obstructive Sleep Apnoea in Schizophrenia, Bipolar Disorder and Major Depressive Disorder: A Systematic Review With Meta-Analysis.” Acta psychiatrica Scandinavica (2026). PMID: 42334316 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Complications, Comorbidity and Iatrogenic Harm
  260. [260]

    Salazar de Pablo G, Laherran-Cantera N, Aymerich C et al.. “Systematic Review and Meta-Analysis: Prevalence, Correlates, and Impact of Cannabis Use and Cannabis Use Disorder in Early-Onset Psychosis.” Journal of the American Academy of Child and Adolescent Psychiatry (2026). PMID: 42331312 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors
  261. [261]

    Carswell C, Nisbet RE, Khan J et al.. “Prevalence of chronic kidney disease in people with severe mental illness: systematic review and meta-analysis.” The British journal of psychiatry : the journal of mental science (2026). PMID: 42187349 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors
  262. [262]

    Solmi M, Seitidis G, Mavridis D et al.. “Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the Global Burden of Disease (GBD) 2019.” Molecular psychiatry (2023). PMID: 37500825 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Complications, Comorbidity and Iatrogenic Harm, Special Populations, Pregnancy and Perinatal Psychiatry
  263. [263]

    Gordovez FJA, McMahon FJ. “The genetics of bipolar disorder.” Molecular psychiatry (2020). PMID: 31907381 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors
  264. [264]

    Vaucher J, Keating BJ, Lasserre AM et al.. “Cannabis use and risk of schizophrenia: a Mendelian randomization study.” Molecular psychiatry (2017). PMID: 28115737 ↗

    L3OTHERCited in: Epidemiology, Etiology and Risk Factors
  265. [265]

    Socrates AJ, Mullins N, Gur RC et al.. “Polygenic risk of social isolation behavior and its influence on psychopathology and personality.” Molecular psychiatry (2024). PMID: 38811692 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Special Populations, Pregnancy and Perinatal Psychiatry
  266. [266]

    Chang H, Xiao X, Li M. “The schizophrenia risk gene ZNF804A: clinical associations, biological mechanisms and neuronal functions.” Molecular psychiatry (2017). PMID: 28289284 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors
  267. [267]

    Delhaye S, Bardoni B. “Role of phosphodiesterases in the pathophysiology of neurodevelopmental disorders.” Molecular psychiatry (2021). PMID: 33414502 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment
  268. [268]

    Deary V, Hagenaars SP, Harris SE et al.. “Genetic contributions to self-reported tiredness.” Molecular psychiatry (2017). PMID: 28194004 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Special Populations, Pregnancy and Perinatal Psychiatry
  269. [269]

    Howes OD, McCutcheon R, Agid O et al.. “Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.” The American journal of psychiatry (2016). PMID: 27919182 ↗

    L1SR_OBSCited in: Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  270. [270]

    Helfer B, Samara MT, Huhn M et al.. “Efficacy and Safety of Antidepressants Added to Antipsychotics for Schizophrenia: A Systematic Review and Meta-Analysis.” The American journal of psychiatry (2016). PMID: 27282362 ↗

    L1SR_OBSCited in: Clinical Presentation
  271. [271]

    Zhao G, Sun Y, Zhang Y et al.. “Efficacy and Tolerability of Seven Antipsychotic Drugs in Acutely Ill Patients With Schizophrenia: A Randomized, Multicenter, Assessor-Blinded Trial.” The American journal of psychiatry (2025). PMID: 41152254 ↗

    L1RCTCited in: Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Acute Management and Psychiatric Emergencies, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment, Prognosis and Natural History, Special Populations, Pregnancy and Perinatal Psychiatry
  272. [272]

    Pillinger T, McCutcheon RA, Vano L et al.. “Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis.” The lancet. Psychiatry (2019). PMID: 31860457 ↗

    L1SR_OBSCited in: Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Acute Management and Psychiatric Emergencies, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  273. [273]

    Riehle M, Straková A, Lincoln TM. “Emotional Experience of People With Schizophrenia and People at Risk for Psychosis: A Meta-Analysis.” JAMA psychiatry (2024). PMID: 37755868 ↗

    L1SR_OBSCited in: Clinical Presentation
  274. [274]

    Penney D, Sauvé G, Mendelson D et al.. “Immediate and Sustained Outcomes and Moderators Associated With Metacognitive Training for Psychosis: A Systematic Review and Meta-analysis.” JAMA psychiatry (2022). PMID: 35320347 ↗

    L1SR_OBSCited in: Clinical Presentation
  275. [275]

    Siskind D, Baker A, Arnautovska U et al.. “Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator- blinded, randomised controlled trial in Australia.” The lancet. Psychiatry (2025). PMID: 40506208 ↗

    L1RCTCited in: Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment, Prognosis and Natural History, Special Populations, Pregnancy and Perinatal Psychiatry
  276. [276]

    Barkham M, Saxon D, Hardy GE et al.. “Person-centred experiential therapy versus cognitive behavioural therapy delivered in the English Improving Access to Psychological Therapies service for the treatment of moderate or severe depression (PRaCTICED): a pragmatic, randomised, non-inferiority trial.” The lancet. Psychiatry (2021). PMID: 34000240 ↗

    L1RCTCited in: Clinical Presentation, Severity, Course Specifiers and Risk Stratification, Acute Management and Psychiatric Emergencies, History and Evolution of Treatment
  277. [277]

    Plewnia C, Brendel B, Schwippel T et al.. “Theta burst stimulation of temporo-parietal cortex regions for the treatment of persistent auditory hallucinations: a multicentre, randomised, sham-controlled, triple-blind phase 3 trial in Germany.” The lancet. Psychiatry (2025). PMID: 40774272 ↗

    L1RCTCited in: Clinical Presentation, History and Evolution of Treatment
  278. [278]

    Ganeshalingam AA, Uhrenholt N, Arnfred S et al.. “Semaglutide Treatment of Antipsychotic-Treated Patients With Schizophrenia, Prediabetes, and Obesity: The HISTORI Randomized Clinical Trial.” JAMA psychiatry (2025). PMID: 40900607 ↗

    L1RCTCited in: Clinical Presentation, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment, Special Populations, Pregnancy and Perinatal Psychiatry
  279. [279]

    Larsen JR, Vedtofte L, Jakobsen MSL et al.. “Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial.” JAMA psychiatry (2017). PMID: 28601891 ↗

    L1RCTCited in: Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), History and Evolution of Treatment, Complications, Comorbidity and Iatrogenic Harm
  280. [280]

    Walther S, Alexaki D, Weiss F et al.. “Psychomotor Slowing in Psychosis and Inhibitory Repetitive Transcranial Magnetic Stimulation: A Randomized Clinical Trial.” JAMA psychiatry (2024). PMID: 38416468 ↗

    L1RCTCited in: Clinical Presentation, History and Evolution of Treatment
  281. [281]

    Daumit GL, Dickerson FB, Wang NY et al.. “A behavioral weight-loss intervention in persons with serious mental illness.” The New England journal of medicine (2013). PMID: 23517118 ↗

    L1RCTCited in: Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment
  282. [282]

    Szöke A, Trandafir A, Dupont ME et al.. “Longitudinal studies of cognition in schizophrenia: meta-analysis.” The British journal of psychiatry : the journal of mental science (2008). PMID: 18378982 ↗

    L1SR_OBSCited in: Clinical Presentation, Prognosis and Natural History
  283. [283]

    Jauhar S, McKenna PJ, Radua J et al.. “Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias.” The British journal of psychiatry : the journal of mental science (2014). PMID: 24385461 ↗

    L1SR_OBSCited in: Clinical Presentation
  284. [284]

    Hutton P, Taylor PJ, Mulligan L et al.. “Quetiapine immediate release v. placebo for schizophrenia: systematic review, meta-analysis and reappraisal.” The British journal of psychiatry : the journal of mental science (2015). PMID: 25934300 ↗

    L1SR_OBSCited in: Clinical Presentation, Prognosis and Natural History
  285. [285]

    Siafis S, Brandt L, McCutcheon RA et al.. “Relapse in clinically stable adult patients with schizophrenia or schizoaffective disorder: evidence-based criteria derived by equipercentile linking and diagnostic test accuracy meta-analysis.” The lancet. Psychiatry (2023). PMID: 38043562 ↗

    L1SR_OBSCited in: Clinical Presentation
  286. [286]

    Birnbaum R, Mahjani B, Loos RJF et al.. “Clinical Characterization of Copy Number Variants Associated With Neurodevelopmental Disorders in a Large-scale Multiancestry Biobank.” JAMA psychiatry (2022). PMID: 35080590 ↗

    L4SR_OBSCited in: Clinical Presentation
  287. [287]

    Furukawa TA, Levine SZ, Tanaka S et al.. “Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.” JAMA psychiatry (2015). PMID: 25372935 ↗

    L1SR_OBSCited in: Clinical Presentation, Acute Management and Psychiatric Emergencies, History and Evolution of Treatment
  288. [288]

    Wu RR, Zhao JP, Jin H et al.. “Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial.” JAMA (2008). PMID: 18182600 ↗

    L1RCTCited in: Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment
  289. [289]

    McEvoy JP, Byerly M, Hamer RM et al.. “Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial.” JAMA (2014). PMID: 24846035 ↗

    L1RCTCited in: Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Acute Management and Psychiatric Emergencies, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment, Complications, Comorbidity and Iatrogenic Harm, Prognosis and Natural History
  290. [290]

    Leucht S, Corves C, Arbter D et al.. “Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis.” Lancet (London, England) (2008). PMID: 19058842 ↗

    L1SR_OBSCited in: Clinical Presentation, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  291. [291]

    Corlett PR, Fraser KM. “20 Years of Aberrant Salience in Psychosis: What Have We Learned?” The American journal of psychiatry (2025). PMID: 40134268 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  292. [292]

    Tampi RR, Jeste DV. “Dementia Is More Than Memory Loss: Neuropsychiatric Symptoms of Dementia and Their Nonpharmacological and Pharmacological Management.” The American journal of psychiatry (2022). PMID: 35921394 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Complications, Comorbidity and Iatrogenic Harm
  293. [293]

    Ferrarelli F. “Sleep Abnormalities in Schizophrenia: State of the Art and Next Steps.” The American journal of psychiatry (2021). PMID: 33726524 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  294. [294]

    Morgan VA, Leonard H, Bourke J et al.. “Intellectual disability co-occurring with schizophrenia and other psychiatric illness: population-based study.” The British journal of psychiatry : the journal of mental science (2008). PMID: 18978313 ↗

    L4SR_OBSCited in: Clinical Presentation
  295. [295]

    Cui Y, Sun J, Zhang B et al.. “Efficacy and safety of transcutaneous auricular vagus nerve stimulation for patients with treatment-resistant schizophrenia with predominantly negative symptoms: a randomized clinical trial and efficacy sensitivity biomarkers.” Molecular psychiatry (2025). PMID: 40858781 ↗

    L1RCTCited in: Clinical Presentation, Severity, Course Specifiers and Risk Stratification, History and Evolution of Treatment, Prognosis and Natural History
  296. [296]

    Galderisi S, Mucci A, Buchanan RW et al.. “Negative symptoms of schizophrenia: new developments and unanswered research questions.” The lancet. Psychiatry (2018). PMID: 29602739 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), History and Evolution of Treatment
  297. [297]

    Howes OD, Murray RM. “Schizophrenia: an integrated sociodevelopmental-cognitive model.” Lancet (London, England) (2013). PMID: 24315522 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  298. [298]

    Iob E, Pingault JB, Munafò MR et al.. “Testing the causal relationships of physical activity and sedentary behaviour with mental health and substance use disorders: a Mendelian randomisation study.” Molecular psychiatry (2023). PMID: 37479783 ↗

    L4SR_OBSCited in: Clinical Presentation
  299. [299]

    DeMichele-Sweet MAA, Klei L, Creese B et al.. “Genome-wide association identifies the first risk loci for psychosis in Alzheimer disease.” Molecular psychiatry (2021). PMID: 34112972 ↗

    L3SR_OBSCited in: Clinical Presentation
  300. [300]

    Werneke U, Turner T, Priebe S. “Complementary medicines in psychiatry: review of effectiveness and safety.” The British journal of psychiatry : the journal of mental science (2006). PMID: 16449696 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Psychopharmacology Monitoring and Safety Surveillance
  301. [301]

    Kirkpatrick B, Galderisi S. “Deficit schizophrenia: an update.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2008). PMID: 18836581 ↗

    L5OTHERCited in: Clinical Presentation, Prognosis and Natural History
  302. [302]

    Hsu M, Shah A, Jordan A et al.. “Therapeutic Use of Cannabis and Cannabinoids: A Review.” JAMA (2026). PMID: 41296368 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Acute Management and Psychiatric Emergencies
  303. [303]

    Moran LV, Skinner JP, Shinn AK et al.. “Risk of Incident Psychosis and Mania With Prescription Amphetamines.” The American journal of psychiatry (2024). PMID: 39262211 ↗

    L3OTHERCited in: Clinical Presentation, Special Populations, Pregnancy and Perinatal Psychiatry, Prevention, Screening and Early Intervention
  304. [304]

    Brady RO, Gonsalvez I, Lee I et al.. “Cerebellar-Prefrontal Network Connectivity and Negative Symptoms in Schizophrenia.” The American journal of psychiatry (2019). PMID: 30696271 ↗

    L4OTHERCited in: Clinical Presentation
  305. [305]

    Guaiana G, Abbatecola M, Aali G et al.. “Cognitive behavioural therapy (group) for schizophrenia.” The Cochrane database of systematic reviews (2022). PMID: 35866377 ↗

    L1SR_OBSCited in: Clinical Presentation, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Prevention, Screening and Early Intervention
  306. [306]

    Agarwal SM, Stogios N, Ahsan ZA et al.. “Pharmacological interventions for prevention of weight gain in people with schizophrenia.” The Cochrane database of systematic reviews (2022). PMID: 36190739 ↗

    L1SR_OBSCited in: Clinical Presentation, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Complications, Comorbidity and Iatrogenic Harm
  307. [307]

    Koch K, Mansi K, Haynes E et al.. “Trifluoperazine versus placebo for schizophrenia.” The Cochrane database of systematic reviews (2014). PMID: 24414883 ↗

    L1SR_OBSCited in: Clinical Presentation, Complications, Comorbidity and Iatrogenic Harm
  308. [308]

    Every-Palmer S, Newton-Howes G, Clarke MJ. “Pharmacological treatment for antipsychotic-related constipation.” The Cochrane database of systematic reviews (2017). PMID: 28116777 ↗

    L1SR_OBSCited in: Clinical Presentation, Complications, Comorbidity and Iatrogenic Harm, Prognosis and Natural History
  309. [309]

    Sinclair DJ, Zhao S, Qi F et al.. “Electroconvulsive therapy for treatment-resistant schizophrenia.” The Cochrane database of systematic reviews (2019). PMID: 30888709 ↗

    L1SR_OBSCited in: Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Prognosis and Natural History
  310. [310]

    Mollon J, Almasy L, Jacquemont S et al.. “The contribution of copy number variants to psychiatric symptoms and cognitive ability.” Molecular psychiatry (2023). PMID: 36737482 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  311. [311]

    Bloch-Gallego E, Anderson DI. “Key role of Rho GTPases in motor disorders associated with neurodevelopmental pathologies.” Molecular psychiatry (2022). PMID: 35918397 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  312. [312]

    Jablensky A. “Subtyping schizophrenia: implications for genetic research.” Molecular psychiatry (2006). PMID: 16801952 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  313. [313]

    Crowley S, McDonagh S, O'Riain C et al.. “Does Sex Affect Antipsychotic-Induced Weight Gain in Patients Being Treated for Psychotic Disorders: A Systematic Review and Meta-analysis.” Schizophrenia bulletin (2026). PMID: 42241483 ↗

    L2SR_OBSCited in: Clinical Presentation, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  314. [314]

    Kyte S, Bukovsky D, Song J et al.. “Virtual Reality for the Treatment of Auditory Hallucinations in Schizophrenia Spectrum Disorders: a Systematic Review and Meta-Analysis.” Schizophrenia bulletin (2026). PMID: 42084440 ↗

    L1SR_OBSCited in: Clinical Presentation
  315. [315]

    Simonsson O, Mosing MA, Osika W et al.. “Adolescent Psychedelic Use and Psychotic or Manic Symptoms.” JAMA psychiatry (2024). PMID: 38477889 ↗

    L2OTHERCited in: Clinical Presentation
  316. [316]

    Hamdan FF, Gauthier J, Spiegelman D et al.. “Mutations in SYNGAP1 in autosomal nonsyndromic mental retardation.” The New England journal of medicine (2009). PMID: 19196676 ↗

    L4OTHERCited in: Clinical Presentation, Special Populations, Pregnancy and Perinatal Psychiatry
  317. [317]

    Lorente-Rovira E, Luengo A, Barrigón ML et al.. “Randomized Controlled Trial on the Effects of Metacognitive Training (MCT) in a Sample of Patients With Recent Onset Psychosis: Study of the Impact on the Severity and Dimensions of Delusions, Self-Esteem and Depression.” Clinical psychology & psychotherapy (2026). PMID: 42152571 ↗

    L1RCTCited in: Clinical Presentation, Prognosis and Natural History
  318. [318]

    Rodriguez-Cabo B, Armanino M, Puges AG et al.. “Adult catatonia: Prospective cohort study in a Spanish general hospital.” General hospital psychiatry (2026). PMID: 42139810 ↗

    L2COHORTCited in: Clinical Presentation, Complications, Comorbidity and Iatrogenic Harm, Special Populations, Pregnancy and Perinatal Psychiatry
  319. [319]

    Wu G, Shen M, Lin Y et al.. “Effects of fronto-occipital transcranial alternating current stimulation for treating schizophrenia with prominent negative symptoms: A double-blind, randomized, sham-controlled trial.” Psychiatry research (2026). PMID: 42114330 ↗

    L1RCTCited in: Clinical Presentation
  320. [320]

    Wong SY, Chan SC, Mo YF et al.. “Effects of Empagliflozin and Lifestyle Intervention on Improving Body Weight and Other Metabolic Parameters in Atypical Antipsychotics-treated Patients with Schizophrenia Spectrum Disorders-A Double-blind Randomized Placebo-controlled Trial.” Schizophrenia bulletin (2026). PMID: 42104798 ↗

    L1RCTCited in: Clinical Presentation, Complications, Comorbidity and Iatrogenic Harm
  321. [321]

    Chinman M, Wang T, Dodge JR et al.. “Predictors of Weight Loss Among Adults With Mental Illness: A Secondary Analysis of a Randomized Clinical Trial.” Psychiatric services (Washington, D.C.) (2026). PMID: 42087320 ↗

    L2RCTCited in: Clinical Presentation
  322. [322]

    Hall J. “Schizophrenia - an anxiety disorder?” The British journal of psychiatry : the journal of mental science (2017). PMID: 29092833 ↗

    L5OTHERCited in: Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Prevention, Screening and Early Intervention
  323. [323]

    Luhrmann TM, Padmavati R, Tharoor H et al.. “Differences in voice-hearing experiences of people with psychosis in the U.S.A., India and Ghana: interview-based study.” The British journal of psychiatry : the journal of mental science (2014). PMID: 24970772 ↗

    L4OTHERCited in: Clinical Presentation
  324. [324]

    Valli I, Fabbri C, Young AH. “Uncovering neurodevelopmental features in bipolar affective disorder.” The British journal of psychiatry : the journal of mental science (2019). PMID: 31113507 ↗

    L5OTHERCited in: Clinical Presentation
  325. [325]

    Kohrt BA, Jordans MJ, Tol WA et al.. “Comparison of mental health between former child soldiers and children never conscripted by armed groups in Nepal.” JAMA (2008). PMID: 18698067 ↗

    L3OTHERCited in: Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Special Populations, Pregnancy and Perinatal Psychiatry
  326. [326]

    Correll CU, Manu P, Olshanskiy V et al.. “Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.” JAMA (2009). PMID: 19861668 ↗

    L2OTHERCited in: Clinical Presentation, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Special Populations, Pregnancy and Perinatal Psychiatry
  327. [327]

    Kummeling J, Stremmelaar DE, Raun N et al.. “Characterization of SETD1A haploinsufficiency in humans and Drosophila defines a novel neurodevelopmental syndrome.” Molecular psychiatry (2020). PMID: 32346159 ↗

    L4OTHERCited in: Clinical Presentation, Special Populations, Pregnancy and Perinatal Psychiatry
  328. [328]

    Ciulkinyte A, Mountford HS, Fontanillas P et al.. “Genetic neurodevelopmental clustering and dyslexia.” Molecular psychiatry (2024). PMID: 39009701 ↗

    L3OTHERCited in: Clinical Presentation
  329. [329]

    Moore TR, Almeyda TD, Silberman EK et al.. “Catatonia Associated with Psychosis: A Retrospective Study of 164 Inpatients.” Psychopharmacology bulletin (2026). PMID: 42267244 ↗

    L4COHORTCited in: Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Prognosis and Natural History
  330. [330]

    Dolati A, Ahmadimoghaddam D, Zamanirafe M et al.. “Empagliflozin as an Alternative to Metformin for Antipsychotic-Related Weight Gain: Double-Blind Randomized Controlled Trial.” Human psychopharmacology (2026). PMID: 42135901 ↗

    L1RCTCited in: Clinical Presentation
  331. [331]

    Yu Y, Ge R, Frangou S. “Neuroimaging-Based Subgroups in Schizophrenia: A Critical Appraisal of Clustering Studies.” Biological psychiatry global open science (2026). PMID: 42318040 ↗

    L2REVIEW_NARRATIVECited in: Clinical Presentation
  332. [332]

    Stanghellini G, Langer AI, Ambrosini A et al.. “Quality of hallucinatory experiences: differences between a clinical and a non-clinical sample.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2012). PMID: 22654943 ↗

    L3OTHERCited in: Clinical Presentation
  333. [333]

    Leucht S, Leucht C, Huhn M et al.. “Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors.” The American journal of psychiatry (2017). PMID: 28541090 ↗

    L1SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Acute Management and Psychiatric Emergencies, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Complications, Comorbidity and Iatrogenic Harm, Prognosis and Natural History
  334. [334]

    Horan WP, Sauder C, Harvey PD et al.. “The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Two Phase 3 Trials.” The American journal of psychiatry (2024). PMID: 39659157 ↗

    L1RCTCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Acute Management and Psychiatric Emergencies, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment, Prognosis and Natural History
  335. [335]

    Gallucci J, Yu JC, Oliver LD et al.. “Neural Circuitry and Therapeutic Targeting of Depressive Symptoms in Schizophrenia Spectrum Disorders.” The American journal of psychiatry (2024). PMID: 39350625 ↗

    L4RCTCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), History and Evolution of Treatment
  336. [336]

    Bighelli I, Rodolico A, García-Mieres H et al.. “Psychosocial and psychological interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis.” The lancet. Psychiatry (2021). PMID: 34653393 ↗

    L1SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Prognosis and Natural History, Prevention, Screening and Early Intervention
  337. [337]

    Kishimoto T, Hagi K, Kurokawa S et al.. “Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies.” The lancet. Psychiatry (2021). PMID: 33862018 ↗

    L2SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Prognosis and Natural History
  338. [338]

    Salahuddin NH, Schütz A, Pitschel-Walz G et al.. “Psychological and psychosocial interventions for treatment-resistant schizophrenia: a systematic review and network meta-analysis.” The lancet. Psychiatry (2024). PMID: 38879276 ↗

    L1SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Prognosis and Natural History, Prevention, Screening and Early Intervention
  339. [339]

    Skapinakis P, Caldwell DM, Hollingworth W et al.. “Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis.” The lancet. Psychiatry (2016). PMID: 27318812 ↗

    L1SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Prognosis and Natural History
  340. [340]

    Schneider-Thoma J, Hamza T, Chalkou K et al.. “Efficacy of clozapine versus second-generation antipsychotics in people with treatment-resistant schizophrenia: a systematic review and individual patient data meta-analysis.” The lancet. Psychiatry (2025). PMID: 40023172 ↗

    L1SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Prognosis and Natural History
  341. [341]

    Correll CU, Galling B, Pawar A et al.. “Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis: A Systematic Review, Meta-analysis, and Meta-regression.” JAMA psychiatry (2018). PMID: 29800949 ↗

    L1SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Prevention, Screening and Early Intervention
  342. [342]

    Huhn M, Nikolakopoulou A, Schneider-Thoma J et al.. “Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis.” Lancet (London, England) (2019). PMID: 31303314 ↗

    L1SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Acute Management and Psychiatric Emergencies, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Prognosis and Natural History
  343. [343]

    Schneider-Thoma J, Chalkou K, Dörries C et al.. “Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis.” Lancet (London, England) (2022). PMID: 35219395 ↗

    L1SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Prognosis and Natural History
  344. [344]

    Moncrieff J, Crellin N, Stansfeld J et al.. “Antipsychotic dose reduction and discontinuation versus maintenance treatment in people with schizophrenia and other recurrent psychotic disorders in England (the RADAR trial): an open, parallel-group, randomised controlled trial.” The lancet. Psychiatry (2023). PMID: 37778356 ↗

    L1RCTCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment, Prognosis and Natural History, Special Populations, Pregnancy and Perinatal Psychiatry
  345. [345]

    Kaul I, Sawchak S, Walling DP et al.. “Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial.” JAMA psychiatry (2024). PMID: 38691387 ↗

    L1RCTCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Acute Management and Psychiatric Emergencies, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment, Prognosis and Natural History
  346. [346]

    Leffa DT, Grevet EH, Bau CHD et al.. “Transcranial Direct Current Stimulation vs Sham for the Treatment of Inattention in Adults With Attention-Deficit/Hyperactivity Disorder: The TUNED Randomized Clinical Trial.” JAMA psychiatry (2022). PMID: 35921102 ↗

    L1RCTCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), History and Evolution of Treatment, Prognosis and Natural History
  347. [347]

    Li X, Lu C, Zhai Z et al.. “Clozapine After 1 Failed Antipsychotic Drug Trial in First-Episode Psychosis: A Randomized Clinical Trial.” JAMA psychiatry (2026). PMID: 41811299 ↗

    L1RCTCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment, Prognosis and Natural History, Special Populations, Pregnancy and Perinatal Psychiatry
  348. [348]

    Kaul I, Sawchak S, Correll CU et al.. “Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.” Lancet (London, England) (2023). PMID: 38104575 ↗

    L1RCTCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Acute Management and Psychiatric Emergencies, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment, Prognosis and Natural History
  349. [349]

    Németh G, Laszlovszky I, Czobor P et al.. “Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial.” Lancet (London, England) (2017). PMID: 28185672 ↗

    L1RCTCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment, Prognosis and Natural History
  350. [350]

    Marwick KFM, Stevenson AJ, Davies C et al.. “Application of n-of-1 treatment trials in schizophrenia: systematic review.” The British journal of psychiatry : the journal of mental science (2018). PMID: 29745363 ↗

    L4SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Prognosis and Natural History
  351. [351]

    El-Sayeh HG, Morganti C, Adams CE. “Aripiprazole for schizophrenia. Systematic review.” The British journal of psychiatry : the journal of mental science (2006). PMID: 16880478 ↗

    L1SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Prognosis and Natural History
  352. [352]

    Kambeitz J, Abi-Dargham A, Kapur S et al.. “Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies.” The British journal of psychiatry : the journal of mental science (2014). PMID: 25029687 ↗

    L3SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
  353. [353]

    Komatsu H, Onoguchi G, Silverstein SM et al.. “Retina as a potential biomarker in schizophrenia spectrum disorders: a systematic review and meta-analysis of optical coherence tomography and electroretinography.” Molecular psychiatry (2023). PMID: 38081943 ↗

    L3SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
  354. [354]

    Aymerich C, Salazar de Pablo G, Pacho M et al.. “All-cause mortality risk in long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis.” Molecular psychiatry (2024). PMID: 39174648 ↗

    L2SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Risk and Safety Assessment, Capacity and Therapeutic Setting, Complications, Comorbidity and Iatrogenic Harm
  355. [355]

    Rajji TK, Ismail Z, Mulsant BH. “Age at onset and cognition in schizophrenia: meta-analysis.” The British journal of psychiatry : the journal of mental science (2009). PMID: 19794194 ↗

    L3SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Special Populations, Pregnancy and Perinatal Psychiatry
  356. [356]

    Kang J, Lee H, Yu S et al.. “Effects and safety of transcranial direct current stimulation on multiple health outcomes: an umbrella review of randomized clinical trials.” Molecular psychiatry (2024). PMID: 38816583 ↗

    L1SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Prognosis and Natural History
  357. [357]

    Keefe RS. “Should cognitive impairment be included in the diagnostic criteria for schizophrenia?” World psychiatry : official journal of the World Psychiatric Association (WPA) (2008). PMID: 18458774 ↗

    L5OTHERCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
  358. [358]

    Philip NS, Nelson BG, Frohlich F et al.. “Low-Intensity Transcranial Current Stimulation in Psychiatry.” The American journal of psychiatry (2017). PMID: 28231716 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), History and Evolution of Treatment, Prognosis and Natural History
  359. [359]

    Fenton M, Rathbone J, Reilly J et al.. “Thioridazine for schizophrenia.” The Cochrane database of systematic reviews (2007). PMID: 17636691 ↗

    L1SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Prognosis and Natural History
  360. [360]

    Ortiz-Orendain J, Castiello-de Obeso S, Colunga-Lozano LE et al.. “Antipsychotic combinations for schizophrenia.” The Cochrane database of systematic reviews (2017). PMID: 28658515 ↗

    L1SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Prognosis and Natural History
  361. [361]

    Hay A, Byers A, Sereno M et al.. “Asenapine versus placebo for schizophrenia.” The Cochrane database of systematic reviews (2015). PMID: 26599405 ↗

    L1SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Prognosis and Natural History
  362. [362]

    Zare M, Bazrafshan A. “Chlorpromazine versus metiapine for schizophrenia.” The Cochrane database of systematic reviews (2017). PMID: 28349512 ↗

    L1SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Prognosis and Natural History
  363. [363]

    Soares-Weiser K, Maayan N, Bergman H et al.. “First rank symptoms for schizophrenia.” The Cochrane database of systematic reviews (2015). PMID: 25879096 ↗

    L3SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, History and Evolution of Treatment, Special Populations, Pregnancy and Perinatal Psychiatry, Prevention, Screening and Early Intervention
  364. [364]

    Adams CE, Bergman H, Irving CB et al.. “Haloperidol versus placebo for schizophrenia.” The Cochrane database of systematic reviews (2013). PMID: 24242360 ↗

    L1SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Acute Management and Psychiatric Emergencies
  365. [365]

    Marshall M, Rathbone J. “Early intervention for psychosis.” The Cochrane database of systematic reviews (2006). PMID: 17054213 ↗

    L1SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
  366. [366]

    Bosnjak Kuharic D, Kekin I, Hew J et al.. “Interventions for prodromal stage of psychosis.” The Cochrane database of systematic reviews (2019). PMID: 31689359 ↗

    L1SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
  367. [367]

    Marshall M, Rathbone J. “Early intervention for psychosis.” The Cochrane database of systematic reviews (2011). PMID: 21678345 ↗

    L1SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Risk and Safety Assessment, Capacity and Therapeutic Setting
  368. [368]

    Datta SS, Daruvala R, Kumar A. “Psychological interventions for psychosis in adolescents.” The Cochrane database of systematic reviews (2020). PMID: 32633858 ↗

    L1SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Special Populations, Pregnancy and Perinatal Psychiatry
  369. [369]

    Samara MT, Klupp E, Helfer B et al.. “Increasing antipsychotic dose for non response in schizophrenia.” The Cochrane database of systematic reviews (2018). PMID: 29750432 ↗

    L1SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
  370. [370]

    Palaniyappan L, Maayan N, Bergman H et al.. “Voxel-based morphometry for separation of schizophrenia from other types of psychosis in first episode psychosis.” The Cochrane database of systematic reviews (2015). PMID: 26252640 ↗

    L3SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
  371. [371]

    Sampford JR, Sampson S, Li BG et al.. “Fluphenazine (oral) versus atypical antipsychotics for schizophrenia.” The Cochrane database of systematic reviews (2016). PMID: 27370402 ↗

    L1SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
  372. [372]

    Sousa V, Mazer P, Gomes A et al.. “N170 and N250 in schizophrenia spectrum disorder: systematic review and meta-analysis.” The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry (2026). PMID: 42251651 ↗

    L3SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
  373. [373]

    Siskind D, Northwood K, Pillinger T et al.. “Absolute neutrophil count and adverse drug reaction monitoring during clozapine treatment: consensus guidelines from a global Delphi panel.” The lancet. Psychiatry (2025). PMID: 40617246 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  374. [374]

    Tiihonen J, Mittendorfer-Rutz E, Majak M et al.. “Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia.” JAMA psychiatry (2017). PMID: 28593216 ↗

    L2OTHERCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Prognosis and Natural History, Special Populations, Pregnancy and Perinatal Psychiatry
  375. [375]

    Herzog S, Bartlett EA, Zanderigo F et al.. “Neuroinflammation, Stress-Related Suicidal Ideation, and Negative Mood in Depression.” JAMA psychiatry (2025). PMID: 39504032 ↗

    L3OTHERCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Acute Management and Psychiatric Emergencies, Risk and Safety Assessment, Capacity and Therapeutic Setting
  376. [376]

    Tiihonen J, Taipale H, Mehtälä J et al.. “Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia.” JAMA psychiatry (2019). PMID: 30785608 ↗

    L2OTHERCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Complications, Comorbidity and Iatrogenic Harm, Prognosis and Natural History
  377. [377]

    Araujo GB, Nicolau CAM, Maladogi BM et al.. “Impact of Structured Physical Exercise Programs (SPEs) on Symptoms and Clinical Outcomes in Schizophrenia: A Systematic Review With Qualitative Synthesis of Randomized Controlled Trials (2015-2025).” Actas espanolas de psiquiatria (2026). PMID: 42343729 ↗

    L1SR_MA_RCTCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Prognosis and Natural History
  378. [378]

    Craddock N, Sklar P. “Genetics of bipolar disorder.” Lancet (London, England) (2013). PMID: 23663951 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Risk and Safety Assessment, Capacity and Therapeutic Setting
  379. [379]

    Jones I, Chandra PS, Dazzan P et al.. “Bipolar disorder, affective psychosis, and schizophrenia in pregnancy and the post-partum period.” Lancet (London, England) (2014). PMID: 25455249 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Risk and Safety Assessment, Capacity and Therapeutic Setting, Special Populations, Pregnancy and Perinatal Psychiatry
  380. [380]

    Bøgh Jacobsen N, Nørgaard B, Marcussen M. “Caregiver burden among relatives of individuals with severe mental illness: a qualitative systematic review.” Nordic journal of psychiatry (2026). PMID: 42312619 ↗

    L5SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
  381. [381]

    Legge SE, Dennison CA, Pardiñas AF et al.. “Clinical indicators of treatment-resistant psychosis.” The British journal of psychiatry : the journal of mental science (2020). PMID: 31155017 ↗

    L2OTHERCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment, Prognosis and Natural History
  382. [382]

    Ando V, Claridge G, Clark K. “Psychotic traits in comedians.” The British journal of psychiatry : the journal of mental science (2014). PMID: 24434072 ↗

    L4OTHERCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Special Populations, Pregnancy and Perinatal Psychiatry
  383. [383]

    Kirkpatrick B, Luther L, Strauss GP. “Negative symptoms in the clinic: we treat what we can describe.” The British journal of psychiatry : the journal of mental science (2023). PMID: 37424200 ↗

    L5OTHERCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
  384. [384]

    Fernandez-Egea E, McCutcheon RA. “Clozapine monitoring requirements: is it time for an update?” The British journal of psychiatry : the journal of mental science (2025). PMID: 39359180 ↗

    L5OTHERCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  385. [385]

    Zanetti MV, Schaufelberger MS, de Castro CC et al.. “White-matter hyperintensities in first-episode psychosis.” The British journal of psychiatry : the journal of mental science (2008). PMID: 18700214 ↗

    L3OTHERCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
  386. [386]

    Curtis D, Adlington K, Bhui KS. “Pursuing parity: genetic tests for psychiatric conditions in the UK National Health Service.” The British journal of psychiatry : the journal of mental science (2019). PMID: 30900968 ↗

    L5OTHERCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
  387. [387]

    Treur JL, Thijssen AB, Smit DJA et al.. “Associations of schizophrenia with arrhythmic disorders and electrocardiogram traits: genetic exploration of population samples.” The British journal of psychiatry : the journal of mental science (2024). PMID: 39512114 ↗

    L2OTHERCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
  388. [388]

    Xiao Y, Meng Y, Brown TT et al.. “Addictive Screen Use Trajectories and Suicidal Behaviors, Suicidal Ideation, and Mental Health in US Youths.” JAMA (2025). PMID: 40531519 ↗

    L2OTHERCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Risk and Safety Assessment, Capacity and Therapeutic Setting, Special Populations, Pregnancy and Perinatal Psychiatry
  389. [389]

    Owen MJ, Legge SE, Rees E et al.. “Genomic findings in schizophrenia and their implications.” Molecular psychiatry (2023). PMID: 37853064 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Special Populations, Pregnancy and Perinatal Psychiatry
  390. [390]

    Chen S, Tan Y, Tian L. “Immunophenotypes in psychosis: is it a premature inflamm-aging disorder?” Molecular psychiatry (2024). PMID: 38532012 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
  391. [391]

    Horwitz T, Lam K, Chen Y et al.. “A decade in psychiatric GWAS research.” Molecular psychiatry (2018). PMID: 29942042 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), History and Evolution of Treatment
  392. [392]

    Wolff A, Northoff G. “Temporal imprecision of phase coherence in schizophrenia and psychosis-dynamic mechanisms and diagnostic marker.” Molecular psychiatry (2024). PMID: 38228893 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
  393. [393]

    Bladon S, Ainsworth J, Cahuantzi R et al.. “Evaluating Wearable Devices for Remote Monitoring in Psychosis: Pilot Study Nested Within the CONNECT Cohort Study.” JMIR formative research (2026). PMID: 42413039 ↗

    L2COHORTCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
  394. [394]

    Ragalmuto FGM, Oranje B, Ziermans T. “Basic sensory risk markers characteristic of schizophrenia in autism spectrum disorder: A systematic review and meta-analysis.” Neuroscience and biobehavioral reviews (2026). PMID: 42167419 ↗

    L3SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
  395. [395]

    Xiong Y, Zhang Y, Hua H et al.. “Differential Effects of Morning Versus Afternoon Accelerated High-Frequency Repetitive Transcranial Magnetic Stimulation on Sleep Outcomes in Hospitalised Patients With Schizophrenia: Retrospective Cohort Study.” Actas espanolas de psiquiatria (2026). PMID: 42343718 ↗

    L3COHORTCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Prognosis and Natural History
  396. [396]

    Bellanti A, Volkmer S, Altinok DCA et al.. “Replicable subcortical alterations linked to neurological soft signs in schizophrenia spectrum disorders.” Psychological medicine (2026). PMID: 42402909 ↗

    L3OTHERCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
  397. [397]

    Korošec Hudnik L, Kosmačin I, Pjevac M et al.. “Dopamine supersensitivity psychosis: a critical evaluation of diagnostic validators.” Journal of neural transmission (Vienna, Austria : 1996) (2026). PMID: 42397413 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
  398. [398]

    Northoff G, Hua J, Ge X. “Dynamics of thoughts-novel candidate marker for differential-diagnosis of mental disorders?” Journal of psychiatry & neuroscience : JPN (2026). PMID: 42390033 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
  399. [399]

    Pérez-Ramos A, Plasse J, Chéreau-Boudet I et al.. “Mapping personal recovery in schizophrenia spectrum disorders: an exploratory machine learning study of self-reported stage classifications.” Frontiers in public health (2026). PMID: 42375587 ↗

    L4OTHERCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
  400. [400]

    Ciampelli S, de Boer JN, Koops S et al.. “Automated Speech-Based Modeling of Item-Level Symptom Severity in Schizophrenia.” JAMA network open (2026). PMID: 42348208 ↗

    L2OTHERCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
  401. [401]

    Morgan AJ, Ross AM, McNaught G et al.. “Stigmatising Attitudes Towards People With Depression, Bipolar Disorder, Borderline Personality, ADHD and Early and Long-Term/Untreated Schizophrenia: Representative Survey of Australian Adults.” The Medical journal of Australia (2026). PMID: 42334100 ↗

    L2OTHERCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
  402. [402]

    Nordgaard J, Revsbech R, Sæbye D et al.. “Assessing the diagnostic validity of a structured psychiatric interview in a first-admission hospital sample.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2012). PMID: 23024678 ↗

    L4OTHERCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
  403. [403]

    Kaul I, Claxton A, Sauder C et al.. “Long-Term Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia: A 52-Week Open-Label Extension Trial.” The American journal of psychiatry (2026). PMID: 41634905 ↗

    L4RCTCited in: Severity, Course Specifiers and Risk Stratification, Acute Management and Psychiatric Emergencies
  404. [404]

    Bschor T, Nagel L, Unger J et al.. “Differential Outcomes of Placebo Treatment Across 9 Psychiatric Disorders: A Systematic Review and Meta-Analysis.” JAMA psychiatry (2024). PMID: 38809560 ↗

    L1SR_OBSCited in: Severity, Course Specifiers and Risk Stratification, Prognosis and Natural History
  405. [405]

    Tseng PT, Zeng BS, Hung CM et al.. “Assessment of Noninvasive Brain Stimulation Interventions for Negative Symptoms of Schizophrenia: A Systematic Review and Network Meta-analysis.” JAMA psychiatry (2022). PMID: 35731533 ↗

    L1SR_OBSCited in: Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  406. [406]

    Vita A, Barlati S, Ceraso A et al.. “Effectiveness, Core Elements, and Moderators of Response of Cognitive Remediation for Schizophrenia: A Systematic Review and Meta-analysis of Randomized Clinical Trials.” JAMA psychiatry (2021). PMID: 33877289 ↗

    L1SR_OBSCited in: Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Prevention, Screening and Early Intervention
  407. [407]

    Correll CU, Davis RE, Weingart M et al.. “Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial.” JAMA psychiatry (2020). PMID: 31913424 ↗

    L1RCTCited in: Severity, Course Specifiers and Risk Stratification, Acute Management and Psychiatric Emergencies, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment
  408. [408]

    Tiihonen J, Tanskanen A, Mittendorfer-Rutz E et al.. “Effectiveness of clozapine augmentation with specific doses of other antipsychotics in schizophrenia: a meta-analysis from two nationwide cohorts.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2025). PMID: 40371869 ↗

    L2SR_OBSCited in: Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  409. [409]

    Hyde J, Carr H, Kelley N et al.. “Efficacy of neurostimulation across mental disorders: systematic review and meta-analysis of 208 randomized controlled trials.” Molecular psychiatry (2022). PMID: 35365806 ↗

    L1SR_MA_RCTCited in: Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  410. [410]

    Mullins N, Bigdeli TB, Børglum AD et al.. “GWAS of Suicide Attempt in Psychiatric Disorders and Association With Major Depression Polygenic Risk Scores.” The American journal of psychiatry (2019). PMID: 31164008 ↗

    L3SR_OBSCited in: Severity, Course Specifiers and Risk Stratification, Risk and Safety Assessment, Capacity and Therapeutic Setting
  411. [411]

    Woodberry KA, Giuliano AJ, Seidman LJ. “Premorbid IQ in schizophrenia: a meta-analytic review.” The American journal of psychiatry (2008). PMID: 18413704 ↗

    L2SR_OBSCited in: Severity, Course Specifiers and Risk Stratification
  412. [412]

    Knowles EE, David AS, Reichenberg A. “Processing speed deficits in schizophrenia: reexamining the evidence.” The American journal of psychiatry (2010). PMID: 20439390 ↗

    L2SR_OBSCited in: Severity, Course Specifiers and Risk Stratification
  413. [413]

    Wagner E, Korman N, Solmi M et al.. “Multidisciplinary consensus on prevention, screening and monitoring of clozapine-associated myocarditis and clozapine rechallenge after myocarditis.” The British journal of psychiatry : the journal of mental science (2025). PMID: 40452212 ↗

    L1SR_OBSCited in: Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Prevention, Screening and Early Intervention
  414. [414]

    Siskind D, Orr S, Sinha S et al.. “Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis.” The British journal of psychiatry : the journal of mental science (2022). PMID: 35049446 ↗

    L2SR_OBSCited in: Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  415. [415]

    Singh SP, Singh V, Kar N et al.. “Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis.” The British journal of psychiatry : the journal of mental science (2010). PMID: 20807960 ↗

    L1SR_OBSCited in: Severity, Course Specifiers and Risk Stratification
  416. [416]

    Govind R, Fonseca de Freitas D, Pritchard M et al.. “Clozapine treatment and risk of COVID-19 infection: retrospective cohort study.” The British journal of psychiatry : the journal of mental science (2021). PMID: 32713374 ↗

    L2COHORTCited in: Severity, Course Specifiers and Risk Stratification
  417. [417]

    Taipale H, Siskind D, Tanskanen A et al.. “Real-world effectiveness of clozapine augmentation with antidepressants: within-subject data evidence from two European nationwide cohorts.” The lancet. Psychiatry (2025). PMID: 40675714 ↗

    L2SR_OBSCited in: Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Prognosis and Natural History
  418. [418]

    Solmi M, Cortese S, Vita G et al.. “An umbrella review of candidate predictors of response, remission, recovery, and relapse across mental disorders.” Molecular psychiatry (2023). PMID: 37957292 ↗

    L2SR_OBSCited in: Severity, Course Specifiers and Risk Stratification, Prognosis and Natural History
  419. [419]

    Carr R, Cannon A, Finelli V et al.. “Non-Clozapine interventions in treatment-resistant schizophrenia: a systematic review and meta-analysis.” Molecular psychiatry (2025). PMID: 41044402 ↗

    L1SR_OBSCited in: Severity, Course Specifiers and Risk Stratification, Prognosis and Natural History
  420. [420]

    Huneke NTM, Amin J, Baldwin DS et al.. “Placebo effects in randomized trials of pharmacological and neurostimulation interventions for mental disorders: An umbrella review.” Molecular psychiatry (2024). PMID: 38914807 ↗

    L1SR_OBSCited in: Severity, Course Specifiers and Risk Stratification
  421. [421]

    Li QS, Shabalin AA, DiBlasi E et al.. “Genome-wide association study meta-analysis of suicide death and suicidal behavior.” Molecular psychiatry (2022). PMID: 36253440 ↗

    L3SR_OBSCited in: Severity, Course Specifiers and Risk Stratification, Risk and Safety Assessment, Capacity and Therapeutic Setting
  422. [422]

    Xiong Y, Krebs K, Jermy B et al.. “Genome-wide association meta-analysis and rare copy number variant analysis of treatment-resistant depression.” Molecular psychiatry (2025). PMID: 40571737 ↗

    L3SR_OBSCited in: Severity, Course Specifiers and Risk Stratification
  423. [423]

    Nakahara T, Tsugawa S, Noda Y et al.. “Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: a meta-analysis of 1H-magnetic resonance spectroscopy studies.” Molecular psychiatry (2021). PMID: 34584230 ↗

    L3SR_OBSCited in: Severity, Course Specifiers and Risk Stratification
  424. [424]

    Correll CU, Cortese S, Solmi M et al.. “Beyond symptom improvement: transdiagnostic and disorder-specific ways to assess functional and quality of life outcomes across mental disorders in adults.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2025). PMID: 40948079 ↗

    L5OTHERCited in: Severity, Course Specifiers and Risk Stratification
  425. [425]

    van Os J, Guloksuz S. “A critique of the "ultra-high risk" and "transition" paradigm.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2017). PMID: 28498576 ↗

    L5OTHERCited in: Severity, Course Specifiers and Risk Stratification, Prognosis and Natural History
  426. [426]

    Fusar-Poli P, McGorry PD, Kane JM. “Improving outcomes of first-episode psychosis: an overview.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2017). PMID: 28941089 ↗

    L5OTHERCited in: Severity, Course Specifiers and Risk Stratification, Prevention, Screening and Early Intervention
  427. [427]

    van Os J, Reininghaus U. “Psychosis as a transdiagnostic and extended phenotype in the general population.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2016). PMID: 27265696 ↗

    L5OTHERCited in: Severity, Course Specifiers and Risk Stratification
  428. [428]

    Maj M, van Os J, De Hert M et al.. “The clinical characterization of the patient with primary psychosis aimed at personalization of management.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2021). PMID: 33432763 ↗

    L5OTHERCited in: Severity, Course Specifiers and Risk Stratification, History and Evolution of Treatment, Complications, Comorbidity and Iatrogenic Harm, Prognosis and Natural History
  429. [429]

    Lysaker PH, Pattison ML, Leonhardt BL et al.. “Insight in schizophrenia spectrum disorders: relationship with behavior, mood and perceived quality of life, underlying causes and emerging treatments.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2018). PMID: 29352540 ↗

    L5OTHERCited in: Severity, Course Specifiers and Risk Stratification, History and Evolution of Treatment
  430. [430]

    Partanen JJ, Häppölä P, Kämpe A et al.. “High Burden of Ileus and Pneumonia in Clozapine-Treated Individuals With Schizophrenia: A Finnish 25-Year Follow-Up Register Study.” The American journal of psychiatry (2024). PMID: 39262212 ↗

    L2OTHERCited in: Severity, Course Specifiers and Risk Stratification, Acute Management and Psychiatric Emergencies, Psychopharmacology Monitoring and Safety Surveillance, Complications, Comorbidity and Iatrogenic Harm
  431. [431]

    Kochunov P, Huang J, Chen S et al.. “White Matter in Schizophrenia Treatment Resistance.” The American journal of psychiatry (2019). PMID: 31352812 ↗

    L3OTHERCited in: Severity, Course Specifiers and Risk Stratification
  432. [432]

    Kang J, Castro VM, Ripperger M et al.. “Genome-Wide Association Study of Treatment-Resistant Depression: Shared Biology With Metabolic Traits.” The American journal of psychiatry (2024). PMID: 38745458 ↗

    L3OTHERCited in: Severity, Course Specifiers and Risk Stratification
  433. [433]

    Rizk MM, Mann JJ. “An Update on Somatic Treatments for Suicide Risk.” The American journal of psychiatry (2026). PMID: 42219565 ↗

    L5REVIEW_NARRATIVECited in: Severity, Course Specifiers and Risk Stratification, Risk and Safety Assessment, Capacity and Therapeutic Setting, Complications, Comorbidity and Iatrogenic Harm
  434. [434]

    Schwarz C, Volz A, Li C et al.. “Valproate for schizophrenia.” The Cochrane database of systematic reviews (2008). PMID: 18646098 ↗

    L1SR_OBSCited in: Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Psychopharmacology Monitoring and Safety Surveillance
  435. [435]

    Wang Y, Xia J, Helfer B et al.. “Valproate for schizophrenia.” The Cochrane database of systematic reviews (2016). PMID: 27884042 ↗

    L1SR_OBSCited in: Severity, Course Specifiers and Risk Stratification
  436. [436]

    Sivaraman P, Rattehalli RD, Jayaram MB. “Levomepromazine for schizophrenia.” The Cochrane database of systematic reviews (2010). PMID: 20927765 ↗

    L1SR_OBSCited in: Severity, Course Specifiers and Risk Stratification
  437. [437]

    Volz A, Khorsand V, Gillies D et al.. “Benzodiazepines for schizophrenia.” The Cochrane database of systematic reviews (2007). PMID: 17253592 ↗

    L1SR_OBSCited in: Severity, Course Specifiers and Risk Stratification
  438. [438]

    Välimäki M, Lantta T, Kontio R. “Risk assessment for aggressive behaviour in schizophrenia.” The Cochrane database of systematic reviews (2024). PMID: 38695777 ↗

    L1SR_OBSCited in: Severity, Course Specifiers and Risk Stratification, Risk and Safety Assessment, Capacity and Therapeutic Setting
  439. [439]

    Belgamwar RB, El-Sayeh HG. “Aripiprazole versus placebo for schizophrenia.” The Cochrane database of systematic reviews (2011). PMID: 21833956 ↗

    L1SR_OBSCited in: Severity, Course Specifiers and Risk Stratification
  440. [440]

    Kennedy E, Kumar A, Datta SS. “Antipsychotic medication for childhood-onset schizophrenia.” The Cochrane database of systematic reviews (2007). PMID: 17636744 ↗

    L1SR_OBSCited in: Severity, Course Specifiers and Risk Stratification, Special Populations, Pregnancy and Perinatal Psychiatry
  441. [441]

    Lally J, Docherty MJ, MacCabe JH. “Pharmacological interventions for clozapine-induced sinus tachycardia.” The Cochrane database of systematic reviews (2016). PMID: 27277334 ↗

    L1SR_OBSCited in: Severity, Course Specifiers and Risk Stratification
  442. [442]

    Legge SE, Pardiñas AF, Woolway G et al.. “Genetic and Phenotypic Features of Schizophrenia in the UK Biobank.” JAMA psychiatry (2024). PMID: 38536179 ↗

    L4OTHERCited in: Severity, Course Specifiers and Risk Stratification, Special Populations, Pregnancy and Perinatal Psychiatry
  443. [443]

    Vasileva SS, Yang Y, Baker A et al.. “Associations of the Gut Microbiome With Treatment Resistance in Schizophrenia.” JAMA psychiatry (2024). PMID: 38294805 ↗

    L3OTHERCited in: Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Complications, Comorbidity and Iatrogenic Harm
  444. [444]

    Thornicroft G, Brohan E, Rose D et al.. “Global pattern of experienced and anticipated discrimination against people with schizophrenia: a cross-sectional survey.” Lancet (London, England) (2009). PMID: 19162314 ↗

    L4OTHERCited in: Severity, Course Specifiers and Risk Stratification
  445. [445]

    Salomon JA, Vos T, Hogan DR et al.. “Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010.” Lancet (London, England) (2012). PMID: 23245605 ↗

    L4OTHERCited in: Severity, Course Specifiers and Risk Stratification, Acute Management and Psychiatric Emergencies
  446. [446]

    Sarpeleh S, Looi JCL, Allison S et al.. “Effectiveness of clozapine as a transdiagnostic treatment for aggression: a systematic review.” East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan (2026). PMID: 42374952 ↗

    L2SR_OBSCited in: Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Risk and Safety Assessment, Capacity and Therapeutic Setting
  447. [447]

    Fernandez-Egea E, Flanagan RJ, Taylor D et al.. “Mortality associated with clozapine: what is the evidence?” The British journal of psychiatry : the journal of mental science (2024). PMID: 39354861 ↗

    L5OTHERCited in: Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Risk and Safety Assessment, Capacity and Therapeutic Setting, Complications, Comorbidity and Iatrogenic Harm
  448. [448]

    Zhou H, Luo H, Tang JY et al.. “Population-based study of long-term mortality risk associated with clozapine use among patients with schizophrenia.” The British journal of psychiatry : the journal of mental science (2025). PMID: 40611596 ↗

    L2OTHERCited in: Severity, Course Specifiers and Risk Stratification, Complications, Comorbidity and Iatrogenic Harm
  449. [449]

    Suzuki T, Remington G, Arenovich T et al.. “Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia.” The British journal of psychiatry : the journal of mental science (2011). PMID: 22187729 ↗

    L1REVIEW_NARRATIVECited in: Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  450. [450]

    Foster T. “Schizophrenia and bipolar disorder: no recovery without suicide prevention.” The British journal of psychiatry : the journal of mental science (2015). PMID: 26527661 ↗

    L5OTHERCited in: Severity, Course Specifiers and Risk Stratification, Risk and Safety Assessment, Capacity and Therapeutic Setting
  451. [451]

    Hoshino A, Nakamura Y, Morimoto T et al.. “Cultural adaptation and feasibility of action over inertia in Japan: a multi-site pilot intervention study.” Frontiers in psychiatry (2026). PMID: 42368801 ↗

    L4TRIAL_NONRANDOMCited in: Severity, Course Specifiers and Risk Stratification
  452. [452]

    Fornells-Ambrojo M, Plaistow J, Hardy A et al.. “Narrative exposure therapy in early intervention in psychosis services (NETp): protocol of a multi-site feasibility randomised controlled trial study .” BMJ open (2026). PMID: 42331582 ↗

    L5TRIAL_NONRANDOMCited in: Severity, Course Specifiers and Risk Stratification, Acute Management and Psychiatric Emergencies, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment
  453. [453]

    Ding W, Li R, Gong L et al.. “Efficacy and Safety of Fecal Microbiota Transplantation for Patients with Treatment-resistant Schizophrenia: A Double-blind, Randomized Clinical Trial Protocol.” Current neuropharmacology (2026). PMID: 42304911 ↗

    L5TRIAL_NONRANDOMCited in: Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  454. [454]

    Ricci V, De Berardis D, Martinotti G et al.. “Duration of untreated psychosis and long-term outcomes: A systematic review examining the critical window hypothesis.” Journal of psychiatric research (2026). PMID: 42365845 ↗

    L2SR_OBSCited in: Severity, Course Specifiers and Risk Stratification
  455. [455]

    Guo G, Naqvi SZF, Hanchate NK. “Oxytocin dysfunction in severe mental illnesses following adverse childhood experiences: a systematic review.” BMC psychiatry (2026). PMID: 42332629 ↗

    L5SR_OBSCited in: Severity, Course Specifiers and Risk Stratification, History and Evolution of Treatment
  456. [456]

    Fässler L, Koop S, Opper F et al.. “Psychological Interventions Targeting Auditory Hallucinations in Persons With Psychotic Disorders: A Systematic Review and Meta-Analysis.” JAMA psychiatry (2026). PMID: 42307965 ↗

    L1SR_OBSCited in: Severity, Course Specifiers and Risk Stratification
  457. [457]

    Coşkun F, Ağır H, Ildız RE et al.. “Reduced serum cortisol, IGF-1, GLP-1, and T3 levels in medication-free children and adolescents with obsessive-compulsive disorder: a case-control study.” Frontiers in psychiatry (2026). PMID: 42318098 ↗

    L3CASE_CONTROLCited in: Severity, Course Specifiers and Risk Stratification
  458. [458]

    Chen H, Lai T, Jin W et al.. “Diazepam combined with aripiprazole in the treatment of a catatonic stupor patient with venous thrombosis: a case report.” Frontiers in psychiatry (2026). PMID: 42325985 ↗

    L4CASE_REPORTCited in: Severity, Course Specifiers and Risk Stratification
  459. [459]

    Schneider-Thoma J, Efthimiou O, Huhn M et al.. “Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials.” The lancet. Psychiatry (2018). PMID: 30042077 ↗

    L1SR_MA_RCTCited in: Acute Management and Psychiatric Emergencies, Complications, Comorbidity and Iatrogenic Harm
  460. [460]

    Reddy LF, Glynn SM, McGovern JE et al.. “A Novel Psychosocial Intervention for Motivational Negative Symptoms in Schizophrenia: Combined Motivational Interviewing and CBT.” The American journal of psychiatry (2023). PMID: 36891649 ↗

    L1RCTCited in: Acute Management and Psychiatric Emergencies
  461. [461]

    Correll CU, Skuban A, Ouyang J et al.. “Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial.” The American journal of psychiatry (2015). PMID: 25882325 ↗

    L1RCTCited in: Acute Management and Psychiatric Emergencies
  462. [462]

    Yildiz A, Siafis S, Mavridis D et al.. “Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis.” The lancet. Psychiatry (2023). PMID: 37595997 ↗

    L1SR_OBSCited in: Acute Management and Psychiatric Emergencies, Complications, Comorbidity and Iatrogenic Harm
  463. [463]

    Halstead S, Siskind D, Amft M et al.. “Alteration patterns of peripheral concentrations of cytokines and associated inflammatory proteins in acute and chronic stages of schizophrenia: a systematic review and network meta-analysis.” The lancet. Psychiatry (2023). PMID: 36863384 ↗

    L2SR_OBSCited in: Acute Management and Psychiatric Emergencies, Prevention, Screening and Early Intervention
  464. [464]

    Zhu Y, Krause M, Huhn M et al.. “Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses.” The lancet. Psychiatry (2017). PMID: 28736102 ↗

    L1SR_OBSCited in: Acute Management and Psychiatric Emergencies
  465. [465]

    Ostuzzi G, Vita G, Bertolini F et al.. “Continuing, reducing, switching, or stopping antipsychotics in individuals with schizophrenia-spectrum disorders who are clinically stable: a systematic review and network meta-analysis.” The lancet. Psychiatry (2022). PMID: 35753323 ↗

    L1SR_OBSCited in: Acute Management and Psychiatric Emergencies
  466. [466]

    Dudeck L, Nussbaumer M, Nickl-Jockschat T et al.. “Differences in Blood Leukocyte Subpopulations in Schizophrenia: A Systematic Review and Meta-Analysis.” JAMA psychiatry (2025). PMID: 40042836 ↗

    L2SR_OBSCited in: Acute Management and Psychiatric Emergencies, Prevention, Screening and Early Intervention
  467. [467]

    Lesem MD, Tran-Johnson TK, Riesenberg RA et al.. “Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine.” The British journal of psychiatry : the journal of mental science (2011). PMID: 21200077 ↗

    L1RCTCited in: Acute Management and Psychiatric Emergencies
  468. [468]

    Hallak JE, Maia-de-Oliveira JP, Abrao J et al.. “Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial.” JAMA psychiatry (2013). PMID: 23699763 ↗

    L1RCTCited in: Acute Management and Psychiatric Emergencies
  469. [469]

    Leucht S, Schneider-Thoma J, Burschinski A et al.. “Long-term efficacy of antipsychotic drugs in initially acutely ill adults with schizophrenia: systematic review and network meta-analysis.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2023). PMID: 37159349 ↗

    L1SR_OBSCited in: Acute Management and Psychiatric Emergencies
  470. [470]

    Leucht S, Crippa A, Siafis S et al.. “Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.” The American journal of psychiatry (2019). PMID: 31838873 ↗

    L1SR_OBSCited in: Acute Management and Psychiatric Emergencies, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  471. [471]

    Smith KA, Boyce N, Chevance A et al.. “Triangulating evidence from the GALENOS living systematic review on trace amine-associated receptor 1 (TAAR1) agonists in psychosis.” The British journal of psychiatry : the journal of mental science (2024). PMID: 39710623 ↗

    L5SR_OBSCited in: Acute Management and Psychiatric Emergencies
  472. [472]

    Byng R, Creanor S, Jones B et al.. “The effectiveness of a primary care-based collaborative care model to improve quality of life in people with severe mental illness: PARTNERS2 cluster randomised controlled trial.” The British journal of psychiatry : the journal of mental science (2023). PMID: 37078520 ↗

    L1RCTCited in: Acute Management and Psychiatric Emergencies
  473. [473]

    McCue RE, Waheed R, Urcuyo L et al.. “Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia.” The British journal of psychiatry : the journal of mental science (2006). PMID: 17077434 ↗

    L1RCTCited in: Acute Management and Psychiatric Emergencies
  474. [474]

    Nomura N, Siafis S, Schneider-Thoma J et al.. “The trajectory of sedative adverse events caused by antipsychotics: a meta-analysis of individual participant data from randomised, placebo-controlled, clinical trials in acute phase schizophrenia.” The lancet. Psychiatry (2025). PMID: 40113354 ↗

    L1SR_OBSCited in: Acute Management and Psychiatric Emergencies
  475. [475]

    Fusar-Poli P, Cappucciati M, Bonoldi I et al.. “Prognosis of Brief Psychotic Episodes: A Meta-analysis.” JAMA psychiatry (2016). PMID: 26764163 ↗

    L2SR_OBSCited in: Acute Management and Psychiatric Emergencies
  476. [476]

    Brandt L, Efthimiou O, Siafis S et al.. “Antipsychotic Acute-Phase Treatment in Individuals With and Without Recent Treatment: An Individual Participant Data Meta-Analysis.” JAMA psychiatry (2025). PMID: 40332874 ↗

    L1SR_OBSCited in: Acute Management and Psychiatric Emergencies
  477. [477]

    Siafis S, Wu H, Wang D et al.. “Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis.” Molecular psychiatry (2023). PMID: 37537284 ↗

    L1SR_OBSCited in: Acute Management and Psychiatric Emergencies, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Complications, Comorbidity and Iatrogenic Harm
  478. [478]

    Fornaro M, Caiazza C, Billeci M et al.. “Nutraceuticals and phytoceuticals in the treatment of schizophrenia: a systematic review and network meta-analysis "Nutra NMA SCZ".” Molecular psychiatry (2024). PMID: 39026098 ↗

    L1SR_OBSCited in: Acute Management and Psychiatric Emergencies, Prognosis and Natural History
  479. [479]

    Kokkinou M, Ashok AH, Howes OD. “The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders.” Molecular psychiatry (2017). PMID: 28972576 ↗

    L2SR_OBSCited in: Acute Management and Psychiatric Emergencies
  480. [480]

    Mitchell AJ, Lawrence D. “Revascularisation and mortality rates following acute coronary syndromes in people with severe mental illness: comparative meta-analysis.” The British journal of psychiatry : the journal of mental science (2011). PMID: 21628705 ↗

    L2SR_OBSCited in: Acute Management and Psychiatric Emergencies
  481. [481]

    Williams R, Penington E, Gupta V et al.. “Critical components of 'Early Intervention in Psychosis': national retrospective cohort study.” The British journal of psychiatry : the journal of mental science (2025). PMID: 40566951 ↗

    L3COHORTCited in: Acute Management and Psychiatric Emergencies, Complications, Comorbidity and Iatrogenic Harm, Prognosis and Natural History, Prevention, Screening and Early Intervention
  482. [482]

    Fleetwood K, Wild SH, Smith DJ et al.. “Association of severe mental illness with stroke outcomes and process-of-care quality indicators: nationwide cohort study.” The British journal of psychiatry : the journal of mental science (2022). PMID: 35049490 ↗

    L3COHORTCited in: Acute Management and Psychiatric Emergencies
  483. [483]

    Jeon HL, Kwon JS, Park SH et al.. “Association of mental disorders with SARS-CoV-2 infection and severe health outcomes: nationwide cohort study.” The British journal of psychiatry : the journal of mental science (2021). PMID: 33407954 ↗

    L3COHORTCited in: Acute Management and Psychiatric Emergencies
  484. [484]

    McCutcheon RA, Pillinger T, Mizuno Y et al.. “The efficacy and heterogeneity of antipsychotic response in schizophrenia: A meta-analysis.” Molecular psychiatry (2019). PMID: 31471576 ↗

    L1SR_OBSCited in: Acute Management and Psychiatric Emergencies, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  485. [485]

    Stroup TS, Gray N. “Management of common adverse effects of antipsychotic medications.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2018). PMID: 30192094 ↗

    L5OTHERCited in: Acute Management and Psychiatric Emergencies, Psychopharmacology Monitoring and Safety Surveillance
  486. [486]

    Schaffer A, Sinyor M, Kurdyak P et al.. “Population-based analysis of health care contacts among suicide decedents: identifying opportunities for more targeted suicide prevention strategies.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2016). PMID: 27265704 ↗

    L4OTHERCited in: Acute Management and Psychiatric Emergencies
  487. [487]

    Correll CU, Rubio JM, Kane JM. “What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?” World psychiatry : official journal of the World Psychiatric Association (WPA) (2018). PMID: 29856543 ↗

    L5OTHERCited in: Acute Management and Psychiatric Emergencies, Psychopharmacology Monitoring and Safety Surveillance
  488. [488]

    Rognli EB, Heiberg IH, Jacobsen BK et al.. “Transition From Substance-Induced Psychosis to Schizophrenia Spectrum Disorder or Bipolar Disorder.” The American journal of psychiatry (2023). PMID: 37132221 ↗

    L3OTHERCited in: Acute Management and Psychiatric Emergencies
  489. [489]

    Ostinelli EG, Hussein M, Ahmed U et al.. “Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation).” The Cochrane database of systematic reviews (2018). PMID: 29634083 ↗

    L1SR_OBSCited in: Acute Management and Psychiatric Emergencies
  490. [490]

    Ostinelli EG, Jajawi S, Spyridi S et al.. “Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation).” The Cochrane database of systematic reviews (2018). PMID: 29308601 ↗

    L1SR_OBSCited in: Acute Management and Psychiatric Emergencies
  491. [491]

    Ostinelli EG, Brooke-Powney MJ, Li X et al.. “Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation).” The Cochrane database of systematic reviews (2017). PMID: 28758203 ↗

    L1SR_OBSCited in: Acute Management and Psychiatric Emergencies
  492. [492]

    Chattopadhyay A, Frey S, Green G. “Bifeprunox versus placebo for schizophrenia.” The Cochrane database of systematic reviews (2016). PMID: 27732740 ↗

    L1SR_OBSCited in: Acute Management and Psychiatric Emergencies
  493. [493]

    Powney MJ, Adams CE, Jones H. “Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation).” The Cochrane database of systematic reviews (2012). PMID: 23152276 ↗

    L1SR_OBSCited in: Acute Management and Psychiatric Emergencies
  494. [494]

    Adams CE, Awad GA, Rathbone J et al.. “Chlorpromazine versus placebo for schizophrenia.” The Cochrane database of systematic reviews (2014). PMID: 24395698 ↗

    L1SR_OBSCited in: Acute Management and Psychiatric Emergencies
  495. [495]

    Magalhães PV, Dean O, Andreazza AC et al.. “Antioxidant treatments for schizophrenia.” The Cochrane database of systematic reviews (2016). PMID: 26848926 ↗

    L1SR_OBSCited in: Acute Management and Psychiatric Emergencies
  496. [496]

    Jayakody K, Gibson RC, Kumar A et al.. “Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses.” The Cochrane database of systematic reviews (2012). PMID: 22513898 ↗

    L1SR_OBSCited in: Acute Management and Psychiatric Emergencies, Risk and Safety Assessment, Capacity and Therapeutic Setting
  497. [497]

    Wu H, Jiang J, Cao X et al.. “Magnetic seizure therapy for people with schizophrenia.” The Cochrane database of systematic reviews (2023). PMID: 37272857 ↗

    L1SR_OBSCited in: Acute Management and Psychiatric Emergencies, Prevention, Screening and Early Intervention
  498. [498]

    Jauhar S, Lawrie SM. “What is the evidence for antipsychotic medication and alternative psychosocial interventions for people with acute, non-affective psychosis?” The lancet. Psychiatry (2022). PMID: 35114137 ↗

    L5REVIEW_NARRATIVECited in: Acute Management and Psychiatric Emergencies
  499. [499]

    Wienand D, Goodwin GM, Simon J. “Non-mental health inpatient and emergency care hospital costs associated with four mental disorders in Europe: a modelling study.” The lancet. Psychiatry (2025). PMID: 40506210 ↗

    L2OTHERCited in: Acute Management and Psychiatric Emergencies
  500. [500]

    Wei Y, Yan VKC, Castle DJ et al.. “Disease relapse, all-cause mortality, and adverse events associated with long-acting injectable antipsychotics versus oral antipsychotics in older people with schizophrenia in Hong Kong: a population-based within-subject analysis.” The lancet. Psychiatry (2025). PMID: 41043453 ↗

    L3OTHERCited in: Acute Management and Psychiatric Emergencies
  501. [501]

    Myran DT, Harrison LD, Pugliese M et al.. “Transition to Schizophrenia Spectrum Disorder Following Emergency Department Visits Due to Substance Use With and Without Psychosis.” JAMA psychiatry (2023). PMID: 37755727 ↗

    L3OTHERCited in: Acute Management and Psychiatric Emergencies
  502. [502]

    Kendler KS, Ohlsson H, Sundquist J et al.. “Profiles of Genetic Risks for Psychotic Disorders.” JAMA psychiatry (2025). PMID: 40632548 ↗

    L3OTHERCited in: Acute Management and Psychiatric Emergencies
  503. [503]

    Ranger TA, Clift AK, Patone M et al.. “Preexisting Neuropsychiatric Conditions and Associated Risk of Severe COVID-19 Infection and Other Acute Respiratory Infections.” JAMA psychiatry (2023). PMID: 36350602 ↗

    L3OTHERCited in: Acute Management and Psychiatric Emergencies
  504. [504]

    Citrome L, Bell Lynum KS, Zhang Z et al.. “Aripiprazole Once-Monthly for Patients Diagnosed With Schizophrenia: Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed.” The Journal of clinical psychiatry (2026). PMID: 42138587 ↗

    L2RCTCited in: Acute Management and Psychiatric Emergencies
  505. [505]

    Rodkin S, Gasanov M, Tushev A et al.. “The Dual Role of Connexins in Stroke, Neurotrauma, Neurodegenerative and Psychiatric Disorders: A Global Systematic Review.” Molecules (Basel, Switzerland) (2026). PMID: 42076023 ↗

    L5SR_OBSCited in: Acute Management and Psychiatric Emergencies
  506. [506]

    Marneros A. “Beyond the Kraepelinian dichotomy: acute and transient psychotic disorders and the necessity for clinical differentiation.” The British journal of psychiatry : the journal of mental science (2006). PMID: 16816298 ↗

    L5OTHERCited in: Acute Management and Psychiatric Emergencies
  507. [507]

    Queirazza F, Semple DM, Lawrie SM. “Transition to schizophrenia in acute and transient psychotic disorders.” The British journal of psychiatry : the journal of mental science (2013). PMID: 24357576 ↗

    L3OTHERCited in: Acute Management and Psychiatric Emergencies
  508. [508]

    Murray RM, Quattrone D, Natesan S et al.. “Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?” The British journal of psychiatry : the journal of mental science (2016). PMID: 27802977 ↗

    L5REVIEW_NARRATIVECited in: Acute Management and Psychiatric Emergencies
  509. [509]

    Furukawa Y, Siafis S, Schneider-Thoma J et al.. “Reclassifying dropouts from antipsychotic trials due to study-reported adverse events: a systematic review and individual-participant-data meta-analyses.” European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology (2026). PMID: 42139983 ↗

    L1SR_OBSCited in: Acute Management and Psychiatric Emergencies
  510. [510]

    Haddad N, Farhat N, Gravel CA et al.. “Antipsychotic Drugs and the Risk of Diabetic Complications: A Systematic Review of Clinical Evidence.” Journal of clinical medicine (2026). PMID: 42074909 ↗

    L4SR_OBSCited in: Acute Management and Psychiatric Emergencies
  511. [511]

    Wu J, Xu J, Bi J et al.. “Effectiveness and Feasibility of Self-Monitoring for Weight Management in Individuals With Mental Disorders Using Digital Intervention: Protocol for a Stepped-Wedge Cluster Randomized Trial ("SWIM" Study).” JMIR research protocols (2026). PMID: 42044368 ↗

    L5TRIAL_NONRANDOMCited in: Acute Management and Psychiatric Emergencies
  512. [512]

    Cadogan SL, Gore-Langton GR, Mansfield KE et al.. “Infections and severe mental illness: a population-based matched cohort study.” BMJ mental health (2026). PMID: 42203437 ↗

    L3COHORTCited in: Acute Management and Psychiatric Emergencies
  513. [513]

    Frajerman A, Barruel D, Legrand A et al.. “Evolution of Paris' public hospital psychiatrics outpatients from 2019 to 2023: a retrospective cohort study.” European archives of psychiatry and clinical neuroscience (2026). PMID: 42118282 ↗

    L3COHORTCited in: Acute Management and Psychiatric Emergencies
  514. [514]

    Sridhar S, Hasenstab KA, Lochotzki H et al.. “Factors associated with high-cost patients with first-episode psychosis: a retrospective study of direct healthcare costs using US private-payer claims data.” BMJ open (2026). PMID: 42055606 ↗

    L3COHORTCited in: Acute Management and Psychiatric Emergencies, Special Populations, Pregnancy and Perinatal Psychiatry
  515. [515]

    Fernàndez-Castillo N, Cabana-Domínguez J, Corominas R et al.. “Molecular genetics of cocaine use disorders in humans.” Molecular psychiatry (2021). PMID: 34453125 ↗

    L5REVIEW_NARRATIVECited in: Acute Management and Psychiatric Emergencies
  516. [516]

    Liao Y, Yu H, Zhang Y et al.. “Genome-wide association study implicates lipid pathway dysfunction in antipsychotic-induced weight gain: multi-ancestry validation.” Molecular psychiatry (2024). PMID: 38336841 ↗

    L3OTHERCited in: Acute Management and Psychiatric Emergencies
  517. [517]

    Hashimoto Y, Suzuki T, Hashimoto K. “Mechanisms of action of fluvoxamine for COVID-19: a historical review.” Molecular psychiatry (2022). PMID: 34997196 ↗

    L5REVIEW_NARRATIVECited in: Acute Management and Psychiatric Emergencies
  518. [518]

    Kumar J, Liddle EB, Fernandes CC et al.. “Glutathione and glutamate in schizophrenia: a 7T MRS study.” Molecular psychiatry (2018). PMID: 29934548 ↗

    L3OTHERCited in: Acute Management and Psychiatric Emergencies
  519. [519]

    Knight JG, Menkes DB, Highton J et al.. “Rationale for a trial of immunosuppressive therapy in acute schizophrenia.” Molecular psychiatry (2007). PMID: 17245324 ↗

    L5REVIEW_NARRATIVECited in: Acute Management and Psychiatric Emergencies
  520. [520]

    Schultebraucks K, Blekic W, Basaraba C et al.. “The impact of preexisting psychiatric disorders and antidepressant use on COVID-19 related outcomes: a multicenter study.” Molecular psychiatry (2023). PMID: 37069343 ↗

    L3OTHERCited in: Acute Management and Psychiatric Emergencies
  521. [521]

    Ragg J, Innes S, Bannon F et al.. “Clozapine-Induced Acute Interstitial Nephritis: A Systematic Review.” Journal of clinical psychopharmacology (2026). PMID: 42159486 ↗

    L4SR_OBSCited in: Acute Management and Psychiatric Emergencies, History and Evolution of Treatment
  522. [522]

    Plever S, Kisely SR, Bonevski B et al.. “Interventions for smoking cessation in inpatient psychiatry settings.” The Cochrane database of systematic reviews (2026). PMID: 42389948 ↗

    L1SR_OBSCited in: Acute Management and Psychiatric Emergencies, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  523. [523]

    Zhong H, Zhou S. “Acute liver failure and hemolytic anemia induced by quetiapine and aripiprazole overdose in a patient with schizophrenia and metastatic breast cancer: a unique case report.” Frontiers in psychiatry (2026). PMID: 42052532 ↗

    L4CASE_REPORTCited in: Acute Management and Psychiatric Emergencies
  524. [524]

    Efthimiou O, Taipale H, Radua J et al.. “Efficacy and effectiveness of antipsychotics in schizophrenia: network meta-analyses combining evidence from randomised controlled trials and real-world data.” The lancet. Psychiatry (2024). PMID: 38215784 ↗

    L1SR_MA_RCTCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Special Populations, Pregnancy and Perinatal Psychiatry
  525. [525]

    Kane JM, Robinson DG, Schooler NR et al.. “Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program.” The American journal of psychiatry (2015). PMID: 26481174 ↗

    L1RCTCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment, Special Populations, Pregnancy and Perinatal Psychiatry
  526. [526]

    Pillinger T, Howes OD, Correll CU et al.. “Antidepressant and antipsychotic side-effects and personalised prescribing: a systematic review and digital tool development.” The lancet. Psychiatry (2023). PMID: 37774723 ↗

    L5SR_OBSCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Complications, Comorbidity and Iatrogenic Harm
  527. [527]

    Rodolico A, Bighelli I, Avanzato C et al.. “Family interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis.” The lancet. Psychiatry (2022). PMID: 35093198 ↗

    L1SR_OBSCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  528. [528]

    Feber L, Peter NL, Chiocchia V et al.. “Antipsychotic Drugs and Cognitive Function: A Systematic Review and Network Meta-Analysis.” JAMA psychiatry (2025). PMID: 39412783 ↗

    L1SR_OBSCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  529. [529]

    Lee M, Cernvall M, Borg J et al.. “Cognitive Function and Variability in Antipsychotic Drug-Naive Patients With First-Episode Psychosis: A Systematic Review and Meta-Analysis.” JAMA psychiatry (2024). PMID: 38416480 ↗

    L2SR_OBSCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  530. [530]

    Leucht S, Tardy M, Komossa K et al.. “Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis.” Lancet (London, England) (2012). PMID: 22560607 ↗

    L1SR_OBSCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment, Complications, Comorbidity and Iatrogenic Harm, Prognosis and Natural History
  531. [531]

    Correll CU, Solmi M, Croatto G et al.. “Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2022). PMID: 35524619 ↗

    L2SR_OBSCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Complications, Comorbidity and Iatrogenic Harm
  532. [532]

    Ostuzzi G, Bertolini F, Tedeschi F et al.. “Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2022). PMID: 35524620 ↗

    L1SR_OBSCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  533. [533]

    Kishimoto T, Hagi K, Nitta M et al.. “Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2019). PMID: 31059621 ↗

    L1SR_OBSCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Prognosis and Natural History
  534. [534]

    Rosenheck RA, Krystal JH, Lew R et al.. “Long-acting risperidone and oral antipsychotics in unstable schizophrenia.” The New England journal of medicine (2011). PMID: 21366475 ↗

    L1RCTCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment
  535. [535]

    Gregory A, Mallikarjun P, Upthegrove R. “Treatment of depression in schizophrenia: systematic review and meta-analysis.” The British journal of psychiatry : the journal of mental science (2017). PMID: 28882827 ↗

    L1SR_OBSCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  536. [536]

    Moncrieff J, Pillai E, Marston L et al.. “The association between relapse and the outcome of schizophrenia and recurrent psychotic disorders.” The British journal of psychiatry : the journal of mental science (2025). PMID: 40226993 ↗

    L2RCTCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment, Prognosis and Natural History
  537. [537]

    Solmi M, Croatto G, Piva G et al.. “Efficacy and acceptability of psychosocial interventions in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence.” Molecular psychiatry (2022). PMID: 35999275 ↗

    L1SR_OBSCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Prognosis and Natural History
  538. [538]

    Sinanaj L, Pallis K, Dehkordi AF et al.. “Mapping symptom-general and symptom-specific targets for transcranial magnetic stimulation in schizophrenia: an electric-field modeling meta-analysis.” Molecular psychiatry (2025). PMID: 40983650 ↗

    L1SR_OBSCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  539. [539]

    Marques D, Vaziri N, Greenway SC et al.. “DNA methylation and histone modifications associated with antipsychotic treatment: a systematic review.” Molecular psychiatry (2024). PMID: 39227433 ↗

    L3SR_OBSCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  540. [540]

    Turkington D, Kingdon D, Weiden PJ. “Cognitive behavior therapy for schizophrenia.” The American journal of psychiatry (2006). PMID: 16513854 ↗

    L5REVIEW_NARRATIVECited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Prognosis and Natural History
  541. [541]

    Geretsegger M, Mössler KA, Bieleninik Ł et al.. “Music therapy for people with schizophrenia and schizophrenia-like disorders.” The Cochrane database of systematic reviews (2017). PMID: 28553702 ↗

    L1SR_OBSCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Prevention, Screening and Early Intervention
  542. [542]

    McLoughlin BC, Pushpa-Rajah JA, Gillies D et al.. “Cannabis and schizophrenia.” The Cochrane database of systematic reviews (2014). PMID: 25314586 ↗

    L1SR_OBSCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  543. [543]

    Premkumar TS, Pick J. “Lamotrigine for schizophrenia.” The Cochrane database of systematic reviews (2006). PMID: 17054266 ↗

    L1SR_OBSCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  544. [544]

    Elias A, Kumar A. “Testosterone for schizophrenia.” The Cochrane database of systematic reviews (2007). PMID: 17636833 ↗

    L1SR_OBSCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  545. [545]

    Hartung B, Sampson S, Leucht S. “Perphenazine for schizophrenia.” The Cochrane database of systematic reviews (2015). PMID: 25749632 ↗

    L1SR_OBSCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  546. [546]

    Leucht S, Helfer B, Dold M et al.. “Carbamazepine for schizophrenia.” The Cochrane database of systematic reviews (2014). PMID: 24789267 ↗

    L1SR_OBSCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment, Prognosis and Natural History
  547. [547]

    Leucht S, Helfer B, Dold M et al.. “Lithium for schizophrenia.” The Cochrane database of systematic reviews (2015). PMID: 26509923 ↗

    L1SR_OBSCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  548. [548]

    Shen X, Xia J, Adams CE. “Acupuncture for schizophrenia.” The Cochrane database of systematic reviews (2014). PMID: 25330045 ↗

    L1SR_OBSCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  549. [549]

    Punnoose S, Belgamwar MR. “Nicotine for schizophrenia.” The Cochrane database of systematic reviews (2006). PMID: 16437497 ↗

    L1SR_OBSCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  550. [550]

    Coteur K, Tops L, Bekkering GE et al.. “Values and preferences of patients with severe mental illness regarding smoking cessation interventions: a systematic review with best-fit framework synthesis.” BMJ open (2026). PMID: 42259564 ↗

    L3SR_OBSCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  551. [551]

    McCutcheon RA, Pillinger T, Varvari I et al.. “INTEGRATE: international guidelines for the algorithmic treatment of schizophrenia.” The lancet. Psychiatry (2025). PMID: 40179920 ↗

    L1REVIEW_NARRATIVECited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  552. [552]

    McCutcheon RA, Reis Marques T, Howes OD. “Schizophrenia-An Overview.” JAMA psychiatry (2020). PMID: 31664453 ↗

    L5REVIEW_NARRATIVECited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  553. [553]

    Owen MJ, Sawa A, Mortensen PB. “Schizophrenia.” Lancet (London, England) (2016). PMID: 26777917 ↗

    L5REVIEW_NARRATIVECited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  554. [554]

    Patel V, Araya R, Chatterjee S et al.. “Treatment and prevention of mental disorders in low-income and middle-income countries.” Lancet (London, England) (2007). PMID: 17804058 ↗

    L5REVIEW_NARRATIVECited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  555. [555]

    Huang HZ, Chen YB, Wang XQ et al.. “Effects of virtual reality technology on core symptoms of schizophrenia patients: A systematic review and meta-analysis.” Archives of psychiatric nursing (2026). PMID: 42236033 ↗

    L1SR_OBSCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  556. [556]

    Freeman D. “Developing psychological treatments for psychosis.” The British journal of psychiatry : the journal of mental science (2024). PMID: 38652062 ↗

    L5OTHERCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  557. [557]

    Goodwin GM, Geddes JR. “What is the heartland of psychiatry?” The British journal of psychiatry : the journal of mental science (2007). PMID: 17766755 ↗

    L5OTHERCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  558. [558]

    Summerfield D. “What kind of in-patient psychiatry for Africa? Report from Zimbabwe.” The British journal of psychiatry : the journal of mental science (2020). PMID: 31902379 ↗

    L5OTHERCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  559. [559]

    Merenlender Wagner A, Perlstein I, Farkas P et al.. “A Phase 1 Open-Label Study Assessing the Safety and Pharmacokinetics of TV-46000, an Extended-Release Injectable Suspension of Risperidone for Subcutaneous Use.” CNS drugs (2026). PMID: 42295697 ↗

    L4TRIAL_NONRANDOMCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment
  560. [560]

    Weissman MM, Pilowsky DJ, Wickramaratne PJ et al.. “Remissions in maternal depression and child psychopathology: a STAR*D-child report.” JAMA (2006). PMID: 16551710 ↗

    L2OTHERCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Prognosis and Natural History, Special Populations, Pregnancy and Perinatal Psychiatry
  561. [561]

    Furukawa Y, Salahuddin NH, Wei Y et al.. “Next-step treatment for schizophrenia non-responsive to antipsychotics: a systematic review and network meta-analysis.” EClinicalMedicine (2026). PMID: 42232685 ↗

    L1SR_OBSCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  562. [562]

    Ma M, Li Y, Tong J et al.. “Associations among homocysteine, left cortical thickness, and working memory in patients with treatment-resistant schizophrenia: preliminary findings of a cohort study.” BMC psychiatry (2026). PMID: 42288748 ↗

    L3COHORTCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  563. [563]

    Etyemez S, Sivananthan R, Faria AV et al.. “Brain structural abnormalities in treatment-resistant schizophrenia.” Molecular psychiatry (2026). PMID: 41904268 ↗

    L2OTHERCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  564. [564]

    Henkel ND, Wu X, O'Donovan SM et al.. “Schizophrenia: a disorder of broken brain bioenergetics.” Molecular psychiatry (2022). PMID: 35264726 ↗

    L5REVIEW_NARRATIVECited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  565. [565]

    Chestnykh D, Mühle C, Schumacher F et al.. “Acid sphingomyelinase activity suggests a new antipsychotic pharmaco-treatment strategy for schizophrenia.” Molecular psychiatry (2025). PMID: 39825014 ↗

    L5OTHERCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  566. [566]

    Wada M, Noda Y, Iwata Y et al.. “Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment.” Molecular psychiatry (2022). PMID: 35444257 ↗

    L5REVIEW_NARRATIVECited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  567. [567]

    Gray JA, Roth BL. “The pipeline and future of drug development in schizophrenia.” Molecular psychiatry (2007). PMID: 17667958 ↗

    L5REVIEW_NARRATIVECited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment
  568. [568]

    Sugimori C, Kawajiri R, Urata K et al.. “Clozapine-associated systemic inflammatory reaction with adult-onset Still's disease-like features and marked interleukin-18 elevation in a patient with schizophrenia: a case report.” BMC psychiatry (2026). PMID: 42271308 ↗

    L4CASE_REPORTCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  569. [569]

    Okon-Rocha E, Taylor D. “Cariprazine augmentation for negative symptoms of schizophrenia: a prospective analysis and literature review.” Therapeutic advances in psychopharmacology (2026). PMID: 42253762 ↗

    L4CASE_REPORTCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  570. [570]

    Wiafe SL, Kinsey S, Soleimani N et al.. “Aberrant recovery of timescale-aligned amplitude balance links to symptoms and cognition in schizophrenia.” Translational psychiatry (2026). PMID: 42431898 ↗

    L4OTHERCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  571. [571]

    Lee BJ, Driscoll B, Scheinberg R et al.. “Clozapine facilitates sustained improvement in psychotic symptoms with a subsequent cascade of effects on functioning and quality of life.” Journal of psychiatric research (2026). PMID: 42419167 ↗

    L2OTHERCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  572. [572]

    Modica de Mohac L, Keeley A, Taylor D et al.. “Assessment of clozapine taste in healthy volunteers: evidence for non-aversive sensory profile.” Therapeutic advances in psychopharmacology (2026). PMID: 42403510 ↗

    L4OTHERCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
  573. [573]

    Rosenheck RA, Leslie DL, Sindelar J et al.. “Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.” The American journal of psychiatry (2006). PMID: 17151158 ↗

    L1RCTCited in: Psychopharmacology Monitoring and Safety Surveillance
  574. [574]

    Miller DD, Caroff SN, Davis SM et al.. “Extrapyramidal side-effects of antipsychotics in a randomised trial.” The British journal of psychiatry : the journal of mental science (2008). PMID: 18827289 ↗

    L1RCTCited in: Psychopharmacology Monitoring and Safety Surveillance
  575. [575]

    Rubio JM, Schoretsanitis G, John M et al.. “Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis.” The lancet. Psychiatry (2020). PMID: 32828165 ↗

    L2SR_OBSCited in: Psychopharmacology Monitoring and Safety Surveillance
  576. [576]

    Oloyede E, Bachmann CJ, Dzahini O et al.. “Identifying clinically relevant agranulocytosis in people registered on the UK clozapine Central Non-Rechallenge Database: retrospective cohort study.” The British journal of psychiatry : the journal of mental science (2024). PMID: 39149780 ↗

    L3COHORTCited in: Psychopharmacology Monitoring and Safety Surveillance
  577. [577]

    Volpi S, Heaton C, Mack K et al.. “Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia.” Molecular psychiatry (2008). PMID: 18521091 ↗

    L3TRIAL_NONRANDOMCited in: Psychopharmacology Monitoring and Safety Surveillance
  578. [578]

    Legge SE, Hamshere ML, Ripke S et al.. “Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia.” Molecular psychiatry (2016). PMID: 27400856 ↗

    L3SR_OBSCited in: Psychopharmacology Monitoring and Safety Surveillance
  579. [579]

    Tenback DE, van Harten PN, Slooff CJ et al.. “Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study.” The American journal of psychiatry (2006). PMID: 16877660 ↗

    L2OTHERCited in: Psychopharmacology Monitoring and Safety Surveillance
  580. [580]

    Murtough S, Stellakis O, Mills D et al.. “ACKR1/Duffy-null genotype testing for clozapine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).” British journal of clinical pharmacology (2026). PMID: 42125771 ↗

    L1GUIDELINECited in: Psychopharmacology Monitoring and Safety Surveillance
  581. [581]

    Edwards MJ, Michel Llorca P, Driessen MT et al.. “Clinical practice guidelines for the treatment of tardive dyskinesia in Europe: A descriptive review.” European psychiatry : the journal of the Association of European Psychiatrists (2025). PMID: 40671306 ↗

    L5GUIDELINECited in: Psychopharmacology Monitoring and Safety Surveillance
  582. [582]

    Kassar O, Shaheen O, Selim A et al.. “Efficacy and safety of ondansetron in schizophrenia: A systematic review and meta-analysis of randomized controlled trials.” General hospital psychiatry (2025). PMID: 40482395 ↗

    L1SR_MA_RCTCited in: Psychopharmacology Monitoring and Safety Surveillance
  583. [583]

    Taipale H, Schneider-Thoma J, Pinzón-Espinosa J et al.. “Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials.” JAMA psychiatry (2022). PMID: 35080618 ↗

    L3OTHERCited in: Psychopharmacology Monitoring and Safety Surveillance
  584. [584]

    Ponsford M, Castle D, Tahir T et al.. “Clozapine is associated with secondary antibody deficiency.” The British journal of psychiatry : the journal of mental science (2018). PMID: 30259827 ↗

    L3OTHERCited in: Psychopharmacology Monitoring and Safety Surveillance
  585. [585]

    Sarró S, Pomarol-Clotet E, Canales-Rodríguez EJ et al.. “Structural brain changes associated with tardive dyskinesia in schizophrenia.” The British journal of psychiatry : the journal of mental science (2012). PMID: 23222039 ↗

    L3OTHERCited in: Psychopharmacology Monitoring and Safety Surveillance
  586. [586]

    Diederich F, Oloyede E, Taylor D et al.. “Economic evaluation of different haematological monitoring schemes for patients with treatment-resistant schizophrenia using clozapine.” The British journal of psychiatry : the journal of mental science (2025). PMID: 41229349 ↗

    L2OTHERCited in: Psychopharmacology Monitoring and Safety Surveillance
  587. [587]

    Wallman P, Govind R, Casetta C et al.. “Evaluation of 96 cases of apparent clozapine-induced severe neutropenia.” The British journal of psychiatry : the journal of mental science (2025). PMID: 41059642 ↗

    L4OTHERCited in: Psychopharmacology Monitoring and Safety Surveillance
  588. [588]

    Meyer JM, Kramer K, Vuocolo S et al.. “From theory to therapy: unlocking the potential of muscarinic receptor activation in schizophrenia with the dual M1/M4 muscarinic receptor agonist xanomeline and trospium chloride and insights from clinical trials.” The international journal of neuropsychopharmacology (2025). PMID: 40056428 ↗

    L5TRIAL_NONRANDOMCited in: Psychopharmacology Monitoring and Safety Surveillance
  589. [589]

    Casetta C, Loane E, Taylor D et al.. “Risk factors associated with blood dyscrasia during clozapine treatment: a systematic review and meta-analysis.” Psychological medicine (2026). PMID: 42112559 ↗

    L2SR_OBSCited in: Psychopharmacology Monitoring and Safety Surveillance
  590. [590]

    Sagués T, Ferrer A, Delgado JF et al.. “Clozapine use and COVID-19 risk: A systematic review, meta-analysis, and retrospective cohort evidence.” Psychiatry research (2026). PMID: 41762542 ↗

    L3SR_OBSCited in: Psychopharmacology Monitoring and Safety Surveillance
  591. [591]

    Sampson S, Mansour M, Maayan N et al.. “Intermittent drug techniques for schizophrenia.” The Cochrane database of systematic reviews (2013). PMID: 23881657 ↗

    L1SR_OBSCited in: Psychopharmacology Monitoring and Safety Surveillance, Prognosis and Natural History
  592. [592]

    Soares-Weiser K, Maayan N, Bergman H. “Vitamin E for antipsychotic-induced tardive dyskinesia.” The Cochrane database of systematic reviews (2018). PMID: 29341067 ↗

    L1SR_OBSCited in: Psychopharmacology Monitoring and Safety Surveillance, Complications, Comorbidity and Iatrogenic Harm
  593. [593]

    Essali A, Soares-Weiser K, Bergman H et al.. “Calcium channel blockers for antipsychotic-induced tardive dyskinesia.” The Cochrane database of systematic reviews (2018). PMID: 29578611 ↗

    L1SR_OBSCited in: Psychopharmacology Monitoring and Safety Surveillance
  594. [594]

    Bergman H, Rathbone J, Agarwal V et al.. “Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia.” The Cochrane database of systematic reviews (2018). PMID: 29409162 ↗

    L1SR_OBSCited in: Psychopharmacology Monitoring and Safety Surveillance
  595. [595]

    Ali M, Mufti AA, Razaq A et al.. “A retrospective study on clozapine-induced blood dyscrasias in the first 20 weeks of therapy.” Journal of psychiatric research (2025). PMID: 41052486 ↗

    L3COHORTCited in: Psychopharmacology Monitoring and Safety Surveillance
  596. [596]

    Arranz MJ, de Leon J. “Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.” Molecular psychiatry (2007). PMID: 17549063 ↗

    L5REVIEW_NARRATIVECited in: Psychopharmacology Monitoring and Safety Surveillance
  597. [597]

    Legge SE, Pardiñas AF, Helthuis M et al.. “A genome-wide association study in individuals of African ancestry reveals the importance of the Duffy-null genotype in the assessment of clozapine-related neutropenia.” Molecular psychiatry (2019). PMID: 30647433 ↗

    L3OTHERCited in: Psychopharmacology Monitoring and Safety Surveillance
  598. [598]

    Ismail O, Albdour K, Jaber Y et al.. “Efficacy and safety of different pharmacological interventions in the treatment of tardive dyskinesia: a systematic review and network meta-analysis.” European journal of clinical pharmacology (2026). PMID: 41981317 ↗

    L1SR_OBSCited in: Psychopharmacology Monitoring and Safety Surveillance
  599. [599]

    Hailes HP, Yu R, Danese A et al.. “Long-term outcomes of childhood sexual abuse: an umbrella review.” The lancet. Psychiatry (2019). PMID: 31519507 ↗

    L2SR_OBSCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting, Special Populations, Pregnancy and Perinatal Psychiatry
  600. [600]

    Henriksen MG, Raballo A, Nordgaard J. “Self-disorders and psychopathology: a systematic review.” The lancet. Psychiatry (2021). PMID: 34688345 ↗

    L2SR_OBSCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  601. [601]

    Whiting D, Gulati G, Geddes JR et al.. “Association of Schizophrenia Spectrum Disorders and Violence Perpetration in Adults and Adolescents From 15 Countries: A Systematic Review and Meta-analysis.” JAMA psychiatry (2022). PMID: 34935869 ↗

    L2SR_OBSCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting, Complications, Comorbidity and Iatrogenic Harm, Special Populations, Pregnancy and Perinatal Psychiatry
  602. [602]

    Das-Munshi J, Chang CK, Dutta R et al.. “Ethnicity and excess mortality in severe mental illness: a cohort study.” The lancet. Psychiatry (2017). PMID: 28330589 ↗

    L2COHORTCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  603. [603]

    Madsen T, Karstoft KI, Secher RG et al.. “Trajectories of suicidal ideation in patients with first-episode psychosis: secondary analysis of data from the OPUS trial.” The lancet. Psychiatry (2016). PMID: 26948484 ↗

    L2RCTCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  604. [604]

    Olsen L, Sparsø T, Weinsheimer SM et al.. “Prevalence of rearrangements in the 22q11.2 region and population-based risk of neuropsychiatric and developmental disorders in a Danish population: a case-cohort study.” The lancet. Psychiatry (2018). PMID: 29886042 ↗

    L2COHORTCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  605. [605]

    Hunt IM, Richards N, Bhui K et al.. “Suicide rates by ethnic group among patients in contact with mental health services: an observational cohort study in England and Wales.” The lancet. Psychiatry (2021). PMID: 34762843 ↗

    L2COHORTCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  606. [606]

    Burton BK, Thorup AAE, Jepsen JR et al.. “Impairments of motor function among children with a familial risk of schizophrenia or bipolar disorder at 7 years old in Denmark: an observational cohort study.” The lancet. Psychiatry (2017). PMID: 28344044 ↗

    L2COHORTCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  607. [607]

    Kantrowitz JT, Woods SW, Petkova E et al.. “D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial.” The lancet. Psychiatry (2015). PMID: 26360284 ↗

    L1RCTCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  608. [608]

    Tzur Bitan D, Kridin K, Cohen AD et al.. “COVID-19 hospitalisation, mortality, vaccination, and postvaccination trends among people with schizophrenia in Israel: a longitudinal cohort study.” The lancet. Psychiatry (2021). PMID: 34364406 ↗

    L2COHORTCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  609. [609]

    Chen PH, Tsai SY, Chen PY et al.. “Lipid-modifying agents and risk of all-cause, natural and suicide mortality in schizophrenia: nationwide cohort study.” The British journal of psychiatry : the journal of mental science (2024). PMID: 38751180 ↗

    L2COHORTCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  610. [610]

    Kim H, Jung JH, Han K et al.. “Risk of suicide and all-cause death in patients with mental disorders: a nationwide cohort study.” Molecular psychiatry (2025). PMID: 39843548 ↗

    L2COHORTCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  611. [611]

    Morgan C, Gayer-Anderson C, Beards S et al.. “Threat, hostility and violence in childhood and later psychotic disorder: population-based case-control study.” The British journal of psychiatry : the journal of mental science (2020). PMID: 32778182 ↗

    L3CASE_CONTROLCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  612. [612]

    Buchanan A, Sint K, Swanson J et al.. “Correlates of Future Violence in People Being Treated for Schizophrenia.” The American journal of psychiatry (2019). PMID: 31014102 ↗

    L2OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  613. [613]

    Zhang JP, Robinson D, Yu J et al.. “Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis.” The American journal of psychiatry (2018). PMID: 30392411 ↗

    L2OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  614. [614]

    van Os J, Drukker M, à Campo J et al.. “Validation of remission criteria for schizophrenia.” The American journal of psychiatry (2006). PMID: 17074953 ↗

    L2OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  615. [615]

    Keers R, Ullrich S, Destavola BL et al.. “Association of violence with emergence of persecutory delusions in untreated schizophrenia.” The American journal of psychiatry (2014). PMID: 24220644 ↗

    L2OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  616. [616]

    Riglin L, Hammerton G, Heron J et al.. “Developmental Contributions of Schizophrenia Risk Alleles and Childhood Peer Victimization to Early-Onset Mental Health Trajectories.” The American journal of psychiatry (2018). PMID: 30486671 ↗

    L2OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  617. [617]

    Gershon ES, Alliey-Rodriguez N. “New ethical issues for genetic counseling in common mental disorders.” The American journal of psychiatry (2013). PMID: 23897273 ↗

    L5REVIEW_NARRATIVECited in: Risk and Safety Assessment, Capacity and Therapeutic Setting, Prevention, Screening and Early Intervention
  618. [618]

    Malone D, Newron-Howes G, Simmonds S et al.. “Community mental health teams (CMHTs) for people with severe mental illnesses and disordered personality.” The Cochrane database of systematic reviews (2007). PMID: 17636625 ↗

    L1SR_OBSCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  619. [619]

    Muralidharan S, Fenton M. “Containment strategies for people with serious mental illness.” The Cochrane database of systematic reviews (2006). PMID: 16855984 ↗

    L1SR_OBSCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  620. [620]

    Dieterich M, Irving CB, Bergman H et al.. “Intensive case management for severe mental illness.” The Cochrane database of systematic reviews (2017). PMID: 28067944 ↗

    L1SR_OBSCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  621. [621]

    Tang W, Guan C, Ling Z et al.. “Development of a risk prediction model for relapse in patients with schizophrenia based on a systematic review and meta-analysis.” Psychiatry research (2026). PMID: 41955842 ↗

    L2SR_OBSCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting, Prevention, Screening and Early Intervention
  622. [622]

    Ahle G, Henriksen MG, Mølstrøm IM et al.. “Predictors of violence against others in non-affective psychosis: A systematic review and meta-analysis.” Schizophrenia research (2026). PMID: 41747436 ↗

    L2SR_OBSCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  623. [623]

    Ghizlane C, Zougrar I, Benayad A et al.. “Prevalence of suicidal thoughts and behaviors among individuals with mental disorders in Africa: a systematic review and meta-analysis of the past 25 years.” BMC psychiatry (2026). PMID: 41680683 ↗

    L2SR_OBSCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  624. [624]

    . “The burden of mental disorders across the states of India: the Global Burden of Disease Study 1990-2017.” The lancet. Psychiatry (2019). PMID: 31879245 ↗

    L2OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  625. [625]

    Janiri D, Doucet GE, Pompili M et al.. “Risk and protective factors for childhood suicidality: a US population-based study.” The lancet. Psychiatry (2020). PMID: 32171431 ↗

    L4OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  626. [626]

    Gohar SM, Hegelstad WTV, Auestad B et al.. “Association between early suicidal trajectories in first-episode psychosis and 10-year follow-up: TIPS registry-linked study.” The lancet. Psychiatry (2023). PMID: 37353264 ↗

    L2OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  627. [627]

    Robson D, Spaducci G, McNeill A et al.. “Effect of implementation of a smoke-free policy on physical violence in a psychiatric inpatient setting: an interrupted time series analysis.” The lancet. Psychiatry (2017). PMID: 28624180 ↗

    L2OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  628. [628]

    Østergaard SD, Mundy J, Hall ASM et al.. “Genetic Confounding in the Association Between Traumatic Brain Injury and Mental Disorder or Suicide.” JAMA psychiatry (2025). PMID: 40172901 ↗

    L2OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  629. [629]

    Olfson M, Stroup TS, Huang C et al.. “Suicide Risk in Medicare Patients With Schizophrenia Across the Life Span.” JAMA psychiatry (2021). PMID: 34037667 ↗

    L3OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  630. [630]

    Olfson M, Wall M, Wang S et al.. “Short-term Suicide Risk After Psychiatric Hospital Discharge.” JAMA psychiatry (2016). PMID: 27654151 ↗

    L3OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  631. [631]

    Ray WA, Stein CM, Murray KT et al.. “Association of Antipsychotic Treatment With Risk of Unexpected Death Among Children and Youths.” JAMA psychiatry (2019). PMID: 30540347 ↗

    L3OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  632. [632]

    Lee PH, Doyle AE, Silberstein M et al.. “Associations Between Genetic Risk for Adult Suicide Attempt and Suicidal Behaviors in Young Children in the US.” JAMA psychiatry (2022). PMID: 36044238 ↗

    L3OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  633. [633]

    Svob C, Wickramaratne PJ, Reich L et al.. “Association of Parent and Offspring Religiosity With Offspring Suicide Ideation and Attempts.” JAMA psychiatry (2018). PMID: 30090928 ↗

    L2OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  634. [634]

    Sariaslan A, Arseneault L, Larsson H et al.. “Risk of Subjection to Violence and Perpetration of Violence in Persons With Psychiatric Disorders in Sweden.” JAMA psychiatry (2020). PMID: 31940015 ↗

    L3OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  635. [635]

    Wu Y, Yuan Y, Zhou X et al.. “Oxidative balance score, inflammatory biomarkers, and risk of psychiatric disorders and suicide attempts: A prospective cohort study.” Journal of affective disorders (2026). PMID: 41881111 ↗

    L2COHORTCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  636. [636]

    Tang JY, Wong GH, Zhou H et al.. “Ten-year risk prediction models for atherosclerotic cardiovascular disease in Chinese patients with schizophrenia-spectrum disorders: A population-based cohort study.” Schizophrenia research (2026). PMID: 41856022 ↗

    L3COHORTCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  637. [637]

    Alberdi-Páramo Í, Morales-Ríos H, Navas-Tejedor M et al.. “Clinical and epidemiological profiles of suicidal behavior in psychiatric emergency users: A 13-year retrospective study of 40,306 cases in Madrid, Spain.” Journal of affective disorders (2026). PMID: 41651234 ↗

    L3COHORTCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  638. [638]

    Krakowski M, Czobor P. “Disentangling violence in schizophrenia: Interactions between symptom trajectories, conduct disorder, and pharmacotherapy.” Schizophrenia research (2026). PMID: 41638158 ↗

    L1RCTCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  639. [639]

    Liu TH, Hsu CH, Wu JY et al.. “Association between tirzepatide use and risk of mortality, hospitalization, and suicidal behavior in patients with schizophrenia spectrum disorders: A one-year retrospective cohort study of 3618 patients.” European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology (2025). PMID: 41389474 ↗

    L3COHORTCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  640. [640]

    Paljärvi T, Tiihonen J, Lähteenvuo M et al.. “Mortality in psychotic depression: 18-year follow-up study.” The British journal of psychiatry : the journal of mental science (2023). PMID: 36250518 ↗

    L3OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  641. [641]

    De la Hoz JF, Arias A, Service SK et al.. “Characterisation of serious mental illness trajectories through transdiagnostic clinical features.” The British journal of psychiatry : the journal of mental science (2025). PMID: 40545571 ↗

    L3OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  642. [642]

    Crump C, Sundquist K, Winkleby MA et al.. “Mental disorders and risk of accidental death.” The British journal of psychiatry : the journal of mental science (2013). PMID: 23969485 ↗

    L3OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  643. [643]

    Köhler-Forsberg O, Ge F, Hauksdóttir A et al.. “Adverse childhood experiences and psychological functioning among women with schizophrenia or bipolar disorder: population-based study.” The British journal of psychiatry : the journal of mental science (2024). PMID: 37850429 ↗

    L4OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  644. [644]

    Lambe S, Cooper K, Fazel S et al.. “Psychological framework to understand interpersonal violence by forensic patients with psychosis.” The British journal of psychiatry : the journal of mental science (2024). PMID: 37861077 ↗

    L5OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  645. [645]

    Witt K, Lichtenstein P, Fazel S. “Improving risk assessment in schizophrenia: epidemiological investigation of criminal history factors.” The British journal of psychiatry : the journal of mental science (2015). PMID: 25657352 ↗

    L3OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  646. [646]

    Kelleher I. “Psychosis prediction 2.0: why child and adolescent mental health services should be a key focus for schizophrenia and bipolar disorder prevention research.” The British journal of psychiatry : the journal of mental science (2023). PMID: 36632815 ↗

    L5OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  647. [647]

    Fullam RS, Dolan MC. “Executive function and in-patient violence in forensic patients with schizophrenia.” The British journal of psychiatry : the journal of mental science (2008). PMID: 18757987 ↗

    L3OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  648. [648]

    Hill MD, Gill SS, Le-Niculescu H et al.. “Precision medicine for psychotic disorders: objective assessment, risk prediction, and pharmacogenomics.” Molecular psychiatry (2024). PMID: 38326562 ↗

    L2OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  649. [649]

    Sariaslan A, Larsson H, Fazel S. “Genetic and environmental determinants of violence risk in psychotic disorders: a multivariate quantitative genetic study of 1.8 million Swedish twins and siblings.” Molecular psychiatry (2015). PMID: 26666206 ↗

    L3OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  650. [650]

    Mitjans M, Seidel J, Begemann M et al.. “Violent aggression predicted by multiple pre-adult environmental hits.” Molecular psychiatry (2018). PMID: 29795411 ↗

    L3OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  651. [651]

    Bigdeli TB, Barr PB, Rajeevan N et al.. “Correlates of suicidal behaviors and genetic risk among United States veterans with schizophrenia or bipolar I disorder.” Molecular psychiatry (2024). PMID: 38491344 ↗

    L4OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting, Prevention, Screening and Early Intervention
  652. [652]

    Sokolowski M, Wasserman J, Wasserman D. “Polygenic associations of neurodevelopmental genes in suicide attempt.” Molecular psychiatry (2015). PMID: 26666204 ↗

    L3OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  653. [653]

    Crouse JJ, Park SH, Byrne EM et al.. “Patterns of stressful life events and polygenic scores for five mental disorders and neuroticism among adults with depression.” Molecular psychiatry (2024). PMID: 38575805 ↗

    L4OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  654. [654]

    Han S, DiBlasi E, Monson ET et al.. “Whole-genome sequencing analysis of suicide deaths integrating brain-regulatory eQTLs data to identify risk loci and genes.” Molecular psychiatry (2023). PMID: 37794117 ↗

    L3OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  655. [655]

    Huang Y, Chen D, Levin AM et al.. “Cross-phenotype relationship between opioid use disorder and suicide attempts: new evidence from polygenic association and Mendelian randomization analyses.” Molecular psychiatry (2023). PMID: 37340172 ↗

    L2OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting, Prevention, Screening and Early Intervention
  656. [656]

    Alameda L, Liu Z, Sham PC et al.. “Exploring the mediation of DNA methylation across the epigenome between childhood adversity and First Episode of Psychosis-findings from the EU-GEI study.” Molecular psychiatry (2023). PMID: 37062770 ↗

    L3OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  657. [657]

    Garcia-Ruiz B, Jiménez E, Aranda S et al.. “Associations of altered leukocyte DDR1 promoter methylation and childhood trauma with bipolar disorder and suicidal behavior in euthymic patients.” Molecular psychiatry (2024). PMID: 38503928 ↗

    L3OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  658. [658]

    Zheng H, Webster MJ, Weickert CS et al.. “Cytomegalovirus antibodies are associated with mood disorders, suicide, markers of neuroinflammation, and microglia activation in postmortem brain samples.” Molecular psychiatry (2023). PMID: 37391529 ↗

    L3OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  659. [659]

    Christensen MJ, Olesen AV, Ward T et al.. “Psychological and behavioral mechanisms linking childhood trauma profiles to voice-related distress in schizophrenia spectrum disorders: latent class, mediation, and conditional process analyses.” Psychological medicine (2026). PMID: 42253147 ↗

    L4OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
  660. [660]

    Cantor-Graae E, Selten JP. “Schizophrenia and migration: a meta-analysis and review.” The American journal of psychiatry (2005). PMID: 15625195 ↗

    L2SR_OBSCited in: History and Evolution of Treatment
  661. [661]

    Cannon M, Jones PB, Murray RM. “Obstetric complications and schizophrenia: historical and meta-analytic review.” The American journal of psychiatry (2002). PMID: 12091183 ↗

    L2SR_OBSCited in: History and Evolution of Treatment
  662. [662]

    Brandt L, Schneider-Thoma J, Siafis S et al.. “Adverse events after antipsychotic discontinuation: an individual participant data meta-analysis.” The lancet. Psychiatry (2022). PMID: 35183280 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  663. [663]

    Li HJ, Zhang C, Hui L et al.. “Novel Risk Loci Associated With Genetic Risk for Bipolar Disorder Among Han Chinese Individuals: A Genome-Wide Association Study and Meta-analysis.” JAMA psychiatry (2021). PMID: 33263727 ↗

    L3SR_OBSCited in: History and Evolution of Treatment
  664. [664]

    Kane JM, Harary E, Eshet R et al.. “Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria.” The lancet. Psychiatry (2023). PMID: 37924833 ↗

    L1RCTCited in: History and Evolution of Treatment, Prognosis and Natural History, Prevention, Screening and Early Intervention
  665. [665]

    Winter-van Rossum I, Weiser M, Galderisi S et al.. “Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST).” The lancet. Psychiatry (2023). PMID: 36716759 ↗

    L1RCTCited in: History and Evolution of Treatment, Prevention, Screening and Early Intervention
  666. [666]

    Yu H, Yan H, Wang L et al.. “Five novel loci associated with antipsychotic treatment response in patients with schizophrenia: a genome-wide association study.” The lancet. Psychiatry (2018). PMID: 29503163 ↗

    L2RCTCited in: History and Evolution of Treatment
  667. [667]

    Keefe RSE, Harvey PD, Correll CU et al.. “Efficacy and safety of iclepertin for cognitive impairment associated with schizophrenia (CONNEX programme): results from three phase 3 randomised controlled trials.” The lancet. Psychiatry (2025). PMID: 41233083 ↗

    L1RCTCited in: History and Evolution of Treatment
  668. [668]

    Sass MR, Klausen MK, Schwarz CR et al.. “Semaglutide and Early-Stage Metabolic Abnormalities in Individuals With Schizophrenia Spectrum Disorders: A Randomized Clinical Trial.” JAMA psychiatry (2026). PMID: 41335431 ↗

    L1RCTCited in: History and Evolution of Treatment, Complications, Comorbidity and Iatrogenic Harm, Special Populations, Pregnancy and Perinatal Psychiatry, Prevention, Screening and Early Intervention
  669. [669]

    Kane JM, Schooler NR, Marcy P et al.. “Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial.” JAMA psychiatry (2020). PMID: 32667636 ↗

    L1RCTCited in: History and Evolution of Treatment
  670. [670]

    Taylor P, Fleminger JJ. “ECT for schizophrenia.” Lancet (London, England) (1980). PMID: 6104172 ↗

    L1RCTCited in: History and Evolution of Treatment
  671. [671]

    Gregoire AJ, Kumar R, Everitt B et al.. “Transdermal oestrogen for treatment of severe postnatal depression.” Lancet (London, England) (1996). PMID: 8598756 ↗

    L1RCTCited in: History and Evolution of Treatment
  672. [672]

    Kahn RS, Fleischhacker WW, Boter H et al.. “Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.” Lancet (London, England) (2008). PMID: 18374841 ↗

    L1RCTCited in: History and Evolution of Treatment, Prognosis and Natural History, Special Populations, Pregnancy and Perinatal Psychiatry
  673. [673]

    Morrison AP, Turkington D, Pyle M et al.. “Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial.” Lancet (London, England) (2014). PMID: 24508320 ↗

    L1RCTCited in: History and Evolution of Treatment, Prognosis and Natural History
  674. [674]

    Godfrey PS, Toone BK, Carney MW et al.. “Enhancement of recovery from psychiatric illness by methylfolate.” Lancet (London, England) (1990). PMID: 1974941 ↗

    L1RCTCited in: History and Evolution of Treatment
  675. [675]

    Lieberman JA, Stroup TS, McEvoy JP et al.. “Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.” The New England journal of medicine (2005). PMID: 16172203 ↗

    L1RCTCited in: History and Evolution of Treatment
  676. [676]

    McCracken JT, McGough J, Shah B et al.. “Risperidone in children with autism and serious behavioral problems.” The New England journal of medicine (2002). PMID: 12151468 ↗

    L1RCTCited in: History and Evolution of Treatment
  677. [677]

    Carpenter WT, Sadler JH, Light PD et al.. “The therapeutic efficacy of hemodialysis in schizophrenia.” The New England journal of medicine (1983). PMID: 6338385 ↗

    L1RCTCited in: History and Evolution of Treatment
  678. [678]

    Csernansky JG, Mahmoud R, Brenner R. “A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.” The New England journal of medicine (2002). PMID: 11777998 ↗

    L1RCTCited in: History and Evolution of Treatment
  679. [679]

    Rosenheck R, Cramer J, Xu W et al.. “A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.” The New England journal of medicine (1997). PMID: 9295240 ↗

    L1RCTCited in: History and Evolution of Treatment
  680. [680]

    Falloon IR, Boyd JL, McGill CW et al.. “Family management in the prevention of exacerbations of schizophrenia: a controlled study.” The New England journal of medicine (1982). PMID: 6123079 ↗

    L1RCTCited in: History and Evolution of Treatment
  681. [681]

    Geddes JR, Lawrie SM. “Obstetric complications and schizophrenia: a meta-analysis.” The British journal of psychiatry : the journal of mental science (1995). PMID: 8829748 ↗

    L3SR_OBSCited in: History and Evolution of Treatment
  682. [682]

    Højlund M, Andersen K, Ernst MT et al.. “Use of low-dose quetiapine increases the risk of major adverse cardiovascular events: results from a nationwide active comparator-controlled cohort study.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2022). PMID: 36073694 ↗

    L2COHORTCited in: History and Evolution of Treatment, Complications, Comorbidity and Iatrogenic Harm
  683. [683]

    Priebe S, Chevalier A, Hamborg T et al.. “Effectiveness of a volunteer befriending programme for patients with schizophrenia: randomised controlled trial.” The British journal of psychiatry : the journal of mental science (2020). PMID: 30829190 ↗

    L1RCTCited in: History and Evolution of Treatment
  684. [684]

    Rosenheck R, Perlick D, Bingham S et al.. “Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.” JAMA (2003). PMID: 14645311 ↗

    L1RCTCited in: History and Evolution of Treatment
  685. [685]

    Lurie N, Moscovice IS, Finch M et al.. “Does capitation affect the health of the chronically mentally ill? Results from a randomized trial.” JAMA (1992). PMID: 1597911 ↗

    L1RCTCited in: History and Evolution of Treatment
  686. [686]

    Bowden CL, Brugger AM, Swann AC et al.. “Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group.” JAMA (Unknown). PMID: 8120960 ↗

    L1RCTCited in: History and Evolution of Treatment
  687. [687]

    Farrell MS, Werge T, Sklar P et al.. “Evaluating historical candidate genes for schizophrenia.” Molecular psychiatry (2015). PMID: 25754081 ↗

    L3SR_OBSCited in: History and Evolution of Treatment
  688. [688]

    Tsuang MT, Stone WS, Faraone SV. “Toward reformulating the diagnosis of schizophrenia.” The American journal of psychiatry (2000). PMID: 10873908 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  689. [689]

    Sullivan PF, Agrawal A, Bulik CM et al.. “Psychiatric Genomics: An Update and an Agenda.” The American journal of psychiatry (2017). PMID: 28969442 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  690. [690]

    Bassett AS. “Chromosomal aberrations and schizophrenia. Autosomes.” The British journal of psychiatry : the journal of mental science (1992). PMID: 1393302 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  691. [691]

    Hall W, Degenhardt L. “Cannabis use and the risk of developing a psychotic disorder.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2008). PMID: 18560513 ↗

    L5OTHERCited in: History and Evolution of Treatment
  692. [692]

    Guloksuz S, Pries LK, Delespaul P et al.. “Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2019). PMID: 31059627 ↗

    L3OTHERCited in: History and Evolution of Treatment
  693. [693]

    Lång U, Ramsay H, Yates K et al.. “Potential for prediction of psychosis and bipolar disorder in Child and Adolescent Mental Health Services: a longitudinal register study of all people born in Finland in 1987.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2022). PMID: 36073707 ↗

    L2OTHERCited in: History and Evolution of Treatment
  694. [694]

    Correll CU, Sikich L, Reeves G et al.. “Metformin add-on vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2020). PMID: 31922663 ↗

    L1OTHERCited in: History and Evolution of Treatment
  695. [695]

    Grunebaum MF, Oquendo MA, Harkavy-Friedman JM et al.. “Delusions and suicidality.” The American journal of psychiatry (2001). PMID: 11329396 ↗

    L3OTHERCited in: History and Evolution of Treatment
  696. [696]

    Leucht S, Kissling W, McGrath J et al.. “Carbamazepine for schizophrenia.” The Cochrane database of systematic reviews (2007). PMID: 17636660 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  697. [697]

    Lewis R, Bagnall A, Leitner M. “Sertindole for schizophrenia.” The Cochrane database of systematic reviews (2000). PMID: 10796657 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  698. [698]

    Nur S, Adams CE. “Chlorpromazine versus reserpine for schizophrenia.” The Cochrane database of systematic reviews (2016). PMID: 27124109 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  699. [699]

    Tharyan P. “Electroconvulsive therapy for schizophrenia.” The Cochrane database of systematic reviews (2000). PMID: 10796292 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  700. [700]

    Essali A, Alabed S, Guul A et al.. “Preventive interventions for postnatal psychosis.” The Cochrane database of systematic reviews (2013). PMID: 23740790 ↗

    L1SR_OBSCited in: History and Evolution of Treatment, Prevention, Screening and Early Intervention
  701. [701]

    Essali A, Turkmani K, Aboudamaah S et al.. “Haloperidol discontinuation for people with schizophrenia.” The Cochrane database of systematic reviews (2019). PMID: 31006114 ↗

    L1SR_OBSCited in: History and Evolution of Treatment, Complications, Comorbidity and Iatrogenic Harm
  702. [702]

    Leucht S, McGrath J, White P et al.. “Carbamazepine for schizophrenia and schizoaffective psychoses.” The Cochrane database of systematic reviews (2000). PMID: 10796431 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  703. [703]

    Adelufosi AO, Abayomi O, Ojo TM. “Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia.” The Cochrane database of systematic reviews (2015). PMID: 25866243 ↗

    L1SR_OBSCited in: History and Evolution of Treatment, Special Populations, Pregnancy and Perinatal Psychiatry
  704. [704]

    Miller BJ, Murray L, Beckmann MM et al.. “Dietary supplements for preventing postnatal depression.” The Cochrane database of systematic reviews (2013). PMID: 24158923 ↗

    L1SR_OBSCited in: History and Evolution of Treatment, Special Populations, Pregnancy and Perinatal Psychiatry
  705. [705]

    Jones C, Hacker D, Meaden A et al.. “WITHDRAWN: Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia.” The Cochrane database of systematic reviews (2011). PMID: 21491377 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  706. [706]

    Sivakumar K, Okocha CI. “Neurosyphilis and schizophrenia.” The British journal of psychiatry : the journal of mental science (1992). PMID: 1521109 ↗

    L4CASE_REPORTCited in: History and Evolution of Treatment
  707. [707]

    Li H, Zhao Z, Jiang S et al.. “Brain circuits that regulate social behavior.” Molecular psychiatry (2025). PMID: 40287553 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  708. [708]

    MacIntyre DJ, Blackwood DH, Porteous DJ et al.. “Chromosomal abnormalities and mental illness.” Molecular psychiatry (2003). PMID: 12660800 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  709. [709]

    Falkai P, Rossner MJ, Schulze TG et al.. “Kraepelin revisited: schizophrenia from degeneration to failed regeneration.” Molecular psychiatry (2015). PMID: 25824303 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  710. [710]

    Lieberman JA, Girgis RR, Brucato G et al.. “Hippocampal dysfunction in the pathophysiology of schizophrenia: a selective review and hypothesis for early detection and intervention.” Molecular psychiatry (2018). PMID: 29311665 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  711. [711]

    Zhang CY, Xiao X, Zhang Z et al.. “An alternative splicing hypothesis for neuropathology of schizophrenia: evidence from studies on historical candidate genes and multi-omics data.” Molecular psychiatry (2021). PMID: 33686213 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  712. [712]

    Łoś K, Waszkiewicz N. “Quantitative electroencephalography as a potential neurophysiological diagnostic biomarker of schizophrenia and first-episode psychosis: a systematic review of clinical implications.” Frontiers in psychiatry (2026). PMID: 42368794 ↗

    L5SR_OBSCited in: History and Evolution of Treatment
  713. [713]

    Baeza I, Tor J, de la Serna E et al.. “Impact of Obstetric Complications in Subjects at Clinical High Risk for Psychosis: A Systematic Review and Meta-Analysis.” Acta psychiatrica Scandinavica (2025). PMID: 42154536 ↗

    L2SR_OBSCited in: History and Evolution of Treatment, Complications, Comorbidity and Iatrogenic Harm, Special Populations, Pregnancy and Perinatal Psychiatry
  714. [714]

    Mortensen PB, Pedersen CB, Westergaard T et al.. “Effects of family history and place and season of birth on the risk of schizophrenia.” The New England journal of medicine (1999). PMID: 10029644 ↗

    L2OTHERCited in: History and Evolution of Treatment
  715. [715]

    Abram SV, Kyner JM, Vu A et al.. “Metabolic Improvements with a Ketogenic Diet Correlate with Symptom Improvement in Psychosis: A Randomized Controlled Trial.” Schizophrenia bulletin (2026). PMID: 42415343 ↗

    L1RCTCited in: History and Evolution of Treatment
  716. [716]

    Ding R, Zhao M, Xia Y et al.. “Impacts of Community-Based Rehabilitation on Healthcare Utilization and Costs Among People With Schizophrenia in China: A Cluster Randomized Controlled Trial.” Schizophrenia bulletin (2026). PMID: 42241475 ↗

    L1RCTCited in: History and Evolution of Treatment
  717. [717]

    Rifkin L, Lewis S, Jones P et al.. “Low birth weight and schizophrenia.” The British journal of psychiatry : the journal of mental science (1994). PMID: 7994506 ↗

    L3OTHERCited in: History and Evolution of Treatment
  718. [718]

    Kendell RE, Chalmers JC, Platz C. “Epidemiology of puerperal psychoses.” The British journal of psychiatry : the journal of mental science (1987). PMID: 3651704 ↗

    L2OTHERCited in: History and Evolution of Treatment
  719. [719]

    Hare E. “Schizophrenia as a recent disease.” The British journal of psychiatry : the journal of mental science (1988). PMID: 3074859 ↗

    L5OTHERCited in: History and Evolution of Treatment
  720. [720]

    Hoenig J. “The concept of Schizophrenia. Kraepelin-Bleuler-Schneider.” The British journal of psychiatry : the journal of mental science (1983). PMID: 6349735 ↗

    L5OTHERCited in: History and Evolution of Treatment
  721. [721]

    Ahangari M, Bustamante D, Kirkpatrick R et al.. “Relationship between polygenic risk scores and symptom dimensions of schizophrenia and schizotypy in multiplex families with schizophrenia.” The British journal of psychiatry : the journal of mental science (2023). PMID: 36503694 ↗

    L3OTHERCited in: History and Evolution of Treatment
  722. [722]

    Bolos AM, Dean M, Lucas-Derse S et al.. “Population and pedigree studies reveal a lack of association between the dopamine D2 receptor gene and alcoholism.” JAMA (1990). PMID: 1979357 ↗

    L3OTHERCited in: History and Evolution of Treatment
  723. [723]

    Baron M, Levitt M, Perlman R. “Platelet monoamine oxidase values and genetic heterogeneity in schizophrenia research.” JAMA (1981). PMID: 7265444 ↗

    L3OTHERCited in: History and Evolution of Treatment
  724. [724]

    Mason A, Logeswaran Y, Opper F et al.. “The effectiveness and tolerability of trauma-focused interventions for trauma symptoms in individuals who have psychosis: A systematic review and meta-analysis.” Schizophrenia research (2026). PMID: 42284952 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  725. [725]

    Gyselinck B, Vanwetswinkel F, Puttemans F et al.. “Preconception counselling components in women with serious mental illness: a scoping review.” Journal of reproductive and infant psychology (2026). PMID: 42433178 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  726. [726]

    Burschinski A, Schneider-Thoma J, Chiocchia V et al.. “Metabolic side effects in persons with schizophrenia during mid- to long-term treatment with antipsychotics: a network meta-analysis of randomized controlled trials.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2023). PMID: 36640396 ↗

    L1SR_MA_RCTCited in: Complications, Comorbidity and Iatrogenic Harm
  727. [727]

    Hjorthøj C, Stürup AE, McGrath JJ et al.. “Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis.” The lancet. Psychiatry (2017). PMID: 28237639 ↗

    L2SR_OBSCited in: Complications, Comorbidity and Iatrogenic Harm, Special Populations, Pregnancy and Perinatal Psychiatry
  728. [728]

    Luykx JJ, Colgan M, Vieta E et al.. “Transdiagnostic effectiveness and safety of clozapine in individuals with psychotic, affective, and personality disorders: nationwide and meta-analytic comparisons with other antipsychotics.” The lancet. Psychiatry (2025). PMID: 41192460 ↗

    L2SR_OBSCited in: Complications, Comorbidity and Iatrogenic Harm, Prognosis and Natural History
  729. [729]

    Salahuddin NH, Herlitzius E, Schütz A et al.. “Psychological and Psychosocial Interventions for People With Schizophrenia and Co-Occurring Substance Use Disorders: A Systematic Review and Meta-Analysis.” JAMA psychiatry (2026). PMID: 41637064 ↗

    L1SR_OBSCited in: Complications, Comorbidity and Iatrogenic Harm
  730. [730]

    Masuda T, Misawa F, Takase M et al.. “Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics: A Systematic Review and Meta-analysis of Cohort Studies.” JAMA psychiatry (2019). PMID: 31365048 ↗

    L2SR_OBSCited in: Complications, Comorbidity and Iatrogenic Harm
  731. [731]

    Fond G, Nemani K, Etchecopar-Etchart D et al.. “Association Between Mental Health Disorders and Mortality Among Patients With COVID-19 in 7 Countries: A Systematic Review and Meta-analysis.” JAMA psychiatry (2021). PMID: 34313711 ↗

    L2SR_OBSCited in: Complications, Comorbidity and Iatrogenic Harm
  732. [732]

    Taipale H, Tanskanen A, Howes O et al.. “Comparative effectiveness of antipsychotic treatment strategies for relapse prevention in first-episode schizophrenia in Finland: a population-based cohort study.” The lancet. Psychiatry (2025). PMID: 39848730 ↗

    L2COHORTCited in: Complications, Comorbidity and Iatrogenic Harm
  733. [733]

    Vancampfort D, Firth J, Schuch FB et al.. “Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder: a global systematic review and meta-analysis.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2017). PMID: 28941119 ↗

    L2SR_OBSCited in: Complications, Comorbidity and Iatrogenic Harm
  734. [734]

    Kraemer HC, Glick ID, Klein DF. “Clinical trials design lessons from the CATIE study.” The American journal of psychiatry (2009). PMID: 19797435 ↗

    L5TRIAL_NONRANDOMCited in: Complications, Comorbidity and Iatrogenic Harm
  735. [735]

    Zhuo C, Tao R, Jiang R et al.. “Cancer mortality in patients with schizophrenia: systematic review and meta-analysis.” The British journal of psychiatry : the journal of mental science (2017). PMID: 28596246 ↗

    L2SR_OBSCited in: Complications, Comorbidity and Iatrogenic Harm
  736. [736]

    Chan JKN, Wong CSM, Or PCF et al.. “Risk of mortality and complications in patients with schizophrenia and diabetes mellitus: population-based cohort study.” The British journal of psychiatry : the journal of mental science (2021). PMID: 33407970 ↗

    L2COHORTCited in: Complications, Comorbidity and Iatrogenic Harm
  737. [737]

    Chan JKN, Lee KCK, Correll CU et al.. “Adverse obstetric and neonatal outcomes associated with maternal schizophrenia-spectrum disorders and prenatal antipsychotic use: a meta-analysis of 37,214,330 pregnancy deliveries and propensity-score weighted population-based cohort study assessing confounder dependency of risk estimates.” Molecular psychiatry (2024). PMID: 39223277 ↗

    L2SR_OBSCited in: Complications, Comorbidity and Iatrogenic Harm
  738. [738]

    Lee H, Lee JH, Lee S et al.. “Comorbid health outcomes in patients with schizophrenia: an umbrella review of systematic reviews and meta-analyses.” Molecular psychiatry (2024). PMID: 39424931 ↗

    L2SR_OBSCited in: Complications, Comorbidity and Iatrogenic Harm
  739. [739]

    Etchecopar-Etchart D, Mignon R, Boyer L et al.. “Schizophrenia pregnancies should be given greater health priority in the global health agenda: results from a large-scale meta-analysis of 43,611 deliveries of women with schizophrenia and 40,948,272 controls.” Molecular psychiatry (2022). PMID: 35804094 ↗

    L2SR_OBSCited in: Complications, Comorbidity and Iatrogenic Harm, Special Populations, Pregnancy and Perinatal Psychiatry
  740. [740]

    Constantinides C, Han LKM, Alloza C et al.. “Brain ageing in schizophrenia: evidence from 26 international cohorts via the ENIGMA Schizophrenia consortium.” Molecular psychiatry (2022). PMID: 36494461 ↗

    L2SR_OBSCited in: Complications, Comorbidity and Iatrogenic Harm
  741. [741]

    Fernandez-Egea E, Garcia-Rizo C, Kirkpatrick B. “Schizophrenia and accelerated ageing: systematic review and future research directions.” The British journal of psychiatry : the journal of mental science (2026). PMID: 42015596 ↗

    L2SR_OBSCited in: Complications, Comorbidity and Iatrogenic Harm
  742. [742]

    Trott M, Arnautovska U, Johnston D et al.. “The safety and efficacy of semaglutide in people with schizophrenia spectrum disorders: systematic review and meta-analysis of randomised controlled trials.” BJPsych open (2026). PMID: 42179170 ↗

    L1SR_MA_RCTCited in: Complications, Comorbidity and Iatrogenic Harm
  743. [743]

    Taipale H, Tanskanen A, Mehtälä J et al.. “20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20).” World psychiatry : official journal of the World Psychiatric Association (WPA) (2020). PMID: 31922669 ↗

    L2OTHERCited in: Complications, Comorbidity and Iatrogenic Harm
  744. [744]

    DE Hert M, Schreurs V, Vancampfort D et al.. “Metabolic syndrome in people with schizophrenia: a review.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2009). PMID: 19293950 ↗

    L5REVIEW_NARRATIVECited in: Complications, Comorbidity and Iatrogenic Harm, Prevention, Screening and Early Intervention
  745. [745]

    Ahn Y, Kim J, Jung K et al.. “Relationship Between Problematic Alcohol Use and Various Psychiatric Disorders: A Genetically Informed Study.” The American journal of psychiatry (2025). PMID: 40329641 ↗

    L3OTHERCited in: Complications, Comorbidity and Iatrogenic Harm
  746. [746]

    Wimberley T, MacCabe JH, Laursen TM et al.. “Mortality and Self-Harm in Association With Clozapine in Treatment-Resistant Schizophrenia.” The American journal of psychiatry (2017). PMID: 28750580 ↗

    L2OTHERCited in: Complications, Comorbidity and Iatrogenic Harm
  747. [747]

    Anglin DM, Ereshefsky S, Klaunig MJ et al.. “From Womb to Neighborhood: A Racial Analysis of Social Determinants of Psychosis in the United States.” The American journal of psychiatry (2021). PMID: 33934608 ↗

    L5REVIEW_NARRATIVECited in: Complications, Comorbidity and Iatrogenic Harm
  748. [748]

    Rathbone J, McMonagle T. “Pimozide for schizophrenia or related psychoses.” The Cochrane database of systematic reviews (2007). PMID: 17636692 ↗

    L1SR_OBSCited in: Complications, Comorbidity and Iatrogenic Harm
  749. [749]

    Storman D, Koperny M, Styczeñ K et al.. “Lurasidone versus typical antipsychotics for schizophrenia.” The Cochrane database of systematic reviews (2025). PMID: 39831535 ↗

    L1SR_OBSCited in: Complications, Comorbidity and Iatrogenic Harm
  750. [750]

    Ronaldson A, Das-Munshi J, Dregan A et al.. “Characterizing Infectious Disease Mortality in Severe Mental Illness: A Retrospective Matched Cohort Study.” Schizophrenia bulletin (2026). PMID: 42104801 ↗

    L3COHORTCited in: Complications, Comorbidity and Iatrogenic Harm, Special Populations, Pregnancy and Perinatal Psychiatry
  751. [751]

    Khant MM, Fujiwara M, Yamada Y et al.. “Impact of pre-existing schizophrenia spectrum disorder on the receipt of invasive and systemic therapy for gastric cancer: a multicenter nationwide cohort study in Japan.” Japanese journal of clinical oncology (2026). PMID: 42391504 ↗

    L2COHORTCited in: Complications, Comorbidity and Iatrogenic Harm
  752. [752]

    Pathak GA, Pietrzak RH, Lacobelle A et al.. “Epigenetic and genetic profiling of comorbidity patterns among substance dependence diagnoses.” Molecular psychiatry (2025). PMID: 40247127 ↗

    L2OTHERCited in: Complications, Comorbidity and Iatrogenic Harm
  753. [753]

    Luykx JJ, Corbeil O, Kärkkäinen O et al.. “Long term safety of ADHD medication in patients with schizophrenia spectrum disorders.” Molecular psychiatry (2025). PMID: 40595332 ↗

    L2OTHERCited in: Complications, Comorbidity and Iatrogenic Harm, Prognosis and Natural History, Special Populations, Pregnancy and Perinatal Psychiatry
  754. [754]

    Zhao G, Sun Y, Lu Z et al.. “Identifying genetic contributions of 6q21 loci and PPAR pathway to antipsychotic-induced metabolic syndrome: a Sex-Stratified Multi-Omics study.” Molecular psychiatry (2026). PMID: 41865124 ↗

    L3OTHERCited in: Complications, Comorbidity and Iatrogenic Harm
  755. [755]

    Howes OD, Bukala BR, Chen EYH et al.. “Relapse in Schizophrenia: A Systematic Review of Criteria for Clinical Studies and International Consensus Guidelines to Improve Them.” The American journal of psychiatry (2025). PMID: 41058236 ↗

    L1SR_OBSCited in: Prognosis and Natural History
  756. [756]

    Isohanni M, Miettunen J, Mäki P et al.. “Risk factors for schizophrenia. Follow-up data from the Northern Finland 1966 Birth Cohort Study.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2006). PMID: 17139352 ↗

    L2COHORTCited in: Prognosis and Natural History
  757. [757]

    Bschor T, Unger J, Nagel L et al.. “Negative Effects During Placebo Treatment: A Systematic Review and Meta-Analysis.” JAMA psychiatry (2025). PMID: 40238101 ↗

    L1SR_OBSCited in: Prognosis and Natural History
  758. [758]

    Watson AJ, Harrison L, Preti A et al.. “Cognitive trajectories following onset of psychosis: a meta-analysis.” The British journal of psychiatry : the journal of mental science (2022). PMID: 36149012 ↗

    L2SR_OBSCited in: Prognosis and Natural History
  759. [759]

    Penttilä M, Jääskeläinen E, Hirvonen N et al.. “Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis.” The British journal of psychiatry : the journal of mental science (2014). PMID: 25252316 ↗

    L2SR_OBSCited in: Prognosis and Natural History
  760. [760]

    Rabinowitz J, Harvey PD, Eerdekens M et al.. “Premorbid functioning and treatment response in recent-onset schizophrenia.” The British journal of psychiatry : the journal of mental science (2006). PMID: 16816303 ↗

    L2RCTCited in: Prognosis and Natural History
  761. [761]

    Lee R, Leighton SP, Thomas L et al.. “Prediction models in first-episode psychosis: systematic review and critical appraisal.” The British journal of psychiatry : the journal of mental science (2022). PMID: 35067242 ↗

    L2SR_OBSCited in: Prognosis and Natural History
  762. [762]

    Firth J, Solmi M, Wootton RE et al.. “A meta-review of "lifestyle psychiatry": the role of exercise, smoking, diet and sleep in the prevention and treatment of mental disorders.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2020). PMID: 32931092 ↗

    L1REVIEW_NARRATIVECited in: Prognosis and Natural History
  763. [763]

    Green MF, Horan WP, Lee J. “Nonsocial and social cognition in schizophrenia: current evidence and future directions.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2019). PMID: 31059632 ↗

    L5OTHERCited in: Prognosis and Natural History
  764. [764]

    Lewandowski KE, Blotner J, Yao B et al.. “Distinct cognitive trajectories in the early course of psychosis are associated with clinical and functional outcomes longitudinally.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2025). PMID: 40371799 ↗

    L2OTHERCited in: Prognosis and Natural History
  765. [765]

    Häfner H, Maurer K. “Early detection of schizophrenia: current evidence and future perspectives.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2006). PMID: 17139339 ↗

    L5OTHERCited in: Prognosis and Natural History
  766. [766]

    Rosenbaum B, Valbak K, Harder S et al.. “Treatment of patients with first-episode psychosis: two-year outcome data from the Danish National Schizophrenia Project.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2006). PMID: 16946951 ↗

    L2OTHERCited in: Prognosis and Natural History
  767. [767]

    Birnbaum R, Weinberger DR. “The Genesis of Schizophrenia: An Origin Story.” The American journal of psychiatry (2024). PMID: 38822584 ↗

    L5REVIEW_NARRATIVECited in: Prognosis and Natural History, Special Populations, Pregnancy and Perinatal Psychiatry
  768. [768]

    Hurd YL. “An Update on the Behavioral and Neurobiological Effects of Cannabis Use in Adolescents: A Translational Perspective.” The American journal of psychiatry (2025). PMID: 40589258 ↗

    L5REVIEW_NARRATIVECited in: Prognosis and Natural History, Special Populations, Pregnancy and Perinatal Psychiatry
  769. [769]

    Tramazzo S, Lian W, Ajnakina O et al.. “Long-Term Course of Remission and Recovery in Psychotic Disorders.” The American journal of psychiatry (2024). PMID: 38745457 ↗

    L2OTHERCited in: Prognosis and Natural History
  770. [770]

    Xia J, Merinder LB, Belgamwar MR. “Psychoeducation for schizophrenia.” The Cochrane database of systematic reviews (2011). PMID: 21678337 ↗

    L1SR_OBSCited in: Prognosis and Natural History
  771. [771]

    Almerie MQ, Okba Al Marhi M, Jawoosh M et al.. “Social skills programmes for schizophrenia.” The Cochrane database of systematic reviews (2015). PMID: 26059249 ↗

    L1SR_OBSCited in: Prognosis and Natural History
  772. [772]

    McIntosh AM, Conlon L, Lawrie SM et al.. “Compliance therapy for schizophrenia.” The Cochrane database of systematic reviews (2006). PMID: 16856009 ↗

    L1SR_OBSCited in: Prognosis and Natural History
  773. [773]

    Hansen L, Bernstorff M, Enevoldsen K et al.. “Predicting Diagnostic Progression to Schizophrenia or Bipolar Disorder via Machine Learning.” JAMA psychiatry (2025). PMID: 39969874 ↗

    L2OTHERCited in: Prognosis and Natural History
  774. [774]

    Gureje O, Cohen A. “Differential outcome of schizophrenia: where we are and where we would like to be.” The British journal of psychiatry : the journal of mental science (2011). PMID: 21881093 ↗

    L5OTHERCited in: Prognosis and Natural History
  775. [775]

    Yılancıoğlu HY, Bildik T, Pırıldar S et al.. “The Long- Term Course of Adolescent-Onset Major Depressive Disorder in Females: A 10-Year Cohort Study on Recurrence, Suicide Risk, and Service Use.” Neuropsychobiology (2026). PMID: 42166421 ↗

    L2COHORTCited in: Prognosis and Natural History
  776. [776]

    Murphy SM, Flores AT, Sarpal DK et al.. “Quality of life in schizophrenia: Symptomatic markers of improvement over time.” Psychiatric rehabilitation journal (2026). PMID: 42149541 ↗

    L1RCTCited in: Prognosis and Natural History
  777. [777]

    Thapar A, Riglin L. “The importance of a developmental perspective in Psychiatry: what do recent genetic-epidemiological findings show?” Molecular psychiatry (2020). PMID: 31959848 ↗

    L5REVIEW_NARRATIVECited in: Prognosis and Natural History
  778. [778]

    Mahmoudi E, Cairns MJ. “MiR-137: an important player in neural development and neoplastic transformation.” Molecular psychiatry (2016). PMID: 27620842 ↗

    L5REVIEW_NARRATIVECited in: Prognosis and Natural History
  779. [779]

    Chen L, Huai C, Song C et al.. “Refining antipsychotic treatment strategies in schizophrenia: discovery of genetic biomarkers for enhanced drug response prediction.” Molecular psychiatry (2024). PMID: 39562719 ↗

    L2OTHERCited in: Prognosis and Natural History
  780. [780]

    d'Almeida I, Gama-Marques J. “The interictal psychoses of epilepsy: A systematic review of case reports.” Epileptic disorders : international epilepsy journal with videotape (2026). PMID: 42217159 ↗

    L4SR_OBSCited in: Prognosis and Natural History
  781. [781]

    Cao J, Zhou W, Fu L et al.. “Repetitive Transcranial Magnetic Stimulation With Occupational Therapy On Symptoms And Cognition In Schizophrenia: A Retrospective Cohort Study.” Journal of visualized experiments : JoVE (2026). PMID: 42258409 ↗

    L2COHORTCited in: Prognosis and Natural History
  782. [782]

    Zheng J. “PSPH and CXCL2 Predict Treatment Response in First-Episode Schizophrenia: a Retrospective Study.” Clinical laboratory (2026). PMID: 42159130 ↗

    L3COHORTCited in: Prognosis and Natural History
  783. [783]

    Leucht S, Chaimani A, Krause M et al.. “The response of subgroups of patients with schizophrenia to different antipsychotic drugs: a systematic review and meta-analysis.” The lancet. Psychiatry (2022). PMID: 36228647 ↗

    L1SR_OBSCited in: Special Populations, Pregnancy and Perinatal Psychiatry
  784. [784]

    Nord CL, Lawson RP, Dalgleish T. “Disrupted Dorsal Mid-Insula Activation During Interoception Across Psychiatric Disorders.” The American journal of psychiatry (2021). PMID: 34154372 ↗

    L3SR_OBSCited in: Special Populations, Pregnancy and Perinatal Psychiatry
  785. [785]

    Arnone D, Cavanagh J, Gerber D et al.. “Magnetic resonance imaging studies in bipolar disorder and schizophrenia: meta-analysis.” The British journal of psychiatry : the journal of mental science (2009). PMID: 19721106 ↗

    L3SR_OBSCited in: Special Populations, Pregnancy and Perinatal Psychiatry
  786. [786]

    Li Z, Mukherjee D, Duric B et al.. “Systematic review and meta-analysis on the effects of chronic peri-adolescent cannabinoid exposure on schizophrenia-like behaviour in rodents.” Molecular psychiatry (2024). PMID: 39090371 ↗

    L5SR_OBSCited in: Special Populations, Pregnancy and Perinatal Psychiatry
  787. [787]

    Sprong M, Schothorst P, Vos E et al.. “Theory of mind in schizophrenia: meta-analysis.” The British journal of psychiatry : the journal of mental science (2007). PMID: 17602119 ↗

    L3SR_OBSCited in: Special Populations, Pregnancy and Perinatal Psychiatry
  788. [788]

    Kotsakis Ruehlmann A, Sammallahti S, Cortés Hidalgo AP et al.. “Epigenome-wide meta-analysis of prenatal maternal stressful life events and newborn DNA methylation.” Molecular psychiatry (2023). PMID: 36899042 ↗

    L2SR_OBSCited in: Special Populations, Pregnancy and Perinatal Psychiatry
  789. [789]

    Radley J, Grant C, Barlow J et al.. “Parenting interventions for people with schizophrenia or related serious mental illness.” The Cochrane database of systematic reviews (2021). PMID: 34666417 ↗

    L1SR_OBSCited in: Special Populations, Pregnancy and Perinatal Psychiatry
  790. [790]

    Marriott RG, Neil W, Waddingham S. “Antipsychotic medication for elderly people with schizophrenia.” The Cochrane database of systematic reviews (2006). PMID: 16437531 ↗

    L1SR_OBSCited in: Special Populations, Pregnancy and Perinatal Psychiatry
  791. [791]

    Huband N, Ferriter M, Nathan R et al.. “Antiepileptics for aggression and associated impulsivity.” The Cochrane database of systematic reviews (2010). PMID: 20166067 ↗

    L1SR_OBSCited in: Special Populations, Pregnancy and Perinatal Psychiatry
  792. [792]

    Regeru RN, Massey K, Wee YR et al.. “Public health interventions to improve the mental health and mental health literacy of young people in resource-limited settings: a systematic review.” Frontiers in public health (2026). PMID: 42311980 ↗

    L2SR_OBSCited in: Special Populations, Pregnancy and Perinatal Psychiatry
  793. [793]

    Ramos MA, Hernández C, Arranz B. “Iron dysregulation across the schizophrenia lifespan: A systematic review from prenatal risk to postmortem findings.” Psychiatry research (2026). PMID: 42068734 ↗

    L3SR_OBSCited in: Special Populations, Pregnancy and Perinatal Psychiatry
  794. [794]

    Grimes PZ, Adams MJ, Thng G et al.. “Genetic Architectures of Adolescent Depression Trajectories in 2 Longitudinal Population Cohorts.” JAMA psychiatry (2024). PMID: 38748406 ↗

    L2OTHERCited in: Special Populations, Pregnancy and Perinatal Psychiatry
  795. [795]

    Roddy Mitchell A, Lindquist A, Hiscock RJ et al.. “Lithium Use in Pregnancy and the Risk of Spontaneous Preterm Birth: An Australian Statewide Retrospective Cohort Study.” BJOG : an international journal of obstetrics and gynaecology (2026). PMID: 42415243 ↗

    L2COHORTCited in: Special Populations, Pregnancy and Perinatal Psychiatry
  796. [796]

    Miao W, Jiao X, Zeng N et al.. “Functional gradient reorganization and transcriptomic signatures underlying 1 Hz rTMS treatment in first-episode schizophrenia following right orbitofrontal cortex stimulation.” NeuroImage. Clinical (2026). PMID: 42114208 ↗

    L1RCTCited in: Special Populations, Pregnancy and Perinatal Psychiatry
  797. [797]

    Hu Q, Jiao X, Ding Y et al.. “The effects of rTMS over orbitofrontal cortex on cognitive functions in first-episode schizophrenia.” Psychological medicine (2026). PMID: 42046881 ↗

    L1RCTCited in: Special Populations, Pregnancy and Perinatal Psychiatry
  798. [798]

    Kendall KM, Bracher-Smith M, Fitzpatrick H et al.. “Cognitive performance and functional outcomes of carriers of pathogenic copy number variants: analysis of the UK Biobank.” The British journal of psychiatry : the journal of mental science (2019). PMID: 30767844 ↗

    L2OTHERCited in: Special Populations, Pregnancy and Perinatal Psychiatry
  799. [799]

    Howes OD, Onwordi EC. “The synaptic hypothesis of schizophrenia version III: a master mechanism.” Molecular psychiatry (2023). PMID: 37041418 ↗

    L5REVIEW_NARRATIVECited in: Special Populations, Pregnancy and Perinatal Psychiatry
  800. [800]

    Freedman R, Hunter SK, Hoffman MC. “Prenatal Primary Prevention of Mental Illness by Micronutrient Supplements in Pregnancy.” The American journal of psychiatry (2018). PMID: 29558816 ↗

    L1SR_OBSCited in: Prevention, Screening and Early Intervention
  801. [801]

    Vita A, Barlati S, Ceraso A et al.. “Durability of Effects of Cognitive Remediation on Cognition and Psychosocial Functioning in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.” The American journal of psychiatry (2024). PMID: 38476043 ↗

    L1SR_OBSCited in: Prevention, Screening and Early Intervention
  802. [802]

    Solmi M, Fiedorowicz J, Poddighe L et al.. “Disparities in Screening and Treatment of Cardiovascular Diseases in Patients With Mental Disorders Across the World: Systematic Review and Meta-Analysis of 47 Observational Studies.” The American journal of psychiatry (2021). PMID: 34256605 ↗

    L2SR_OBSCited in: Prevention, Screening and Early Intervention
  803. [803]

    Posselt CM, Albert N, Nordentoft M et al.. “The Danish OPUS Early Intervention Services for First-Episode Psychosis: A Phase 4 Prospective Cohort Study With Comparison of Randomized Trial and Real-World Data.” The American journal of psychiatry (2021). PMID: 34315283 ↗

    L2RCTCited in: Prevention, Screening and Early Intervention
  804. [804]

    Crump C, Winkleby MA, Sundquist K et al.. “Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study.” The American journal of psychiatry (2013). PMID: 23318474 ↗

    L2COHORTCited in: Prevention, Screening and Early Intervention
  805. [805]

    Rajkumar AP, Horsdal HT, Wimberley T et al.. “Endogenous and Antipsychotic-Related Risks for Diabetes Mellitus in Young People With Schizophrenia: A Danish Population-Based Cohort Study.” The American journal of psychiatry (2017). PMID: 28103712 ↗

    L2COHORTCited in: Prevention, Screening and Early Intervention
  806. [806]

    Robinson DG, Schooler NR, Correll CU et al.. “Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention.” The American journal of psychiatry (2017). PMID: 28945118 ↗

    L1RCTCited in: Prevention, Screening and Early Intervention
  807. [807]

    Wagner E, Højlund M, Fiedorowicz JG et al.. “Disparities in diabetes treatment and monitoring for people with and without mental disorders: a systematic review and meta-analysis.” The lancet. Psychiatry (2026). PMID: 41506273 ↗

    L2SR_OBSCited in: Prevention, Screening and Early Intervention
  808. [808]

    Ritunnano R, Kleinman J, Whyte Oshodi D et al.. “Subjective experience and meaning of delusions in psychosis: a systematic review and qualitative evidence synthesis.” The lancet. Psychiatry (2022). PMID: 35523211 ↗

    L5SR_OBSCited in: Prevention, Screening and Early Intervention
  809. [809]

    Solmi M, Firth J, Miola A et al.. “Disparities in cancer screening in people with mental illness across the world versus the general population: prevalence and comparative meta-analysis including 4 717 839 people.” The lancet. Psychiatry (2019). PMID: 31787585 ↗

    L2SR_OBSCited in: Prevention, Screening and Early Intervention
  810. [810]

    Laguna-Muñoz D, Pata MP, Jiménez-Peinado A et al.. “Mortality from respiratory diseases in individuals with severe mental illness: a large-scale systematic review and meta-analysis of pooled and specific diagnoses.” The lancet. Psychiatry (2025). PMID: 40967730 ↗

    L2SR_OBSCited in: Prevention, Screening and Early Intervention
  811. [811]

    Subotnik KL, Casaus LR, Ventura J et al.. “Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.” JAMA psychiatry (2015). PMID: 26107752 ↗

    L1RCTCited in: Prevention, Screening and Early Intervention
  812. [812]

    Vancampfort D, Wampers M, Mitchell AJ et al.. “A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls.” World psychiatry : official journal of the World Psychiatric Association (WPA) (2013). PMID: 24096790 ↗

    L2SR_OBSCited in: Prevention, Screening and Early Intervention
  813. [813]

    Aceituno D, Vera N, Prina AM et al.. “Cost-effectiveness of early intervention in psychosis: systematic review.” The British journal of psychiatry : the journal of mental science (2019). PMID: 30696495 ↗

    L2SR_OBSCited in: Prevention, Screening and Early Intervention
  814. [814]

    Rosengard RJ, Malla A, Mustafa S et al.. “Association of Pre-onset Subthreshold Psychotic Symptoms With Longitudinal Outcomes During Treatment of a First Episode of Psychosis.” JAMA psychiatry (2019). PMID: 30304442 ↗

    L2TRIAL_NONRANDOMCited in: Prevention, Screening and Early Intervention
  815. [815]

    Foley C, Heron EA, Harold D et al.. “Identifying schizophrenia patients who carry pathogenic genetic copy number variants using standard clinical assessment: retrospective cohort study.” The British journal of psychiatry : the journal of mental science (2020). PMID: 31964429 ↗

    L2COHORTCited in: Prevention, Screening and Early Intervention
  816. [816]

    Catalán A, Swidzinski S, McCutcheon RA et al.. “The proportion of people with primary affective disorders presenting to early intervention services: systematic review and meta-analysis.” The British journal of psychiatry : the journal of mental science (2026). PMID: 42057639 ↗

    L2SR_OBSCited in: Prevention, Screening and Early Intervention
  817. [817]

    Kim HJ, Kim MH, Choi MG et al.. “Psychiatric adverse events following COVID-19 vaccination: a population-based cohort study in Seoul, South Korea.” Molecular psychiatry (2024). PMID: 38834668 ↗

    L2COHORTCited in: Prevention, Screening and Early Intervention
  818. [818]

    Zajkowska Z, Nikkheslat N, Manfro PH et al.. “Combining neurobiological markers and a sociodemographic risk score to predict adolescent depression - An IDEA RiSCo prospective cohort study.” Molecular psychiatry (2026). PMID: 41765970 ↗

    L2COHORTCited in: Prevention, Screening and Early Intervention
  819. [819]

    Hasseris S, Albiñana C, Vilhjalmsson BJ et al.. “Polygenic Risk and Episode Polarity Among Individuals With Bipolar Disorder.” The American journal of psychiatry (2023). PMID: 36651623 ↗

    L2OTHERCited in: Prevention, Screening and Early Intervention
  820. [820]

    Puntis S, Minichino A, De Crescenzo F et al.. “Specialised early intervention teams for recent-onset psychosis.” The Cochrane database of systematic reviews (2020). PMID: 33135811 ↗

    L1SR_OBSCited in: Prevention, Screening and Early Intervention
  821. [821]

    Puntis S, Minichino A, De Crescenzo F et al.. “Specialised early intervention teams (extended time) for recent-onset psychosis.” The Cochrane database of systematic reviews (2020). PMID: 33135812 ↗

    L1SR_OBSCited in: Prevention, Screening and Early Intervention
  822. [822]

    Bighelli I, Ostuzzi G, Girlanda F et al.. “Implementation of treatment guidelines for specialist mental health care.” The Cochrane database of systematic reviews (2016). PMID: 27977851 ↗

    L1SR_OBSCited in: Prevention, Screening and Early Intervention
  823. [823]

    Chien WT, Clifton AV, Zhao S et al.. “Peer support for people with schizophrenia or other serious mental illness.” The Cochrane database of systematic reviews (2019). PMID: 30946482 ↗

    L1SR_OBSCited in: Prevention, Screening and Early Intervention
  824. [824]

    Barbui C, Girlanda F, Ay E et al.. “Implementation of treatment guidelines for specialist mental health care.” The Cochrane database of systematic reviews (2014). PMID: 24443146 ↗

    L1SR_OBSCited in: Prevention, Screening and Early Intervention
  825. [825]

    Palpandi SB, Palanigurupackiam N, Almatar H et al.. “Artificial intelligence approaches for schizophrenia prediction and its biomarkers using medical imaging data.” Frontiers in psychiatry (2026). PMID: 42206005 ↗

    L5SR_OBSCited in: Prevention, Screening and Early Intervention
  826. [826]

    Bhuvaneswaran MV, Karthikeyan S, Ramamurthy D et al.. “Stereopsis deficits in schizophrenia: a systematic review with exploratory meta-analysis.” BMC psychiatry (2026). PMID: 42185870 ↗

    L2SR_OBSCited in: Prevention, Screening and Early Intervention
  827. [827]

    Long J, Yang B, Zheng Q. “A meta-analysis of the incidence proportion of obesity and associated risk factors in patients with schizophrenia.” Frontiers in psychiatry (2026). PMID: 42125465 ↗

    L2SR_OBSCited in: Prevention, Screening and Early Intervention
  828. [828]

    Kidie AA, Serunjogi D, Demeke SM et al.. “Syndemics and clinical impact of HIV and mental health conditions among people living with HIV: a systematic review and meta-analysis.” Frontiers in public health (2026). PMID: 42088241 ↗

    L2SR_OBSCited in: Prevention, Screening and Early Intervention
  829. [829]

    Warren N, O'Gorman C, Dark F et al.. “Initial physical health assessment for psychosis in Australia and New Zealand: 2026 recommendations.” The Australian and New Zealand journal of psychiatry (2026). PMID: 42035415 ↗

    L5SR_OBSCited in: Prevention, Screening and Early Intervention
  830. [830]

    Jonas K, Lian W, Callahan J et al.. “The Course of General Cognitive Ability in Individuals With Psychotic Disorders.” JAMA psychiatry (2022). PMID: 35583896 ↗

    L2OTHERCited in: Prevention, Screening and Early Intervention
  831. [831]

    Keefe RSE, Davis VG, Harvey PD et al.. “Placebo Response and Practice Effects in Schizophrenia Cognition Trials.” JAMA psychiatry (2017). PMID: 28636694 ↗

    L5OTHERCited in: Prevention, Screening and Early Intervention
  832. [832]

    Tzur Bitan D, Kridin K, Givon-Lavi N et al.. “COVID-19 Booster Vaccination Among Individuals With Schizophrenia in Israel.” JAMA psychiatry (2022). PMID: 35353114 ↗

    L2OTHERCited in: Prevention, Screening and Early Intervention
  833. [833]

    Nori-Sarma A, Sun S, Sun Y et al.. “Association Between Ambient Heat and Risk of Emergency Department Visits for Mental Health Among US Adults, 2010 to 2019.” JAMA psychiatry (2022). PMID: 35195664 ↗

    L3OTHERCited in: Prevention, Screening and Early Intervention
  834. [834]

    Xiao J, Liu C, Shao T et al.. “Circulating propionate and butyrate are associated with metabolic improvements following probiotic and dietary fiber supplementation in patients on antipsychotics: a post-hoc analysis of a randomized controlled trial.” BMC psychiatry (2026). PMID: 42286534 ↗

    L2RCTCited in: Prevention, Screening and Early Intervention
  835. [835]

    Vasile AI, Trifu S, Negoita CA. “Romanian male patients with the dual diagnosis of schizophrenia and alcohol use disorder: a prospective study of clinical, social, and treatment-related factors affecting quality of life.” Frontiers in psychiatry (2026). PMID: 42211196 ↗

    L2COHORTCited in: Prevention, Screening and Early Intervention
  836. [836]

    Eramo A, Correll CU, Walling DP et al.. “Antipsychotic Efficacy and Safety of LB-102 in the Treatment of Adults With Acute Schizophrenia: A Randomized Clinical Trial.” JAMA psychiatry (2026). PMID: 42018313 ↗

    L1RCTCited in: Prevention, Screening and Early Intervention
  837. [837]

    Umbricht D, Abt M, Derks M et al.. “A Phase 2b Multicenter Study to Evaluate Basmisanil as an Adjunctive Treatment in Patients With Cognitive Impairment Associated With Schizophrenia.” The Journal of clinical psychiatry (2026). PMID: 41983730 ↗

    L1RCTCited in: Prevention, Screening and Early Intervention
  838. [838]

    Ng NYT, Tang JY, Zhao JV et al.. “Mendelian randomisation reveals modifiable pathways and epigenetic markers from childhood maltreatment to neuropsychiatric disorders.” The British journal of psychiatry : the journal of mental science (2025). PMID: 41186115 ↗

    L2OTHERCited in: Prevention, Screening and Early Intervention
  839. [839]

    Kalman JL, Olde Loohuis LM, Vreeker A et al.. “Characterisation of age and polarity at onset in bipolar disorder.” The British journal of psychiatry : the journal of mental science (2021). PMID: 35048876 ↗

    L3OTHERCited in: Prevention, Screening and Early Intervention
  840. [840]

    Gao R, Piguel NH, Melendez-Zaidi AE et al.. “CNTNAP2 stabilizes interneuron dendritic arbors through CASK.” Molecular psychiatry (2018). PMID: 29610457 ↗

    L5OTHERCited in: Prevention, Screening and Early Intervention
  841. [841]

    Sellgren CM, Sheridan SD, Gracias J et al.. “Patient-specific models of microglia-mediated engulfment of synapses and neural progenitors.” Molecular psychiatry (2016). PMID: 27956744 ↗

    L5OTHERCited in: Prevention, Screening and Early Intervention
  842. [842]

    Kendler KS, Ohlsson H, Sundquist J et al.. “Exploring the implications of case selection methods for psychiatric molecular genetic studies.” Molecular psychiatry (2025). PMID: 40254710 ↗

    L2OTHERCited in: Prevention, Screening and Early Intervention
  843. [843]

    Ahn K, Gotay N, Andersen TM et al.. “High rate of disease-related copy number variations in childhood onset schizophrenia.” Molecular psychiatry (2013). PMID: 23689535 ↗

    L4OTHERCited in: Prevention, Screening and Early Intervention
  844. [844]

    Potkin SG, Turner JA, Fallon JA et al.. “Gene discovery through imaging genetics: identification of two novel genes associated with schizophrenia.” Molecular psychiatry (2008). PMID: 19065146 ↗

    L3OTHERCited in: Prevention, Screening and Early Intervention
  845. [845]

    Pedersen CB, Bybjerg-Grauholm J, Pedersen MG et al.. “The iPSYCH2012 case-cohort sample: new directions for unravelling genetic and environmental architectures of severe mental disorders.” Molecular psychiatry (2017). PMID: 28924187 ↗

    L2OTHERCited in: Prevention, Screening and Early Intervention

Revision History

All updates applied to this page

Loading revisions…